Details of Disease

General Information of Disease (ID: DISCSPTN)

• Disease Name: Acute myelogenous leukaemia
• Synonyms: leukemia, acute myeloid; acute non lymphoblastic leukaemia; leukemia, acute myeloid, susceptibility to; leukemia, acute myelogenous; acute non lymphoblastic leukemia; acute myelogenous leukemias; acute myelocytic leukaemia; acute Nonlymphocytic leukaemia; acute myeloid leukaemia (AML); acute nonlymphocytic leukemia; leukemia, acute myeloid, somatic; acute myeloblastic leukaemia; acute nonlymphocytic leukaemia; leukemia, myelocytic, acute; acute granulocytic leukemia; leukemia, acute myeloid, autosomal dominant, somatic mutation; leukemia, acute myeloid, reduced survival in, somatic; leukemia, acute myeloid, susceptibility to, autosomal dominant, somatic mutation; AML; hematopoeitic - acute Myleogenous leukaemia (AML); acute myeloid leukemia (AML); myeloid leukemia, acute; acute myelocytic leukemia; acute myeloblastic leukemia; hematopoeitic - acute Myleogenous leukemia (AML); AML - acute myeloid leukaemia; acute myelogenous leukaemia; ANLL; AML - acute myeloid leukemia; acute granulocytic leukaemia; acute myelogenous leukemia; acute myeloid leukemia; myeloid leukemia, acute, M4/M4Eo subtype, somatic; acute myeloid leukemia, somatic; acute Nonlymphocytic leukemia
• Disease Class: 2A41: BCR-ABL1-negative chronic myeloid leukaemia
• Definition: Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. AML manifests by fever, pallor, anemia, hemorrhages and recurrent infections.
• Disease Hierarchy:
  DISMN944: Myeloid leukaemia
  DISDQFDI: Acute leukaemia
  DISCSPTN: Acute myelogenous leukaemia
• ICD Code:
  ICD-11: ICD-11: 2A41
  ICD-10: ICD-10: C92.2
  Expand ICD-11: 'XH8AA5
• Disease Identifiers:
  MONDO ID: MONDO_0018874
  MESH ID: D015470
  UMLS CUI: C0023467
  OMIM ID: 601626
  MedGen ID: 9730
  HPO ID: HP:0004808
  Orphanet ID: 519
  SNOMED CT ID: 1162928000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 15 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldesleukin	DM4YMIS	Approved	NA	[1]
Alemtuzumab	DMZL3IV	Approved	Antibody	[2]
Azacitidine	DMTA5OE	Approved	Small molecular drug	[3]
Clofarabine	DMCVJ86	Approved	Small molecular drug	[4]
Cytarabine	DMZD5QR	Approved	Small molecular drug	[5]
Daunorubicin	DMQUSBT	Approved	Small molecular drug	[6]
Decitabine	DMQL8XJ	Approved	Small molecular drug	[7]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[8]
Etoposide	DMNH3PG	Approved	Small molecular drug	[9]
Fludarabine	DMVRLT7	Approved	Small molecular drug	[10]
Idarubicin	DMM0XGL	Approved	Small molecular drug	[11]
Mitoxantrone	DMM39BF	Approved	Small molecular drug	[12]
Sulindac	DM2QHZU	Approved	Small molecular drug	[13]
Thioguanine	DM7NKEV	Approved	Small molecular drug	[14]
Tretinoin	DM49DUI	Approved	Small molecular drug	[15]

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AG-221	DMS0ZBI	Phase 3	NA	[16]
CP-868596	DMZIM37	Phase 3	Small molecular drug	[16]
MLN4924	DMP36KD	Phase 3	Small molecular drug	[16]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[16]
Nerofe	DMVVBY8	Phase 2	Peptide	[17]
CUDC-907	DMHIQDC	Phase 1/2	Small molecular drug	[18]
GTB-3550	DMK2RIB	Phase 1/2	Recombinant protein	[19]
HuM-195-Ac-225	DMIU1HY	Phase 1/2	NA	[16]
OXi4503	DM8133S	Phase 1/2	Small molecular drug	[16]
NK100	DMC4HT7	Phase 1	Cell therapy	[20]
Tepoditamab	DMC84Y9	Phase 1	Antibody	[21]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 689 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABL2	TT1A6HL	Limited	Genetic Variation	[22]
AGR2	TT9K86S	Limited	Genetic Variation	[23]
AGRP	TT4DE1O	Limited	Genetic Variation	[24]
AHCY	TTE2KUJ	Limited	Altered Expression	[25]
AKR1C3	TT5ZWB6	Limited	Biomarker	[26]
ANG	TTURHFP	Limited	Altered Expression	[27]
ANPEP	TTPHMWB	Limited	Altered Expression	[28]
APOBEC3G	TTP96KH	Limited	Altered Expression	[29]
ASRGL1	TT4WT91	Limited	Biomarker	[30]
ATG7	TTLVB9Z	Limited	Altered Expression	[31]
AXL	TTZPY6J	Limited	Genetic Variation	[32]
BAK1	TTFM7V0	Limited	Biomarker	[33]
BCL11A	TTR61MW	Limited	Altered Expression	[34]
BMI1	TTIPNSR	Limited	Biomarker	[35]
BMP1	TT0L58T	Limited	Biomarker	[36]
BTG1	TTL7N2W	Limited	Biomarker	[37]
BUB1	TT78309	Limited	Altered Expression	[38]
CACNA2D3	TTN7T29	Limited	Genetic Variation	[23]
CALR	TTUZ7OA	Limited	Biomarker	[39]
CASP2	TT12VNG	Limited	Altered Expression	[40]
CASP9	TTB6T7O	Limited	Altered Expression	[41]
CASR	TTBUYHA	Limited	Biomarker	[42]
CCL17	TTMPHAE	Limited	Altered Expression	[43]
CCL22	TTBTWI1	Limited	Altered Expression	[43]
CCND3	TT1JXNR	Limited	Genetic Variation	[44]
CCNE2	TTLDRGX	Limited	Biomarker	[45]
CD14	TT6I7DC	Limited	Biomarker	[46]
CD19	TTW640A	Limited	Biomarker	[42]
CD1A	TTBGTFN	Limited	Biomarker	[47]
CD2	TTJDUNO	Limited	Biomarker	[48]
CD200	TT0BE68	Limited	Altered Expression	[49]
CD274	TT8ZLTI	Limited	Biomarker	[50]
CD40	TT1ERKL	Limited	Altered Expression	[51]
CD47	TT28S46	Limited	Biomarker	[52]
CD58	TT5KSBY	Limited	Biomarker	[53]
CD59	TTBGTEJ	Limited	Biomarker	[54]
CD80	TT89Z17	Limited	Biomarker	[55]
CDA	TTQ12RK	Limited	Biomarker	[56]
CDC25A	TTLZS4Q	Limited	Biomarker	[57]
CDC25B	TTR0SWN	Limited	Altered Expression	[58]
CDCA8	TT04YCM	Limited	Genetic Variation	[23]
CDK1	TTH6V3D	Limited	Altered Expression	[59]
CDK5R1	TTBYM6V	Limited	Genetic Variation	[60]
CDK8	TTBJR4L	Limited	Altered Expression	[61]
CDK9	TT1LVF2	Limited	Biomarker	[62]
CEBPB	TTUI35N	Limited	Biomarker	[63]
CES1	TTMF541	Limited	Altered Expression	[64]
CHN2	TT39YVO	Limited	Genetic Variation	[23]
CHRNA1	TT54JVQ	Limited	Genetic Variation	[23]
CHRNA7	TTLA931	Limited	Genetic Variation	[23]
CNTLN	TT8MI6U	Limited	Genetic Variation	[23]
CSF1	TT0IQER	Limited	Biomarker	[65]
CTLA4	TTI2S1D	Limited	Altered Expression	[66]
CXCL12	TT4UGTF	Limited	Biomarker	[67]
CXCR4	TTBID49	Limited	Biomarker	[67]
CYP1A2	TTS1DTU	Limited	Biomarker	[68]
DDIT4	TTVEOY6	Limited	Altered Expression	[69]
DKK1	TTE3RAC	Limited	Altered Expression	[70]
DNMT3B	TT6VZ78	Limited	Altered Expression	[71]
DPP10	TTOVUPC	Limited	Genetic Variation	[23]
E2F1	TTASI04	Limited	Altered Expression	[72]
EGR1	TTE8LGD	Limited	Biomarker	[73]
EIF4E	TTZGCP6	Limited	Altered Expression	[74]
EIF4EBP1	TTKGEBL	Limited	Biomarker	[75]
ELANE	TTPLTSQ	Limited	Altered Expression	[76]
ENG	TTB30LE	Limited	Altered Expression	[77]
EPHB2	TTKPV6O	Limited	Posttranslational Modification	[78]
ETS2	TT9AH0M	Limited	Altered Expression	[79]
EZH1	TTNJA0C	Limited	Altered Expression	[80]
FCGR2B	TT5RWKQ	Limited	Biomarker	[81]
FES	TTLBY21	Limited	Biomarker	[44]
FGF1	TTMY81X	Limited	Genetic Variation	[82]
FGF4	TTCEKVZ	Limited	Biomarker	[83]
FKBP4	TTHY0FT	Limited	Genetic Variation	[84]
FLT1	TT1VAUK	Limited	Biomarker	[85]
FOLR1	TTVC37M	Limited	Biomarker	[86]
FUS	TTKGYZ9	Limited	Altered Expression	[87]
FUT4	TTNV1KZ	Limited	Altered Expression	[88]
FYN	TT2B9KF	Limited	Altered Expression	[89]
G6PD	TTKN8W0	Limited	Biomarker	[90]
GCLM	TTNFESW	Limited	Altered Expression	[91]
GGT1	TTZVT7O	Limited	Genetic Variation	[92]
GLI1	TTJOMH6	Limited	Altered Expression	[93]
HDAC1	TT6R7JZ	Limited	Biomarker	[94]
HDAC10	TTYHPU6	Limited	Genetic Variation	[23]
HDAC9	TT8M4E1	Limited	Biomarker	[95]
HEXIM1	TTFOKAH	Limited	Biomarker	[96]
HLA-G	TTLKFB3	Limited	Altered Expression	[97]
HOXA13	TTN26OM	Limited	Genetic Variation	[98]
HPGDS	TTCYE56	Limited	Genetic Variation	[99]
HSP90AA1	TT78R5H	Limited	Biomarker	[100]
IDO1	TTZJYKH	Limited	Biomarker	[101]
IL17F	TT2B6PS	Limited	Genetic Variation	[102]
IL2	TTF89GD	Limited	Biomarker	[103]
IL2RB	TT9721Y	Limited	Altered Expression	[104]
INPP5D	TTTP2Z1	Limited	Genetic Variation	[105]
ITGA4	TTJMF9P	Limited	Altered Expression	[106]
ITGA6	TT165T3	Limited	Biomarker	[107]
ITGAM	TTB69FJ	Limited	Biomarker	[108]
JAK1	TT6DM01	Limited	Biomarker	[109]
KDM7A	TT0NYMP	Limited	Genetic Variation	[23]
KDR	TTUTJGQ	Limited	Biomarker	[110]
KIR2DL1	TT4UXPE	Limited	Genetic Variation	[111]
KLRK1	TTLRN4A	Limited	Biomarker	[112]
LGALS3	TTFPQV7	Limited	Biomarker	[113]
LIF	TTGZ5WN	Limited	Altered Expression	[114]
LINGO1	TTZYQ80	Limited	Genetic Variation	[23]
LRP1	TTF2V7I	Limited	Genetic Variation	[115]
MAP2K7	TT6QY3J	Limited	Biomarker	[116]
MAP3K20	TTTUZ3O	Limited	Altered Expression	[117]
MAP3K7	TTJQT60	Limited	Altered Expression	[118]
MAPK10	TT056SO	Limited	Genetic Variation	[23]
MAPK12	TTYT93M	Limited	Genetic Variation	[23]
MAPK8	TT0K6EO	Limited	Biomarker	[119]
MAZ	TT059DA	Limited	Altered Expression	[120]
MCL1	TTL53M6	Limited	Altered Expression	[121]
MET	TTNDSF4	Limited	Genetic Variation	[122]
METAP2	TTZL0OI	Limited	Genetic Variation	[23]
MLANA	TT362RB	Limited	Biomarker	[123]
MME	TT5TKPM	Limited	Biomarker	[46]
MSI2	TTTXQF6	Limited	Biomarker	[124]
MSLN	TT4RXME	Limited	Altered Expression	[125]
MTDH	TTH6SA5	Limited	Biomarker	[126]
MVD	TTE5J6X	Limited	Biomarker	[127]
MYB	TT8V13P	Limited	Biomarker	[128]
NCR1	TTQNRJM	Limited	Altered Expression	[129]
NEDD8	TTNDC4K	Limited	Biomarker	[62]
NFKB2	TTKLNRV	Limited	Genetic Variation	[84]
NQO1	TT8XK6L	Limited	Genetic Variation	[130]
NR1H3	TTECBXN	Limited	Altered Expression	[131]
NR1I3	TTRANFM	Limited	Biomarker	[42]
NR4A1	TTMXE2Q	Limited	Biomarker	[132]
NR4A3	TTJQB49	Limited	Posttranslational Modification	[133]
NT5E	TTK0O6Y	Limited	Biomarker	[134]
NTF3	TTZHKV9	Limited	Genetic Variation	[135]
PAM	TTF4ZPC	Limited	Genetic Variation	[23]
PARP1	TTVDSZ0	Limited	Biomarker	[136]
PCSK5	TTPFWHU	Limited	Genetic Variation	[23]
PCSK6	TT75LN9	Limited	Genetic Variation	[23]
PDE4D	TTSKMI8	Limited	Genetic Variation	[23]
PDE5A	TTJ0IQB	Limited	Genetic Variation	[23]
PDGFRA	TT8FYO9	Limited	Biomarker	[137]
PF4	TTSG7Q5	Limited	Altered Expression	[138]
PIM1	TTTN5QW	Limited	Altered Expression	[139]
PIM3	TTCGOIN	Limited	Biomarker	[140]
PLA2G4C	TTBYG4O	Limited	Genetic Variation	[23]
PLK1	TTH4IP0	Limited	Biomarker	[141]
PLK2	TT976FS	Limited	Biomarker	[142]
PLN	TTMCVJF	Limited	Biomarker	[143]
PRKAR1A	TTNAHEX	Limited	Biomarker	[42]
PRKCQ	TT1MS7X	Limited	Genetic Variation	[23]
PTAFR	TTQL5VC	Limited	Biomarker	[144]
PTGS1	TT8NGED	Limited	Genetic Variation	[23]
PTK2B	TTTEFBV	Limited	Biomarker	[145]
PTPN11	TT7WUAV	Limited	Genetic Variation	[146]
PTPN14	TTNIR6C	Limited	Genetic Variation	[23]
RASA1	TTPNZ1F	Limited	Genetic Variation	[147]
RBCK1	TTIKUVC	Limited	Genetic Variation	[23]
RHCG	TTN5MZ3	Limited	Genetic Variation	[23]
ROBO1	TTND1YP	Limited	Genetic Variation	[23]
RPS6KA2	TT0ZW9O	Limited	Genetic Variation	[23]
RRM1	TTWP0NS	Limited	Genetic Variation	[148]
RUNX2	TTD6SZ8	Limited	Altered Expression	[149]
S100A6	TT716MY	Limited	Altered Expression	[150]
S100A8	TT4AF6N	Limited	Altered Expression	[151]
SATB1	TTLFRIC	Limited	Biomarker	[152]
SLC26A4	TT7X02I	Limited	Biomarker	[153]
TERF1	TT1Y6J2	Limited	Altered Expression	[154]
THRA	TTTSEPU	Limited	Biomarker	[155]
TIE1	TTT4236	Limited	Altered Expression	[156]
TK1	TTP3QRF	Limited	Biomarker	[157]
TMBIM6	TT7QSMG	Limited	Biomarker	[158]
TNFRSF10B	TTW20TU	Limited	Altered Expression	[159]
TOP1	TTGTQHC	Limited	Genetic Variation	[160]
TPP1	TTOVYPT	Limited	Altered Expression	[161]
TPSD1	TTNWD8O	Limited	Altered Expression	[162]
TPT1	TT3PTB6	Limited	Genetic Variation	[60]
TRIM24	TT9Q7AE	Limited	Altered Expression	[163]
USP44	TTJLTNM	Limited	Genetic Variation	[23]
XIAP	TTK3WBU	Limited	Biomarker	[164]
XPO1	TTCJUR4	Limited	Genetic Variation	[165]
ABCC8	TTP835K	Disputed	Genetic Variation	[166]
ANXA2	TT4YANI	Disputed	Biomarker	[167]
CDK4	TT0PG8F	Disputed	Biomarker	[168]
CNR2	TTMSFAW	Disputed	Altered Expression	[169]
CSF2RA	TT6MP2Z	Disputed	Altered Expression	[170]
FOLR2	TTT54CI	Disputed	Biomarker	[171]
HSF1	TTN6STZ	Disputed	Biomarker	[172]
HSP90AB1	TTH5YN2	Disputed	Altered Expression	[173]
IRF3	TTYR7OH	Disputed	Biomarker	[174]
KEAP1	TT3Z6Y9	Disputed	Biomarker	[175]
SELE	TT1PL7M	Disputed	Biomarker	[176]
SIRT2	TTLKF5M	Disputed	Altered Expression	[177]
TMPRSS11D	TTWHYC8	Disputed	Biomarker	[178]
UGCG	TTPHEX3	Disputed	Biomarker	[179]
VDR	TTK59TV	Disputed	Altered Expression	[180]
ABCC3	TTVLG21	moderate	Genetic Variation	[181]
AKR1B1	TTFBNVI	moderate	Biomarker	[182]
AKT2	TTH24WI	moderate	Genetic Variation	[23]
APP	TTE4KHA	moderate	Biomarker	[128]
ASIC2	TTVMWLP	moderate	Genetic Variation	[23]
CACNA1B	TT4FDG6	moderate	Genetic Variation	[23]
CACNA1E	TTYRP0M	moderate	Genetic Variation	[23]
CACNA2D1	TTFK1JQ	moderate	Genetic Variation	[23]
CALCA	TTVSFJW	moderate	Biomarker	[183]
CD96	TT83C4X	moderate	Biomarker	[184]
CHEK2	TT9ABMF	Moderate	Autosomal dominant	[185]
CRTC1	TT4GO0F	moderate	Genetic Variation	[23]
CTAG1A	TTE5ITK	moderate	Biomarker	[186]
CXXC5	TTVS4C3	moderate	Altered Expression	[187]
CYP3A4	TTWP7HQ	moderate	Altered Expression	[188]
DCK	TTJOCE4	moderate	Genetic Variation	[189]
DCLK1	TTOHTCY	moderate	Genetic Variation	[23]
DLK1	TTF4AVB	moderate	Genetic Variation	[190]
EPHA3	TTHS2LR	moderate	Biomarker	[191]
EPHA4	TTG84D3	moderate	Genetic Variation	[23]
EPHA6	TTFAHWI	moderate	Genetic Variation	[23]
ERBB4	TTWALCO	moderate	Genetic Variation	[23]
ETS1	TTTGPSD	moderate	Altered Expression	[192]
F12	TTRJSMV	moderate	Genetic Variation	[23]
FABP4	TTHWMFZ	moderate	Biomarker	[193]
FCER2	TTCH6MU	moderate	Genetic Variation	[23]
FDXR	TT3W4IX	moderate	Biomarker	[182]
FTO	TTFW3BT	moderate	Biomarker	[194]
GPR39	TTTPCNU	moderate	Genetic Variation	[23]
GRIA4	TTPJR0G	moderate	Genetic Variation	[23]
GRIK5	TTO6LI7	moderate	Genetic Variation	[23]
GRIN2B	TTN9D8E	moderate	Genetic Variation	[23]
GRK5	TTTCXO0	moderate	Genetic Variation	[23]
HDAC3	TT4YWTO	moderate	Biomarker	[195]
HDAC4	TTTQGH8	moderate	Genetic Variation	[23]
HMGA2	TTSTVM0	moderate	Altered Expression	[196]
IGFBP2	TTU4QSN	moderate	Biomarker	[197]
IL15	TTJFA35	moderate	Biomarker	[198]
IL15RA	TTGN89I	moderate	Genetic Variation	[23]
KCNB2	TT5PFNG	moderate	Genetic Variation	[23]
KCNH1	TT9XKUC	moderate	Genetic Variation	[23]
KCNN1	TT9R6BE	moderate	Genetic Variation	[23]
KISS1	TTU2O6T	moderate	Genetic Variation	[23]
LYZ	TTAOZBW	moderate	Altered Expression	[199]
MAP3K19	TTRHJA3	moderate	Genetic Variation	[23]
MMP3	TTUZ2L5	moderate	Genetic Variation	[23]
MTTP	TTUS1RD	moderate	Biomarker	[200]
NR5A2	TTAU3SY	moderate	Biomarker	[201]
NRP1	TTIPJCB	moderate	Genetic Variation	[23]
PABPC1	TTHC8EF	moderate	Genetic Variation	[23]
PDCD1	TTNBFWK	moderate	Biomarker	[202]
PDGFD	TTSN0GA	moderate	Genetic Variation	[23]
PEBP1	TT1BGU8	moderate	Biomarker	[203]
PHGDH	TT8DRCK	moderate	Genetic Variation	[23]
PIN1	TTJNTSI	moderate	Altered Expression	[204]
PRTN3	TT5MLC4	moderate	Biomarker	[205]
RARG	TT1Q3IE	moderate	Biomarker	[206]
ROR1	TTDEJAU	moderate	Genetic Variation	[23]
RPSA	TTLUW5B	moderate	Biomarker	[207]
S100A3	TTCDFR1	moderate	Altered Expression	[208]
SELL	TT2IYXF	moderate	Biomarker	[209]
SGCG	TTSMT9W	moderate	Genetic Variation	[23]
SLC1A6	TT6KMPN	moderate	Genetic Variation	[23]
SLC30A8	TTXIGT7	moderate	Genetic Variation	[23]
SMYD3	TTKLJYX	moderate	Genetic Variation	[23]
STAB1	TTJFEOC	moderate	Genetic Variation	[23]
SYK	TT2HUPM	moderate	Biomarker	[210]
TF	TT8WXAV	moderate	Genetic Variation	[23]
TLR2	TTY7ZHS	moderate	Biomarker	[211]
TLR9	TTSHG0T	moderate	Genetic Variation	[212]
TNFRSF18	TTG6LA7	moderate	Biomarker	[213]
TOP2B	TT4NVEM	moderate	Altered Expression	[214]
USP13	TTVJIO2	moderate	Genetic Variation	[23]
WEE1	TTJFOAL	moderate	Biomarker	[215]
WRN	TT2H5WQ	moderate	Genetic Variation	[23]
ZAP70	TTUMHT8	moderate	Genetic Variation	[23]
ABCC2	TTFLHJV	Strong	Altered Expression	[216]
ACKR3	TTRQJTC	Strong	Biomarker	[217]
ACLY	TT0Z6Y2	Strong	Altered Expression	[218]
ADGRL1	TTM5OJN	Strong	Altered Expression	[219]
ADGRL3	TTQST3U	Strong	Genetic Variation	[219]
ADM	TTV14YH	Strong	Biomarker	[220]
ADRA1A	TTNGILX	Strong	Biomarker	[217]
ADRA2B	TTWM4TY	Strong	Biomarker	[217]
ANGPT1	TTWNQ1T	Strong	Biomarker	[221]
ANGPT2	TTKLQTJ	Strong	Biomarker	[222]
ANK1	TTKFPMH	Strong	Altered Expression	[223]
ANXA5	TT2Z83I	Strong	Biomarker	[224]
ANXA8	TTSW16P	Strong	Altered Expression	[225]
APOA4	TTNC3WS	Strong	Altered Expression	[226]
AQP9	TTQEI32	Strong	Therapeutic	[227]
ARHGEF3	TT1R5DZ	Strong	Altered Expression	[228]
ATR	TT8ZYBQ	Strong	Biomarker	[229]
AURKA	TTPS3C0	Strong	Biomarker	[230]
AURKB	TT9RTBL	Strong	Biomarker	[231]
BBC3	TT7JUKC	Strong	Altered Expression	[232]
BCAT1	TTES57P	Strong	Altered Expression	[233]
BCL2A1	TTGT9C7	Strong	Biomarker	[234]
BCL2L1	TTRE6AX	Strong	Biomarker	[235]
BMPR2	TTGKF90	Strong	Altered Expression	[236]
BMX	TTN2I9E	Strong	Biomarker	[237]
BRCA2	TTUARD6	Strong	Genetic Variation	[238]
BRD4	TTSRAOU	Strong	Biomarker	[141]
BRD9	TTR7L5Y	Strong	Altered Expression	[239]
BRIP1	TTZV7LJ	Strong	Biomarker	[240]
BRS3	TTKYEPM	Strong	Biomarker	[217]
BTLA	TTER58P	Strong	Biomarker	[241]
C5AR1	TTHXFA1	Strong	Biomarker	[242]
CACNA1G	TT729IR	Strong	Posttranslational Modification	[243]
CALCRL	TTY6O0Q	Strong	Altered Expression	[244]
CAPN1	TT1WBIJ	Strong	Biomarker	[245]
CAPN2	TTG5QB7	Strong	Biomarker	[224]
CARM1	TTIZQFJ	Strong	Biomarker	[246]
CASP7	TTM7Y45	Strong	Biomarker	[224]
CBL	TT7QT13	Strong	Genetic Variation	[247]
CBS	TTVZJ7G	Strong	Altered Expression	[248]
CCL3	TT8I4WB	Strong	Biomarker	[249]
CCN1	TTPK79J	Strong	Genetic Variation	[250]
CD27	TTDO1MV	Strong	Biomarker	[251]
CD276	TT6CQUM	Strong	Altered Expression	[252]
CD300A	TTI2YFK	Strong	Altered Expression	[253]
CD44	TTWFBT7	Strong	Biomarker	[113]
CD52	TTQT5S9	Strong	Altered Expression	[254]
CD55	TT5Z9WY	Strong	Biomarker	[255]
CD7	TTP6B8O	Strong	Biomarker	[256]
CD70	TTNCIE0	Strong	Biomarker	[251]
CD74	TTCMYP9	Strong	Biomarker	[113]
CD86	TT53XHB	Strong	Altered Expression	[257]
CD9	TTZEIBV	Strong	Altered Expression	[258]
CDC25C	TTESBNC	Strong	Biomarker	[259]
CDH2	TT1WS0T	Strong	Altered Expression	[260]
CDK19	TTNABU9	Strong	Altered Expression	[261]
CDK6	TTO0FDJ	Strong	Biomarker	[262]
CDK7	TTQYF7G	Strong	Biomarker	[263]
CDKL1	TTBTI6P	Strong	Biomarker	[264]
CDKN1C	TTBSUAR	Strong	Genetic Variation	[265]
CEL	TTTRNQW	Strong	Genetic Variation	[266]
CFLAR	TTJZQYH	Strong	Biomarker	[267]
CGA	TTFC29G	Strong	Genetic Variation	[268]
CGB3	TTUH273	Strong	Genetic Variation	[268]
CHIT1	TTDYX6T	Strong	Genetic Variation	[269]
CLEC4C	TT7YT06	Strong	Genetic Variation	[23]
CMA1	TT8VUE0	Strong	Altered Expression	[270]
CNTFR	TTT2F9E	Strong	Biomarker	[271]
CR1	TTEA8OW	Strong	Biomarker	[255]
CREBBP	TTFRCTK	Strong	Genetic Variation	[272]
CRLF2	TTRMZ0N	Strong	Genetic Variation	[273]
CSNK1A1	TTFQEMX	Strong	Biomarker	[263]
CTCFL	TTY0RZT	Strong	Biomarker	[274]
CTDSP1	TTHZAF0	Strong	Biomarker	[275]
CTSG	TTQAJF1	Strong	Biomarker	[276]
CTSH	TT3G406	Strong	Biomarker	[224]
CTSK	TTDZN01	Strong	Biomarker	[277]
CXCL2	TTZF0K2	Strong	Biomarker	[278]
CXCL9	TTWE5PB	Strong	Biomarker	[279]
CXCR6	TT2BVUA	Strong	Biomarker	[217]
CYBB	TT5T8MR	Strong	Biomarker	[280]
CYP2C19	TTZ58XG	Strong	Genetic Variation	[281]
CYP2D6	TTVG215	Strong	Genetic Variation	[282]
CYP2E1	TTWVHQ5	Strong	Genetic Variation	[23]
DBH	TTYIP79	Strong	Biomarker	[283]
DHODH	TTLVP78	Strong	Biomarker	[284]
DICER1	TTTEOPU	Strong	Altered Expression	[285]
DOT1L	TTSZ8T1	Strong	Biomarker	[286]
DPP8	TTJGLZF	Strong	Biomarker	[287]
DPP9	TTNDUL7	Strong	Biomarker	[287]
DYRK1A	TTSBVFO	Strong	Biomarker	[288]
E2F3	TTWIJYH	Strong	Altered Expression	[289]
EBI3	TTJF68X	Strong	Biomarker	[290]
EDNRA	TTKRD0G	Strong	Biomarker	[217]
EGFL7	TT7WD0H	Strong	Biomarker	[291]
EHMT2	TTS6RZT	Strong	Biomarker	[292]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[293]
ENAH	TTY36UA	Strong	Biomarker	[294]
EP300	TTGH73N	Strong	Altered Expression	[295]
EPHA1	TTLFZVU	Strong	Altered Expression	[296]
EPHB4	TTI4ZX2	Strong	Biomarker	[297]
ERN1	TTKIAT3	Strong	Biomarker	[298]
ESRRB	TTKF0XS	Strong	Biomarker	[299]
EYA2	TTUY9C6	Strong	Biomarker	[300]
F11R	TT3C8EG	Strong	Biomarker	[178]
F2R	TTL935N	Strong	Altered Expression	[301]
FANCA	TTV5HJS	Strong	Biomarker	[240]
FANCF	TTNZKFJ	Strong	Biomarker	[240]
FAS	TT7LTUJ	Strong	Altered Expression	[302]
FCGR1A	TTZK4I3	Strong	Biomarker	[303]
FCGR3A	TTIFOC0	Strong	Biomarker	[112]
FCGRT	TTKLPHO	Strong	Biomarker	[304]
FER	TTRA9G0	Strong	Genetic Variation	[305]
FGF19	TTGCH11	Strong	Altered Expression	[306]
FHIT	TTMS54D	Strong	Genetic Variation	[23]
FOXM1	TTD3KOX	Strong	Biomarker	[307]
FOXP1	TT0MUCI	Strong	Genetic Variation	[23]
FTH1	TT975ZT	Strong	Altered Expression	[308]
GAS6	TT69QD2	Strong	Altered Expression	[309]
GHRHR	TTG4R8V	Strong	Biomarker	[310]
GLI2	TT045OH	Strong	Biomarker	[311]
GLIPR1	TTEQF1O	Strong	Biomarker	[312]
GLUL	TTURQ2G	Strong	Biomarker	[313]
GPER1	TTDSB34	Strong	Biomarker	[314]
GPR132	TTNBW4F	Strong	Biomarker	[315]
GPR84	TTG0MQD	Strong	Biomarker	[316]
GPRC5D	TTHRAPJ	Strong	Biomarker	[315]
GRN	TT0LWE3	Strong	Biomarker	[166]
GUSB	TTHS7CM	Strong	Biomarker	[317]
GZMB	TTKEPHX	Strong	Altered Expression	[318]
HCK	TT42OGM	Strong	Biomarker	[319]
HDAC2	TTSHTOI	Strong	Biomarker	[320]
HDAC8	TTT6LFV	Strong	Biomarker	[321]
HDC	TTV9GOF	Strong	Biomarker	[103]
HGF	TT4V2JM	Strong	Biomarker	[65]
HMOX1	TTI6V2A	Strong	Biomarker	[322]
HNF4A	TT2F3CD	Strong	Biomarker	[323]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[324]
HOXA11	TTEX4ZA	Strong	Altered Expression	[325]
HOXA5	TTXSVQP	Strong	Posttranslational Modification	[326]
HOXA7	TTMRE4Q	Strong	Biomarker	[327]
HSPA9	TTMTPG3	Strong	Biomarker	[328]
HSPB1	TT9AZWY	Strong	Altered Expression	[329]
HTR1B	TTK8CXU	Strong	Altered Expression	[330]
ICOS	TTE5VP6	Strong	Altered Expression	[331]
ID1	TTBXVDE	Strong	Altered Expression	[332]
IFNAR1	TTSYFMA	Strong	Biomarker	[333]
IGFBP7	TTUQ01B	Strong	Biomarker	[334]
IKZF2	TTKT5NV	Strong	Biomarker	[335]
IL1R1	TTWOTEA	Strong	Biomarker	[336]
IL1RAP	TTWS50K	Strong	Biomarker	[337]
IL7	TT8FRMO	Strong	Altered Expression	[220]
IMP3	TTEJA2R	Strong	Biomarker	[338]
IRAK1	TTXAJWN	Strong	Biomarker	[339]
IRAK4	TTILUKB	Strong	Biomarker	[340]
IRF8	TTHUBNK	Strong	Genetic Variation	[341]
ITGAL	TT48WR6	Strong	Altered Expression	[342]
ITGAV	TTT1R2L	Strong	Altered Expression	[343]
ITGB2	TTIJWR7	Strong	Biomarker	[344]
ITPR1	TT5HWAT	Strong	Altered Expression	[345]
JUN	TTS7IR5	Strong	Biomarker	[346]
KAT6B	TTH4VJL	Strong	Genetic Variation	[347]
KCNH2	TTQ6VDM	Strong	Altered Expression	[348]
KCNJ5	TTEO25X	Strong	Biomarker	[349]
KDM1A	TTNR0UQ	Strong	Altered Expression	[350]
KDM4A	TTZHPB8	Strong	Biomarker	[351]
KDM4C	TTV8CRH	Strong	Biomarker	[352]
KDM5A	TTIG67W	Strong	Biomarker	[353]
KDM5B	TTCLI75	Strong	Biomarker	[353]
KDM6B	TTDIJUQ	Strong	Biomarker	[354]
KIR2DS2	TTV3CFI	Strong	Genetic Variation	[355]
KLF4	TTTI53X	Strong	Biomarker	[356]
LAG3	TTNVXAW	Strong	Biomarker	[66]
LAIR1	TTSI7A8	Strong	Biomarker	[357]
LAMP2	TTULDG7	Strong	Altered Expression	[358]
LATS2	TTML7FG	Strong	Altered Expression	[359]
LCK	TT860QF	Strong	Biomarker	[360]
LIFR	TTID542	Strong	Genetic Variation	[361]
LILRB2	TTHC6XU	Strong	Biomarker	[362]
LILRB4	TTREOKA	Strong	Altered Expression	[363]
LIN28A	TTO50LN	Strong	Biomarker	[364]
LIPE	TTLUQ8E	Strong	Biomarker	[365]
LONP1	TTM1VPZ	Strong	Altered Expression	[139]
LPAR1	TTQ6S1K	Strong	Biomarker	[224]
LPAR2	TTB7Y8I	Strong	Biomarker	[217]
LTB	TTHQ6US	Strong	Altered Expression	[366]
LYN	TT1RWNJ	Strong	Biomarker	[367]
MAGEA3	TTWSKHD	Strong	Altered Expression	[368]
MAP3K10	TT9FN4J	Strong	Biomarker	[369]
MAP3K5	TTOQCD8	Strong	Biomarker	[370]
MAP4K1	TTSHWUP	Strong	Altered Expression	[371]
MAPK7	TTU6FSC	Strong	Biomarker	[372]
MARK2	TTAJ45Y	Strong	Biomarker	[373]
MELK	TTBZOTY	Strong	Biomarker	[374]
MERTK	TTO7LKR	Strong	Altered Expression	[375]
MIA	TT5HNVS	Strong	Biomarker	[310]
MKNK1	TTEZAUX	Strong	Biomarker	[376]
MKNK2	TTRECN3	Strong	Biomarker	[377]
MPL	TTIHYA4	Strong	Biomarker	[378]
MS4A1	TTUE541	Strong	Biomarker	[379]
MSI1	TTSM4BA	Strong	Biomarker	[124]
MUC1	TTBHFYQ	Strong	Altered Expression	[380]
NCF1	TTZ4JC3	Strong	Biomarker	[381]
NES	TTHZ752	Strong	Altered Expression	[382]
NME1	TTDY8JH	Strong	Genetic Variation	[383]
NOP2	TTBLG3H	Strong	Biomarker	[384]
NOTCH2	TT82FVD	Strong	Altered Expression	[385]
NOTCH4	TTXDIK2	Strong	Genetic Variation	[386]
NR1H2	TTXA6PH	Strong	Genetic Variation	[387]
NRP2	TTRXUVC	Strong	Biomarker	[388]
NSD1	TTTSJ3H	Strong	Genetic Variation	[389]
OGG1	TTRU01G	Strong	Altered Expression	[390]
P2RY14	TT72OKI	Strong	Altered Expression	[391]
PAK4	TT7Y3BZ	Strong	Biomarker	[392]
PARG	TT39J16	Strong	Biomarker	[393]
PAWR	TT3I4WV	Strong	Altered Expression	[394]
PBK	TTMY6BZ	Strong	Altered Expression	[395]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[396]
PDE4B	TTVIAT9	Strong	Biomarker	[224]
PDGFRB	TTI7421	Strong	Biomarker	[397]
PDK1	TTCZOF2	Strong	Altered Expression	[398]
PDK2	TTJGCKM	Strong	Altered Expression	[399]
PDK3	TTDEQIP	Strong	Altered Expression	[399]
PFKFB3	TTTHMQJ	Strong	Biomarker	[400]
PIM2	TT69J2Z	Strong	Altered Expression	[401]
PLAUR	TTNOSTX	Strong	Altered Expression	[402]
PLCB1	TTLPGU7	Strong	Biomarker	[403]
PLCG1	TT6T4JI	Strong	Altered Expression	[404]
PMEL	TT8MK59	Strong	Biomarker	[405]
PPME1	TTXQ54R	Strong	Altered Expression	[406]
PRDX4	TTPBL9I	Strong	Altered Expression	[407]
PRDX5	TTLPJWH	Strong	Altered Expression	[408]
PREP	TTNGKET	Strong	Biomarker	[409]
PRKCA	TTFJ8Q1	Strong	Biomarker	[410]
PRKCD	TT7A1BO	Strong	Altered Expression	[411]
PRKCH	TTONI0R	Strong	Altered Expression	[412]
PRKDC	TTK3PY9	Strong	Genetic Variation	[413]
PRMT1	TTVOJAI	Strong	Biomarker	[414]
PRMT5	TTR1D7X	Strong	Altered Expression	[415]
PSMB9	TTOUSTQ	Strong	Genetic Variation	[416]
PTBP1	TTWMX0U	Strong	Biomarker	[417]
PTK7	TTXH2ZN	Strong	Altered Expression	[418]
PTP4A2	TT1MHKD	Strong	Altered Expression	[419]
PTP4A3	TT7YM8D	Strong	Biomarker	[420]
PTPRC	TTUS45N	Strong	Biomarker	[421]
RAC1	TT2M9CG	Strong	Altered Expression	[422]
REL	TT1ZCTH	Strong	Biomarker	[423]
REN	TTB2MXP	Strong	Biomarker	[424]
RET	TT4DXQT	Strong	Biomarker	[425]
RGS2	TTKB7T3	Strong	Biomarker	[224]
RNF6	TT4S09X	Strong	Biomarker	[426]
ROBO4	TT3S9TY	Strong	Altered Expression	[427]
RPS6KA1	TTIXKA4	Strong	Biomarker	[428]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[429]
RTN4R	TTVRZUO	Strong	Biomarker	[430]
RUNX1	TTWIN3H	Strong	Autosomal dominant	[185]
RXRA	TT6PEUO	Strong	Altered Expression	[431]
S100A9	TT0TMQG	Strong	Altered Expression	[432]
S1PR2	TTVSMOH	Strong	Biomarker	[433]
S1PR3	TTDYP7I	Strong	Altered Expression	[434]
SCN4A	TT84DRB	Strong	Biomarker	[220]
SELPLG	TTS5K8U	Strong	Biomarker	[435]
SEMA3A	TTVKD3S	Strong	Altered Expression	[436]
SEPTIN6	TTAGE7U	Strong	Altered Expression	[437]
SF3B1	TTL2WUI	Strong	Altered Expression	[121]
SGK1	TTTV8EJ	Strong	Biomarker	[224]
SIK1	TT1H6LC	Strong	Biomarker	[438]
SIK3	TTW6L4V	Strong	Biomarker	[439]
SLC12A3	TTP362L	Strong	Biomarker	[440]
SLC19A1	TT09I7D	Strong	Genetic Variation	[441]
SLC22A16	TTITAVR	Strong	Altered Expression	[442]
SLC29A1	TTLXAKE	Strong	Altered Expression	[443]
SLC38A1	TT1YE9Z	Strong	Biomarker	[444]
SLC3A2	TT5CZSM	Strong	Biomarker	[445]
SLC40A1	TT6Y1PG	Strong	Altered Expression	[446]
SLC7A5	TTPH2JB	Strong	Biomarker	[445]
SLCO1B1	TTFGXEB	Strong	Biomarker	[447]
SMAD1	TT9GR53	Strong	Biomarker	[448]
SMAD6	TTON5JB	Strong	Altered Expression	[448]
SMYD2	TT7YJFO	Strong	Altered Expression	[449]
SOCS3	TTI0ME6	Strong	Posttranslational Modification	[450]
SPARC	TTBQFM7	Strong	Biomarker	[451]
SPTBN1	TTS9BDA	Strong	Genetic Variation	[23]
SRGN	TTCHB06	Strong	Altered Expression	[452]
SRPK1	TTU3WV6	Strong	Biomarker	[453]
SRR	TTZFUY6	Strong	Altered Expression	[454]
SSTR4	TTAE1BR	Strong	Biomarker	[217]
STAT3	TTHJT3X	Strong	Altered Expression	[396]
STAT6	TTWOE1T	Strong	Biomarker	[455]
STC1	TTDLUER	Strong	Altered Expression	[456]
TBK1	TTMP03S	Strong	Biomarker	[457]
TBX21	TTNF9PH	Strong	Altered Expression	[458]
TDG	TTEXRQD	Strong	Biomarker	[459]
TEK	TT9VGXW	Strong	Genetic Variation	[460]
TERT	TTQY2EJ	Strong	Autosomal dominant	[185]
TERT	TTQY2EJ	Strong	Biomarker	[461]
TFRC	TT8MG4S	Strong	Biomarker	[462]
THPO	TTCG5PE	Strong	Biomarker	[463]
TIAM1	TTNU6I5	Strong	Altered Expression	[464]
TIGIT	TTWNL74	Strong	Altered Expression	[465]
TLR7	TTRJ1K4	Strong	Biomarker	[466]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[467]
TNFRSF14	TTWGTC1	Strong	Altered Expression	[241]
TNFRSF1B	TT63WSF	Strong	Altered Expression	[468]
TNFRSF4	TTL31H0	Strong	Biomarker	[331]
TNFRSF8	TT2GM5R	Strong	Biomarker	[469]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[470]
TNFSF10	TTA5MS9	Strong	Biomarker	[471]
TNFSF13	TTOI1RM	Strong	Biomarker	[472]
TNFSF4	TTBW580	Strong	Biomarker	[331]
TNKS	TTVUSO7	Strong	Genetic Variation	[473]
TOP2A	TTCGY2K	Strong	Biomarker	[474]
TRAF6	TTCDR6M	Strong	Biomarker	[475]
TRH	TT2Z39D	Strong	Biomarker	[476]
TRPM2	TTEBMN7	Strong	Altered Expression	[477]
TRPV2	TTBECWA	Strong	Biomarker	[478]
TSG101	TTHU7JA	Strong	Biomarker	[479]
TUBB2A	TTJ2PTI	Strong	Biomarker	[224]
TUSC2	TTJ8O14	Strong	Altered Expression	[87]
TXNIP	TTTLDZK	Strong	Altered Expression	[480]
TXNRD1	TTR7UJ3	Strong	Biomarker	[481]
UBE2E2	TTXJEOF	Strong	Biomarker	[482]
UBE2T	TT0A1R8	Strong	Biomarker	[240]
ULK1	TT4D7MJ	Strong	Altered Expression	[483]
USP10	TT5IH09	Strong	Biomarker	[484]
USP2	TTUEQ1W	Strong	Biomarker	[485]
VEGFC	TT0QUFV	Strong	Biomarker	[486]
VEGFD	TTOM5H4	Strong	Biomarker	[487]
VSIR	TT51SK8	Strong	Biomarker	[488]
WAS	TTE8T73	Strong	Genetic Variation	[489]
WNK1	TTJ9UMX	Strong	Biomarker	[490]
WNT5A	TTKG7F8	Strong	Biomarker	[323]
WWP1	TTBWMKT	Strong	Biomarker	[491]
ABCC4	TTUEAFL	Definitive	Genetic Variation	[492]
ADAMTS13	TTUREBK	Definitive	Altered Expression	[493]
ALOX12	TT12ABZ	Definitive	Biomarker	[494]
ALPI	TTHYMUV	Definitive	Biomarker	[495]
ATF4	TTQCKWT	Definitive	Genetic Variation	[496]
BACH1	TT2ME4S	Definitive	Biomarker	[497]
BIRC2	TTQ5LRD	Definitive	Altered Expression	[498]
CBLB	TTHRAIJ	Definitive	Genetic Variation	[499]
CBR1	TTVG0SN	Definitive	Altered Expression	[500]
CBX7	TTBN3HC	Definitive	Altered Expression	[501]
CCL11	TTCF05Y	Definitive	Altered Expression	[502]
CD22	TTM6QSK	Definitive	Altered Expression	[503]
CEBPA	TT5LWG1	Definitive	Autosomal dominant	[504]
COASY	TT4YO0Z	Definitive	Altered Expression	[505]
COL18A1	TT63DI9	Definitive	Genetic Variation	[23]
CSF1R	TT7MRDV	Definitive	Altered Expression	[65]
CXCL13	TT0NIZ1	Definitive	Posttranslational Modification	[506]
DCPS	TTLSW9V	Definitive	Biomarker	[507]
DDX58	TTVB0O3	Definitive	Biomarker	[508]
DFFB	TT2SRE0	Definitive	Biomarker	[509]
DIABLO	TTN74LE	Definitive	Altered Expression	[510]
DLL4	TTV23LH	Definitive	Altered Expression	[511]
DNMT3L	TT3FDAV	Definitive	Genetic Variation	[512]
ENPP3	TTD4TKP	Definitive	Biomarker	[513]
FAT1	TTGUJYV	Definitive	Altered Expression	[514]
FGR	TTPOGS1	Definitive	Altered Expression	[515]
FOXO1	TTLRVIA	Definitive	Biomarker	[516]
FSCN1	TTTRS9B	Definitive	Biomarker	[517]
GGH	TTZJRL0	Definitive	Genetic Variation	[518]
GPRC6A	TTI1PRE	Definitive	Biomarker	[519]
GSK3A	TTQWAU1	Definitive	Biomarker	[520]
HDAC6	TT5ZKDI	Definitive	Biomarker	[521]
HIPK2	TTOB49C	Definitive	Biomarker	[522]
IAPP	TTHN8EM	Definitive	Biomarker	[495]
ICOSLG	TTB9Z8R	Definitive	Altered Expression	[523]
ID2	TTW8A5N	Definitive	Altered Expression	[524]
IL1RL1	TT4GZA4	Definitive	Biomarker	[525]
IL7R	TTAWI51	Definitive	Altered Expression	[526]
ILK	TT7ALZG	Definitive	Biomarker	[527]
ITGA2	TTSJ542	Definitive	Genetic Variation	[528]
ITGA5	TTHIZP9	Definitive	Altered Expression	[343]
JMJD1C	TTBISK4	Definitive	Altered Expression	[529]
KCNQ1	TT846HF	Definitive	Biomarker	[530]
KHDRBS1	TTAT6C7	Definitive	Altered Expression	[531]
LPAR3	TTE2YJR	Definitive	Biomarker	[519]
MAD1L1	TTNE9U7	Definitive	Altered Expression	[532]
MMP15	TTNSTO3	Definitive	Biomarker	[533]
MRGPRX1	TTIX6PK	Definitive	Biomarker	[519]
MTR	TTUTO39	Definitive	Genetic Variation	[534]
MYCN	TT9JBY5	Definitive	Biomarker	[535]
NCL	TTK1V5Q	Definitive	Biomarker	[536]
NELL1	TT7H4BF	Definitive	Genetic Variation	[23]
OPRK1	TTQW87Y	Definitive	Biomarker	[537]
OXER1	TT7WBSV	Definitive	Biomarker	[519]
PLA2R1	TTHKW7D	Definitive	Biomarker	[538]
PNLIP	TTXMY0J	Definitive	Biomarker	[539]
PTPN1	TTELIN2	Definitive	Biomarker	[540]
PTPRJ	TTWMKXP	Definitive	Biomarker	[541]
RACK1	TTJ10AL	Definitive	Biomarker	[542]
RALBP1	TTVSRUA	Definitive	Biomarker	[543]
RIPK1	TTVJHX8	Definitive	Biomarker	[543]
ROCK1	TTZN7RP	Definitive	Biomarker	[544]
RRM2	TT1S4LJ	Definitive	Altered Expression	[545]
RUNX3	TTKCVO7	Definitive	Altered Expression	[149]
S100A12	TTQ4ESF	Definitive	Biomarker	[183]
SAA1	TTY0DN9	Definitive	Altered Expression	[226]
SCN10A	TT90XZ8	Definitive	Altered Expression	[546]
SETD2	TTPC3H4	Definitive	Genetic Variation	[547]
SETD7	TTJ0FSU	Definitive	Biomarker	[449]
SGO1	TTBPKGD	Definitive	Biomarker	[548]
SIK2	TTCUGZR	Definitive	Biomarker	[549]
SIRPA	TTBRJS9	Definitive	Altered Expression	[550]
SLC1A5	TTF7WRM	Definitive	Biomarker	[551]
SLC22A1	TTM5Q4V	Definitive	Biomarker	[552]
SLC9A1	TTGSEFH	Definitive	Altered Expression	[553]
SMPD1	TTJTM88	Definitive	Genetic Variation	[554]
SPN	TTOZAX0	Definitive	Biomarker	[555]
SVIL	TTBLQS5	Definitive	Genetic Variation	[23]
TCL1A	TTUKRDV	Definitive	Genetic Variation	[556]
TP53BP1	TTX4UE9	Definitive	Biomarker	[557]
TYRO3	TTIEMFN	Definitive	Altered Expression	[314]
UBE3A	TTUZX6V	Definitive	Biomarker	[558]
USP1	TTG9MT5	Definitive	Biomarker	[559]
WDR5	TT7OFWB	Definitive	Biomarker	[560]

This Disease Is Related to 22 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC5	DTYVM24	Limited	Biomarker	[561]
SLC5A8	DTE3TAW	Limited	Biomarker	[562]
SLCO6A1	DTIFXNS	Limited	Genetic Variation	[99]
ABCA3	DT2T6VQ	moderate	Altered Expression	[563]
SLC1A4	DTC54PX	moderate	Genetic Variation	[23]
SLC20A2	DTFD4VB	moderate	Genetic Variation	[23]
SLC34A1	DT42EWA	moderate	Genetic Variation	[23]
SLC35F3	DTEHSG0	moderate	Genetic Variation	[23]
SLC39A11	DTEOAND	moderate	Genetic Variation	[23]
SLC9A9	DT8LP62	moderate	Genetic Variation	[23]
ABCB5	DTKVEXO	Strong	Altered Expression	[564]
ABCC11	DTWN7FC	Strong	Genetic Variation	[166]
ATP7A	DT0LT17	Strong	Biomarker	[565]
SLC22A4	DT2EG60	Strong	Altered Expression	[566]
SLC25A10	DTJYKDQ	Strong	Altered Expression	[567]
SLC25A19	DTT82QK	Strong	Genetic Variation	[568]
SLC25A3	DTCRIWV	Strong	Altered Expression	[569]
SLC27A5	DT0TQS3	Strong	Genetic Variation	[266]
SLC28A3	DT4YL5R	Strong	Altered Expression	[570]
SLC2A3	DT9SQ3L	Strong	Biomarker	[571]
SLC2A5	DTOR02F	Strong	Biomarker	[572]
SLC4A1	DTB0Q3P	Strong	Biomarker	[573]

This Disease Is Related to 35 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACP3	DEDW5H6	Limited	Altered Expression	[574]
AKR1C4	DEAJN47	Limited	Biomarker	[575]
BAAT	DERA3OF	Limited	Biomarker	[576]
BCO1	DE6BOK3	Limited	Genetic Variation	[23]
EPHX1	DELB4KP	Limited	Altered Expression	[577]
FARS2	DE0WGR8	Limited	Genetic Variation	[23]
HPRT1	DEVXTP5	Limited	Biomarker	[578]
LAP3	DENZF0O	Limited	Genetic Variation	[23]
NT5C	DE4E31Z	Limited	Altered Expression	[579]
PCYT1A	DEQYXD4	Limited	Biomarker	[580]
UBASH3B	DE10BJ5	Limited	Biomarker	[581]
G6PC3	DEE1B8O	Disputed	Genetic Variation	[582]
GCLC	DESYL1F	Disputed	Biomarker	[179]
SULT1A1	DEYWLRK	Disputed	Altered Expression	[583]
ADH4	DEOCWU3	moderate	Genetic Variation	[23]
CYP4F12	DED26GV	moderate	Genetic Variation	[23]
DDAH1	DEY0TQC	moderate	Genetic Variation	[23]
GLS	DE3E0VT	moderate	Biomarker	[584]
MGST1	DEAPJSO	moderate	Genetic Variation	[23]
MTARC1	DE1VDSF	moderate	Genetic Variation	[23]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[585]
CMPK1	DEMPH4I	Strong	Biomarker	[279]
CYP7A1	DEDZRQ1	Strong	Biomarker	[586]
EGLN3	DEMQTKH	Strong	Genetic Variation	[23]
GSTM1	DEYZEJA	Strong	Biomarker	[587]
NAT2	DER7TA0	Strong	Genetic Variation	[588]
PMM2	DEBRX3L	Strong	Biomarker	[589]
SCLY	DEH4TD6	Strong	Altered Expression	[590]
TGM6	DEUWCVD	Strong	Biomarker	[591]
TPMT	DEFQ8VO	Strong	Altered Expression	[592]
ABO	DESIA7R	Definitive	Biomarker	[593]
ASNS	DEXISVQ	Definitive	Altered Expression	[594]
CBR3	DEIVKZ8	Definitive	Biomarker	[500]
NAT10	DEZV4AP	Definitive	Altered Expression	[595]
UGP2	DE4U39Y	Definitive	Biomarker	[505]

This Disease Is Related to 1355 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CHIC2	OTNE3T6Z	No Known	Unknown	[596]
ABI1	OT5H4M62	Limited	Genetic Variation	[597]
ACOXL	OTW680HT	Limited	Genetic Variation	[23]
ACSL5	OT3L9XO3	Limited	Biomarker	[598]
ACSL6	OT0TT8P8	Limited	Biomarker	[599]
ADAM23	OTVWT6JZ	Limited	Genetic Variation	[23]
ADAMTS9	OTV3Q0DS	Limited	Genetic Variation	[23]
ADARB2	OTDJKS39	Limited	Genetic Variation	[23]
ADD1	OTTF68DC	Limited	Genetic Variation	[600]
ADD2	OTRCPCD2	Limited	Genetic Variation	[23]
ADGRB3	OT1EWGRW	Limited	Genetic Variation	[23]
ADGRG1	OTQBB8NT	Limited	Biomarker	[601]
AGFG2	OTXQZHCR	Limited	Altered Expression	[602]
AHI1	OT8K2YWY	Limited	Genetic Variation	[23]
ALX4	OTNS9A29	Limited	Genetic Variation	[23]
AMER1	OT8EFJPM	Limited	Genetic Variation	[603]
ANKRD16	OTZD4JUO	Limited	Genetic Variation	[23]
ANKRD28	OTRBREQ9	Limited	Biomarker	[505]
AP3B1	OTYTIH5Q	Limited	Genetic Variation	[23]
APOBEC3B	OTHLNI51	Limited	Genetic Variation	[604]
APTX	OTPAS5G8	Limited	Biomarker	[605]
ARHGAP31	OTUYTF4I	Limited	Genetic Variation	[23]
ARHGEF10L	OTUAMHIZ	Limited	Genetic Variation	[23]
ARHGEF12	OTM2D3LT	Limited	Biomarker	[606]
ARHGEF2	OTBQTFRT	Limited	Biomarker	[606]
ARHGEF33	OTHJW0AL	Limited	Genetic Variation	[23]
ARHGEF7	OT9BPJCL	Limited	Biomarker	[607]
ARID1B	OTILK3Q7	Limited	Biomarker	[608]
ARID3A	OTZZ4SFP	Limited	Biomarker	[608]
ARID5A	OTQT7CG9	Limited	Genetic Variation	[23]
ARNT	OTMSIEZY	Limited	Altered Expression	[609]
ARR3	OTRZ00CH	Limited	Biomarker	[42]
ARSD	OTAHW9M8	Limited	Biomarker	[610]
ARTN	OTWIWGL6	Limited	Genetic Variation	[24]
ASCC1	OTH4VAP9	Limited	Biomarker	[607]
ASF1B	OTKXX12I	Limited	Genetic Variation	[23]
ATAD1	OTJ02XFL	Limited	Biomarker	[611]
ATF1	OT251CI0	Limited	Genetic Variation	[612]
ATP8A2	OTDZC2ZT	Limited	Genetic Variation	[23]
ATP8B1	OTALGS63	Limited	Genetic Variation	[23]
B3GALT5	OTWXPEMU	Limited	Genetic Variation	[23]
BCL2L11	OTNQQWFJ	Limited	Biomarker	[428]
BCL3	OT1M5B95	Limited	Biomarker	[613]
BID	OTOSHSHU	Limited	Genetic Variation	[23]
BLVRB	OTHCFN2C	Limited	Genetic Variation	[614]
BTBD9	OTWQ6GA3	Limited	Genetic Variation	[23]
C10orf90	OT6DNZC4	Limited	Genetic Variation	[23]
C4orf19	OTJMU7N6	Limited	Genetic Variation	[23]
CAMK1D	OTU24HAU	Limited	Genetic Variation	[23]
CAMK1G	OT1VEDLV	Limited	Genetic Variation	[23]
CAMLG	OTTSRY39	Limited	Altered Expression	[615]
CAV2	OT1FGRQX	Limited	Genetic Variation	[23]
CBFA2T2	OTNOIB23	Limited	Biomarker	[616]
CBFB	OTIAC6W4	Limited	Unknown	[617]
CC2D2A	OTFGRGFR	Limited	Genetic Variation	[23]
CCDC3	OTUE809X	Limited	Genetic Variation	[23]
CCL19	OTQ2UJMH	Limited	Genetic Variation	[23]
CCL3L1	OTQXCYB1	Limited	Biomarker	[618]
CCN3	OTOW5YL4	Limited	Biomarker	[619]
CCN4	OT69BER9	Limited	Genetic Variation	[23]
CDC37L1	OTGKTFAC	Limited	Genetic Variation	[23]
CDH13	OTD2CYM5	Limited	Genetic Variation	[23]
CDK14	OT385ZH1	Limited	Genetic Variation	[23]
CDX2	OTCG4TSY	Limited	Biomarker	[620]
CEBPZ	OT11BATG	Limited	Genetic Variation	[621]
CEMIP	OTK80FYN	Limited	Genetic Variation	[23]
CEP192	OTBLFV7T	Limited	Genetic Variation	[23]
CFHR1	OT72R16T	Limited	Biomarker	[622]
CHCHD6	OT8F9BHW	Limited	Genetic Variation	[23]
CHGA	OTXYX5JH	Limited	Genetic Variation	[23]
CIB3	OT97EYB9	Limited	Genetic Variation	[23]
CILK1	OTWOYEYP	Limited	Altered Expression	[117]
CKMT2	OT1KNPI1	Limited	Biomarker	[623]
CLC	OTYMYR85	Limited	Altered Expression	[615]
CLSTN2	OT2PJYHX	Limited	Genetic Variation	[23]
CMIP	OTZN8Z4A	Limited	Genetic Variation	[23]
CORO1A	OTVAZOHC	Limited	Posttranslational Modification	[624]
CRABP1	OTISDG5X	Limited	Biomarker	[625]
CRACR2A	OTJUGSVE	Limited	Genetic Variation	[23]
CRADD	OT02TZ4S	Limited	Altered Expression	[626]
CSGALNACT1	OTBML9D9	Limited	Genetic Variation	[23]
CSMD2	OT541Z3W	Limited	Genetic Variation	[23]
CSN2	OT22C0PD	Limited	Biomarker	[627]
CTDSPL	OTZJ0CZK	Limited	Biomarker	[628]
CTNNA1	OTFC725Z	Limited	Genetic Variation	[23]
CXADR	OT9ZP02A	Limited	Biomarker	[42]
DCAF6	OT3EYK1J	Limited	Genetic Variation	[23]
DCLRE1C	OTW3KB1I	Limited	Biomarker	[629]
DDX10	OTH48438	Limited	Biomarker	[630]
DDX41	OT6KEIHP	Limited	Genetic Variation	[631]
DDX43	OTK1RYSK	Limited	Posttranslational Modification	[632]
DESI1	OTFNIW98	Limited	Biomarker	[633]
DIAPH3	OTPOT23F	Limited	Genetic Variation	[23]
DLAT	OT9LBJVN	Limited	Biomarker	[634]
DMP1	OTBWBWW7	Limited	Altered Expression	[635]
DNAH17	OT4G6E70	Limited	Genetic Variation	[23]
DNAJC1	OTCKFOZ0	Limited	Genetic Variation	[23]
DNER	OT2GH2E5	Limited	Biomarker	[636]
DNTT	OTFSEF12	Limited	Altered Expression	[637]
DOCK10	OTI3MBLV	Limited	Genetic Variation	[23]
DOK5	OT2XWUPN	Limited	Genetic Variation	[23]
DUSP7	OT6Z5AHP	Limited	Altered Expression	[638]
EAF2	OTSOET5L	Limited	Genetic Variation	[639]
EDIL3	OTDVVNS0	Limited	Genetic Variation	[640]
EFNA2	OTEAUKRX	Limited	Biomarker	[641]
EFNA5	OTOH4DRR	Limited	Altered Expression	[642]
ELF1	OTV5LKIA	Limited	Biomarker	[641]
ELF2	OTEI347F	Limited	Biomarker	[641]
ELF3	OTUTLEQO	Limited	Biomarker	[643]
ELF4	OT167PR5	Limited	Biomarker	[644]
ELL	OTCBN5LF	Limited	Genetic Variation	[645]
ELOF1	OT8BXS5U	Limited	Biomarker	[641]
EMC3	OTY2H39E	Limited	Biomarker	[646]
ENDOG	OT5IM7B3	Limited	Biomarker	[647]
EPB41	OTGCFPV8	Limited	Biomarker	[648]
EPS15	OT7NPP8U	Limited	Genetic Variation	[649]
FAM107B	OT5RG4J0	Limited	Genetic Variation	[23]
FBH1	OTDJBKO1	Limited	Genetic Variation	[23]
FCGR2C	OTNLMNYB	Limited	Biomarker	[81]
FGF13	OTHNNVSG	Limited	Altered Expression	[650]
FGF3	OT9PK2SI	Limited	Genetic Variation	[651]
FMN2	OTUY7BSV	Limited	Genetic Variation	[23]
FMNL2	OT9OVWCV	Limited	Genetic Variation	[23]
FNBP1	OTSJ5KKA	Limited	Genetic Variation	[147]
FOSB	OTW6C05J	Limited	Altered Expression	[652]
FOXO4	OT90X9LN	Limited	Altered Expression	[653]
FRK	OTEKV1SC	Limited	Genetic Variation	[654]
FRMD4A	OTJDTIK2	Limited	Genetic Variation	[23]
FRMD8	OTTH5DUJ	Limited	Genetic Variation	[23]
FRZB	OTTO3DPY	Limited	Posttranslational Modification	[655]
FSTL5	OT18C29S	Limited	Genetic Variation	[23]
FXR1	OTEMQ1SR	Limited	Genetic Variation	[23]
GAB2	OTBFN705	Limited	Altered Expression	[656]
GADD45GIP1	OT4IZ4TP	Limited	Altered Expression	[657]
GBX1	OTLJ8UR9	Limited	Biomarker	[658]
GBX2	OTW0ZI4D	Limited	Biomarker	[658]
GDPD5	OTUM65JL	Limited	Genetic Variation	[23]
GLCCI1	OTU0R1CU	Limited	Genetic Variation	[23]
GSTK1	OTDNGWAF	Limited	Genetic Variation	[99]
GTF2H4	OTPD1DIU	Limited	Genetic Variation	[84]
GYPA	OTABU4YV	Limited	Biomarker	[659]
GYPB	OTESHUIX	Limited	Biomarker	[659]
GYPE	OTBHAG6A	Limited	Biomarker	[659]
H2AC4	OTMFQ662	Limited	Genetic Variation	[23]
HAVCR2	OTOL603T	Limited	Altered Expression	[660]
HCLS1	OTX7WGYN	Limited	Altered Expression	[104]
HDGFL2	OTWX2GHS	Limited	Genetic Variation	[23]
HIVEP3	OTM3QT3L	Limited	Genetic Variation	[23]
HLA-DOA	OTZE5Q7R	Limited	Biomarker	[661]
HLX	OT7DTH46	Limited	Genetic Variation	[662]
HNRNPH1	OTFRWOLM	Limited	Genetic Variation	[663]
HOXA10	OTB6GQ09	Limited	Altered Expression	[664]
HOXB1	OTGC0EKI	Limited	Altered Expression	[665]
HOXB5	OTU74TB8	Limited	Altered Expression	[665]
HOXB6	OT3TFQ0U	Limited	Altered Expression	[666]
HOXB7	OTC7WYU8	Limited	Altered Expression	[665]
HOXB8	OTKHOD17	Limited	Altered Expression	[665]
HOXB9	OTMVHQOU	Limited	Altered Expression	[665]
HOXD11	OT9XGA4G	Limited	Genetic Variation	[667]
HOXD13	OTWSC8TF	Limited	Biomarker	[668]
HSPB2	OTS01646	Limited	Altered Expression	[329]
IGSF21	OTUFCXBS	Limited	Genetic Variation	[23]
IKBKG	OTNWJWSD	Limited	Altered Expression	[669]
IKZF1	OTCW1FKL	Limited	Genetic Variation	[670]
IL1F10	OTJAASGC	Limited	Genetic Variation	[23]
IL27RA	OTSQBAKI	Limited	Altered Expression	[671]
IL6ST	OT1N9C70	Limited	Altered Expression	[672]
ILKAP	OT2A6FSA	Limited	Genetic Variation	[23]
INPP4B	OTLROA7G	Limited	Altered Expression	[673]
INTS1	OT7TY1M1	Limited	Biomarker	[674]
INTS2	OT2N5TCK	Limited	Genetic Variation	[651]
INVS	OT8KPESR	Limited	Biomarker	[675]
IPO11	OTG19WN0	Limited	Genetic Variation	[23]
ISCA1	OTU230MC	Limited	Genetic Variation	[23]
JDP2	OTW35WKX	Limited	Genetic Variation	[23]
KANSL3	OTWXDTLY	Limited	Genetic Variation	[23]
KAT2A	OTN0W2SW	Limited	Biomarker	[676]
KAT5	OTL7257A	Limited	Biomarker	[677]
KHSRP	OTDHZARB	Limited	Altered Expression	[104]
KLF6	OTQY9S7F	Limited	Altered Expression	[678]
KLHL9	OTRGEG3Z	Limited	Genetic Variation	[23]
KMT2E	OTYOLNOG	Limited	Posttranslational Modification	[679]
KNL1	OT4Q3LHV	Limited	Genetic Variation	[680]
KRT31	OTB6RCAH	Limited	Biomarker	[681]
KSR2	OTSMUL59	Limited	Biomarker	[682]
LARS1	OT4557NF	Limited	Genetic Variation	[23]
LAT2	OTWJDKIH	Limited	Altered Expression	[683]
LBX1	OTQJHICM	Limited	Genetic Variation	[684]
LDB3	OTGQL1AM	Limited	Biomarker	[685]
LIMS1	OT729S0T	Limited	Genetic Variation	[120]
LMLN	OTQF0JPY	Limited	Biomarker	[675]
LNX1	OTZWFMAZ	Limited	Genetic Variation	[23]
LRPPRC	OTXSK5LP	Limited	Altered Expression	[672]
LRRC3B	OT9VDGPR	Limited	Genetic Variation	[23]
MAP1S	OT5WUD4C	Limited	Genetic Variation	[23]
MAPK8IP2	OTDUHLN0	Limited	Biomarker	[686]
MARCHF4	OTK43VNA	Limited	Genetic Variation	[23]
MATN1	OTBRTCTQ	Limited	Biomarker	[687]
MBD2	OTUQPP0R	Limited	Biomarker	[194]
ME3	OT3XMLYG	Limited	Genetic Variation	[23]
MEAK7	OT9A8JSO	Limited	Genetic Variation	[23]
MED1	OTOO24C4	Limited	Altered Expression	[688]
MEIS1	OTH9DKAD	Limited	Biomarker	[689]
MIP	OTEBLU3E	Limited	Altered Expression	[690]
MLC1	OTCNZLSP	Limited	Biomarker	[691]
MLLT1	OT41UZU5	Limited	Genetic Variation	[645]
MLLT3	OTXH4DDG	Limited	Genetic Variation	[692]
MNAT1	OTXLOYCB	Limited	Biomarker	[640]
MNDA	OTCTKR47	Limited	Biomarker	[693]
MRTFA	OTCVXASM	Limited	Biomarker	[694]
MS4A14	OTX8BPFZ	Limited	Genetic Variation	[23]
MVP	OTJGHJRB	Limited	Biomarker	[216]
MYO18B	OTGYY4NK	Limited	Genetic Variation	[23]
MYOT	OTCEW5XW	Limited	Biomarker	[695]
NAT9	OT4ZKCRS	Limited	Biomarker	[696]
NBN	OT73B5MD	Limited	Genetic Variation	[697]
NCEH1	OTZ66CKX	Limited	Genetic Variation	[23]
NCOA2	OTMQFPBB	Limited	Biomarker	[698]
NCR2	OT2H13BX	Limited	Altered Expression	[699]
NEO1	OTGJ1997	Limited	Genetic Variation	[700]
NEUROD6	OTLFL6K8	Limited	Genetic Variation	[23]
NKG7	OTXDD006	Limited	Altered Expression	[161]
NLRP2	OTJA81JU	Limited	Genetic Variation	[697]
NME2	OTCYGLHV	Limited	Altered Expression	[701]
NMU	OTW9X7BQ	Limited	Altered Expression	[702]
NNAT	OTNRLO7G	Limited	Biomarker	[703]
NOMO1	OTIALEI1	Limited	Altered Expression	[704]
NRG3	OTIFZ5CT	Limited	Genetic Variation	[23]
NTM	OTHF0UQU	Limited	Genetic Variation	[23]
NUDC	OT073JKX	Limited	Biomarker	[705]
NUP50	OTOZ98K3	Limited	Genetic Variation	[23]
NVL	OTWTGVTI	Limited	Genetic Variation	[23]
NWD2	OTN47UBK	Limited	Genetic Variation	[23]
OLFML3	OTDN45FN	Limited	Genetic Variation	[23]
OPN1LW	OTFNUZ7O	Limited	Altered Expression	[74]
OSCP1	OTZ4IFGJ	Limited	Altered Expression	[652]
P4HB	OTTYNYPF	Limited	Biomarker	[706]
PAG1	OTFOJUIQ	Limited	Altered Expression	[74]
PARD3B	OTGZ43YI	Limited	Genetic Variation	[23]
PARP15	OTYO1C46	Limited	Biomarker	[707]
PCBP3	OT6EX9N6	Limited	Genetic Variation	[23]
PCBP4	OTDLL4NB	Limited	Altered Expression	[74]
PCGF2	OTIY1J5L	Limited	Altered Expression	[708]
PDE8B	OT4217NK	Limited	Genetic Variation	[23]
PDLIM4	OT23LZYY	Limited	Posttranslational Modification	[709]
PEG3	OTHQW98S	Limited	Genetic Variation	[23]
PER2	OTU2B1DJ	Limited	Altered Expression	[609]
PHAX	OTSHNJ6B	Limited	Genetic Variation	[23]
PHF6	OT8DXI40	Limited	Genetic Variation	[710]
PHYKPL	OTQGELZD	Limited	Genetic Variation	[23]
PICALM	OTQVRPMQ	Limited	Biomarker	[711]
PIK3R3	OTXGJ8N1	Limited	Altered Expression	[104]
PKHD1	OTAH8SMF	Limited	Genetic Variation	[23]
PLA2G5	OTQRSKCZ	Limited	Genetic Variation	[23]
PLAGL2	OT6AP4V2	Limited	Altered Expression	[712]
PLCG2	OTGVC9MY	Limited	Genetic Variation	[23]
PLEKHB1	OTC7TNAX	Limited	Genetic Variation	[23]
PLXDC2	OTS1FUV6	Limited	Genetic Variation	[23]
PLXNA2	OTNNBJMQ	Limited	Genetic Variation	[23]
PNN	OT0HXICH	Limited	Biomarker	[713]
POGLUT1	OTDX7GZD	Limited	Altered Expression	[714]
POLD4	OTG578YH	Limited	Genetic Variation	[715]
POLE4	OTCMWUT6	Limited	Genetic Variation	[715]
POLG2	OTDBMZJB	Limited	Altered Expression	[104]
POLR1D	OTOCZQNA	Limited	Genetic Variation	[23]
POLR3A	OT5MSK10	Limited	Genetic Variation	[23]
PPFIA2	OT34BLXJ	Limited	Genetic Variation	[23]
PPIG	OTZ8BTTM	Limited	Genetic Variation	[716]
PPL	OTTM4WDO	Limited	Genetic Variation	[23]
PPP1R14C	OTZ3F6D2	Limited	Genetic Variation	[23]
PPP2R2C	OTXK0SDM	Limited	Genetic Variation	[23]
PRAP1	OT48QD82	Limited	Biomarker	[717]
PRRX1	OTTZK5G8	Limited	Genetic Variation	[718]
PRXL2A	OTR4X7UH	Limited	Genetic Variation	[23]
PSG11	OTLZJVLL	Limited	Genetic Variation	[23]
PSMD12	OTWICA51	Limited	Altered Expression	[104]
PTGES3	OTPPQWI0	Limited	Genetic Variation	[60]
PTPA	OTRGFOI7	Limited	Altered Expression	[719]
PTPRD	OTZPJ3GX	Limited	Genetic Variation	[23]
PTPRG	OT9N2WOF	Limited	Genetic Variation	[23]
QPRT	OT6SKKLL	Limited	Genetic Variation	[720]
RAB10	OT8ZN26V	Limited	Genetic Variation	[23]
RAB11FIP4	OTIGHER7	Limited	Genetic Variation	[23]
RAB20	OTP9OOVS	Limited	Genetic Variation	[23]
RAD51B	OTCJVRMY	Limited	Genetic Variation	[23]
RAG1	OTV131E4	Limited	Genetic Variation	[721]
RARS1	OTHPZ6JN	Limited	Biomarker	[722]
RASA2	OTL06RG2	Limited	Genetic Variation	[147]
RASGRP4	OT15PWN4	Limited	Biomarker	[723]
RBBP4	OTG3BT3M	Limited	Biomarker	[724]
RBP1	OTRP1MFC	Limited	Altered Expression	[725]
RCL1	OT7O00YX	Limited	Genetic Variation	[23]
REEP5	OTZU4TJI	Limited	Genetic Variation	[726]
RGPD2	OTMUZ0HX	Limited	Altered Expression	[602]
RGS7	OTDQA90X	Limited	Genetic Variation	[23]
RNF126	OTTECSYY	Limited	Genetic Variation	[23]
RNPS1	OT7G4COD	Limited	Genetic Variation	[23]
RPN1	OTEG4KU9	Limited	Biomarker	[727]
RPS24	OTSNKIL5	Limited	Genetic Variation	[23]
RPTOR	OT4TQZ9F	Limited	Genetic Variation	[23]
SALL4	OTC08PR5	Limited	Altered Expression	[728]
SBF2	OTBB8NO8	Limited	Genetic Variation	[23]
SCAPER	OT7S3B3P	Limited	Genetic Variation	[23]
SDC4	OTKUVUGZ	Limited	Biomarker	[729]
SEPTIN11	OTX2O0ZX	Limited	Genetic Variation	[730]
SEPTIN5	OT6JTJBO	Limited	Genetic Variation	[731]
SEPTIN7	OTJI08YX	Limited	Genetic Variation	[732]
SEPTIN9	OT1VMRFQ	Limited	Genetic Variation	[23]
SFRP5	OTLCVVSH	Limited	Altered Expression	[733]
SHROOM3	OTQKC5X2	Limited	Genetic Variation	[23]
SIGLEC7	OTNDLURR	Limited	Altered Expression	[104]
SLC2A4RG	OTW3LX8D	Limited	Biomarker	[606]
SLC35G1	OTKZUA8O	Limited	Biomarker	[633]
SMPD3	OTHQBETH	Limited	Genetic Variation	[734]
SMR3B	OTL5HNM8	Limited	Biomarker	[420]
SNTG1	OT6GBQHI	Limited	Genetic Variation	[23]
SNX9	OTLNQ0ZM	Limited	Genetic Variation	[23]
SORBS1	OTWH8762	Limited	Genetic Variation	[23]
SORCS2	OTBF3DYK	Limited	Genetic Variation	[23]
SPATA6L	OTCQ01F6	Limited	Genetic Variation	[23]
SPESP1	OTWXKKTJ	Limited	Genetic Variation	[735]
SPG7	OT8OY9ST	Limited	Biomarker	[42]
SRBD1	OTL1QJSP	Limited	Genetic Variation	[23]
SSBP2	OTYG1G80	Limited	Biomarker	[736]
ST6GALNAC5	OTH91ETM	Limited	Genetic Variation	[23]
ST7	OTZG8RC6	Limited	Genetic Variation	[737]
ST8SIA3	OTG9MXV9	Limited	Genetic Variation	[23]
STIM2	OTYNXAW0	Limited	Genetic Variation	[23]
SUCLG2	OT0KHLY2	Limited	Genetic Variation	[23]
SUZ12	OT655XF8	Limited	Biomarker	[738]
TACC2	OTW4M7HI	Limited	Genetic Variation	[23]
TAF15	OTNE038N	Limited	Altered Expression	[739]
TBCC	OTBF0X8R	Limited	Biomarker	[740]
TC2N	OT6482WN	Limited	Genetic Variation	[23]
TENM2	OTPLUYEF	Limited	Genetic Variation	[23]
TESC	OTI8C76M	Limited	Biomarker	[440]
TET3	OT76U3YF	Limited	Biomarker	[741]
THSD7B	OTMDDIPT	Limited	Genetic Variation	[23]
TMED10	OTUXSHH7	Limited	Genetic Variation	[60]
TMED5	OT70W1J8	Limited	Genetic Variation	[23]
TMEM248	OT0PHW5T	Limited	Genetic Variation	[23]
TMEM260	OTICII2L	Limited	Genetic Variation	[23]
TMEM266	OTM17VHD	Limited	Genetic Variation	[23]
TMEM87B	OTXT7BCU	Limited	Genetic Variation	[23]
TNFRSF10C	OTVHOL9B	Limited	Altered Expression	[742]
TNFRSF10D	OTOSRDJT	Limited	Altered Expression	[742]
TNFSF8	OTDYGDJ3	Limited	Altered Expression	[743]
TOPORS	OT1ERFFQ	Limited	Genetic Variation	[23]
TP73	OT0LUO47	Limited	Genetic Variation	[23]
TRIM13	OTQIUACB	Limited	Biomarker	[42]
TRIM34	OTJ11U33	Limited	Genetic Variation	[23]
TRIM6	OTBSMX0B	Limited	Genetic Variation	[23]
TRIP11	OT4FJEAR	Limited	Biomarker	[744]
TRPS1	OT7XPPEL	Limited	Genetic Variation	[745]
TSPAN33	OTH6C0WU	Limited	Genetic Variation	[746]
ARHGAP24	OTCQCEZS	Disputed	Altered Expression	[747]
ATG5	OT4T5SMS	Disputed	Biomarker	[748]
ATRNL1	OTY5JUX2	Disputed	Genetic Variation	[749]
BABAM2	OTOY7FNT	Disputed	Genetic Variation	[750]
CCL13	OTNX0JD0	Disputed	Biomarker	[751]
CCL27	OTUZYC61	Disputed	Genetic Variation	[749]
CCND2	OTDULQF9	Disputed	Genetic Variation	[752]
CHST9	OT1DEZRM	Disputed	Biomarker	[753]
CLOCK	OTNEOJY7	Disputed	Biomarker	[754]
CORT	OTX3GUHB	Disputed	Genetic Variation	[755]
CXCL5	OTZOUPCA	Disputed	Biomarker	[751]
DHX15	OT4F98TK	Disputed	Genetic Variation	[756]
DLX4	OTLWVCN4	Disputed	Altered Expression	[757]
FIP1L1	OTF91GTL	Disputed	Genetic Variation	[758]
GNA12	OT3IRZH3	Disputed	Biomarker	[166]
GNG11	OTHIXBGW	Disputed	Biomarker	[759]
KLF1	OT1FK08U	Disputed	Altered Expression	[760]
LGALS12	OTNTQULB	Disputed	Altered Expression	[761]
LPXN	OTUNV3CK	Disputed	Genetic Variation	[762]
MRGPRF	OT74OZ2Z	Disputed	Biomarker	[688]
NT5DC3	OTRHBVM5	Disputed	Altered Expression	[763]
PDLIM3	OTVXQC81	Disputed	Genetic Variation	[749]
PLAG1	OTT9AJQY	Disputed	Biomarker	[764]
PLCE1	OTJISZOX	Disputed	Genetic Variation	[765]
POU4F1	OTMHYGWQ	Disputed	Altered Expression	[766]
RBFOX2	OTXY1WVH	Disputed	Biomarker	[688]
REG1A	OTMHUH1D	Disputed	Altered Expression	[569]
RMDN3	OTKO7AUM	Disputed	Altered Expression	[767]
SHMT1	OTIINA3J	Disputed	Genetic Variation	[534]
SUMO1	OTJFD4P5	Disputed	Altered Expression	[768]
TAS2R10	OT4RWZZD	Disputed	Altered Expression	[769]
TET1	OTZDHT1D	Disputed	Biomarker	[770]
A1CF	OTJBKFA1	moderate	Genetic Variation	[23]
A2ML1	OTWNUXIS	moderate	Biomarker	[771]
AACS	OTGGPR6J	moderate	Genetic Variation	[23]
ABI3BP	OTW8DN50	moderate	Genetic Variation	[23]
ABTB2	OTK5YA5E	moderate	Genetic Variation	[23]
ACACA	OT5CQPZY	moderate	Genetic Variation	[23]
ADCY7	OTAWMGP3	moderate	Altered Expression	[253]
AFF3	OTR0705Z	moderate	Genetic Variation	[23]
AFF4	OTTL5Y8R	moderate	Genetic Variation	[23]
AHCYL2	OTGG9KYG	moderate	Genetic Variation	[23]
AK9	OTWYT1VS	moderate	Genetic Variation	[23]
AMELX	OTIN26MM	moderate	Biomarker	[772]
ANK2	OTWB4R1Y	moderate	Genetic Variation	[23]
ANK3	OTJ3IRBP	moderate	Genetic Variation	[23]
ANKRD55	OT62KZII	moderate	Genetic Variation	[23]
ANP32B	OT3SQMLU	moderate	Altered Expression	[773]
APLF	OTYUR3AH	moderate	Genetic Variation	[23]
ARHGEF1	OTXU4HBW	moderate	Biomarker	[774]
ARHGEF18	OTOXEK8Y	moderate	Genetic Variation	[23]
ARL5C	OT3SIDP7	moderate	Genetic Variation	[23]
ASAH1	OT1DNGXL	moderate	Altered Expression	[121]
ASB15	OTI0ZVLJ	moderate	Genetic Variation	[23]
ATL2	OT93AUOO	moderate	Genetic Variation	[23]
ATP2C2	OTGIHTYQ	moderate	Genetic Variation	[23]
AUTS2	OTAEXHSC	moderate	Genetic Variation	[23]
BPIFB2	OTXWTWQ9	moderate	Genetic Variation	[23]
BTBD8	OT3A3RD7	moderate	Genetic Variation	[23]
C19orf47	OTLG5FQG	moderate	Genetic Variation	[23]
C2orf76	OTIIU4DI	moderate	Genetic Variation	[23]
C7orf33	OTWZ1FAE	moderate	Genetic Variation	[23]
C9	OT7I5FDX	moderate	Genetic Variation	[23]
C9orf153	OT4GKX8W	moderate	Genetic Variation	[23]
CACNB1	OTV42SIT	moderate	Genetic Variation	[23]
CADM2	OT45PVKC	moderate	Genetic Variation	[23]
CALD1	OTNJKJ6Q	moderate	Genetic Variation	[23]
CCDC144A	OTN9UZHR	moderate	Genetic Variation	[23]
CCDC149	OT7S7MU9	moderate	Genetic Variation	[23]
CCDC18	OT0S9DA2	moderate	Genetic Variation	[23]
CCDC39	OTXRCVUD	moderate	Genetic Variation	[23]
CCDC66	OTE8VSSO	moderate	Genetic Variation	[23]
CCER1	OTVA38PS	moderate	Genetic Variation	[23]
CCL28	OTY6XNQ7	moderate	Biomarker	[775]
CCNA1	OTX4HD45	moderate	Altered Expression	[776]
CD244	OTSMR85N	moderate	Altered Expression	[777]
CECR2	OTF54V3W	moderate	Genetic Variation	[23]
CFAP299	OTOSLSAM	moderate	Genetic Variation	[23]
CHEK2	OT8ZPCNS	Moderate	Autosomal dominant	[185]
CHGB	OT7SAQT2	moderate	Biomarker	[778]
CHPT1	OT4FJ0K3	moderate	Biomarker	[779]
CLN8	OT0D4CB5	moderate	Genetic Variation	[23]
CNOT7	OTJBKCPI	moderate	Genetic Variation	[23]
COL11A2	OT3BQUBH	moderate	Biomarker	[136]
COL15A1	OTTFKK18	moderate	Genetic Variation	[23]
COL22A1	OTSWGZRD	moderate	Genetic Variation	[23]
COL23A1	OTYE0N3I	moderate	Genetic Variation	[23]
COL26A1	OTMS7RNF	moderate	Genetic Variation	[23]
COL4A2	OTJK1LKN	moderate	Genetic Variation	[23]
COL4A3	OT6SB8X5	moderate	Genetic Variation	[23]
COL6A5	OTJT8O80	moderate	Genetic Variation	[23]
CPNE4	OTTAGM5L	moderate	Genetic Variation	[23]
CREB3L1	OT2JHIHM	moderate	Genetic Variation	[23]
CREB5	OTJDUJPI	moderate	Genetic Variation	[23]
CSMD1	OTIVDSC4	moderate	Genetic Variation	[23]
CTAG1B	OTIQGW6U	moderate	Biomarker	[186]
CTNNA2	OTJ8G92T	moderate	Genetic Variation	[23]
DAB1	OTPL9MA3	moderate	Genetic Variation	[23]
DCTN6	OTI8PIN9	moderate	Altered Expression	[780]
DECR1	OTCDIR6X	moderate	Biomarker	[781]
DEFB127	OTDLYU1I	moderate	Genetic Variation	[23]
DENND6A	OTA8JL8H	moderate	Genetic Variation	[23]
DGKB	OTTT9SZJ	moderate	Genetic Variation	[23]
DIMT1	OT9J5J1C	moderate	Genetic Variation	[23]
DLST	OTBDF9HJ	moderate	Genetic Variation	[23]
DMGDH	OTPJEWQ8	moderate	Genetic Variation	[23]
DOCK3	OTF3YS2W	moderate	Genetic Variation	[23]
DOK6	OTX55OIF	moderate	Altered Expression	[782]
DPH1	OT0QU3JY	moderate	Genetic Variation	[23]
DR1	OTR081M4	moderate	Genetic Variation	[23]
ELMO1	OTY2ORXK	moderate	Genetic Variation	[23]
ELN	OTFSO7PG	moderate	Biomarker	[783]
EML6	OTE1MUQS	moderate	Genetic Variation	[23]
EPHA10	OT1XJGFG	moderate	Genetic Variation	[23]
ERMP1	OT9CIEO2	moderate	Genetic Variation	[23]
ETV4	OT8C98UZ	moderate	Genetic Variation	[23]
EVPL	OTZIAFEK	moderate	Biomarker	[784]
EXTL3	OT2BRUBN	moderate	Genetic Variation	[23]
FAM149A	OTMDM0RI	moderate	Genetic Variation	[23]
FAM3D	OTM3GWFP	moderate	Genetic Variation	[23]
FANCM	OTNJG99Z	moderate	Biomarker	[240]
FBXO21	OTM8L5VY	moderate	Genetic Variation	[23]
FETUB	OT7V07NI	moderate	Genetic Variation	[23]
FGF12	OTBM9QIO	moderate	Genetic Variation	[23]
FIS1	OT2HL10J	moderate	Altered Expression	[222]
FOXI1	OT2UFOE2	moderate	Genetic Variation	[23]
FSD2	OTJYRESG	moderate	Genetic Variation	[23]
GAB1	OTQKE6V4	moderate	Genetic Variation	[23]
GALNT14	OT9BSDDQ	moderate	Genetic Variation	[23]
GALNT2	OTZZ5386	moderate	Genetic Variation	[23]
GBE1	OTK2N05B	moderate	Genetic Variation	[23]
GCFC2	OTC7FRXL	moderate	Genetic Variation	[23]
GFI1B	OTRDW8YO	moderate	Biomarker	[785]
GLB1L2	OTLI6HCH	moderate	Genetic Variation	[23]
GLIS1	OTBDNB26	moderate	Genetic Variation	[23]
GOLT1B	OTC6QPW3	moderate	Biomarker	[786]
GP2	OTB6TMGY	moderate	Genetic Variation	[23]
GPAT3	OTJUGPK0	moderate	Genetic Variation	[23]
GPR161	OT80FYA3	moderate	Genetic Variation	[23]
GPR26	OTBDYUOH	moderate	Genetic Variation	[23]
GRAMD4	OT1HXEPM	moderate	Genetic Variation	[23]
GRID1	OTJ3WIKC	moderate	Genetic Variation	[23]
GRK6	OT4LZTP9	moderate	Genetic Variation	[23]
HECTD3	OTTGP4OK	moderate	Genetic Variation	[23]
HECW1	OT1PVAZA	moderate	Genetic Variation	[23]
HOMER2	OT4JGKJF	moderate	Genetic Variation	[23]
HOXA4	OTNVTQDT	moderate	Posttranslational Modification	[787]
HOXB3	OT9UC5PE	moderate	Altered Expression	[71]
HPR	OTXSC9UB	moderate	Altered Expression	[788]
HPS1	OTKS5I7T	moderate	Genetic Variation	[23]
HS3ST4	OTO0UBFN	moderate	Genetic Variation	[23]
ICE1	OTOXTBUH	moderate	Genetic Variation	[23]
IFI27	OTI2XGIT	moderate	Altered Expression	[780]
IL36RN	OT5CO95A	moderate	Genetic Variation	[23]
IQUB	OTT1VKEF	moderate	Genetic Variation	[23]
IRF2	OTAZRUW3	moderate	Altered Expression	[673]
ITPK1	OTP4PGL6	moderate	Genetic Variation	[23]
ITPRID1	OT9MH0BX	moderate	Genetic Variation	[23]
KANK1	OT2E7A6W	moderate	Genetic Variation	[23]
KCNAB1	OT25GJE9	moderate	Genetic Variation	[23]
KCNIP3	OTCQPEM4	moderate	Genetic Variation	[23]
KCNJ15	OTZT6EQB	moderate	Genetic Variation	[23]
KHNYN	OT5ZFS95	moderate	Genetic Variation	[23]
KIAA0513	OT7AVTFB	moderate	Genetic Variation	[23]
KIAA0930	OTVJ73LN	moderate	Genetic Variation	[23]
KIAA1958	OTTI1DB4	moderate	Genetic Variation	[23]
KIF2A	OT2WQ6QD	moderate	Genetic Variation	[23]
KLF9	OTBFEJRQ	moderate	Genetic Variation	[23]
KPNA1	OTEMVAJ6	moderate	Genetic Variation	[23]
KRT83	OTNQ040R	moderate	Genetic Variation	[23]
LDLRAD3	OTYAKC55	moderate	Genetic Variation	[23]
LDLRAD4	OTQUX50Z	moderate	Genetic Variation	[23]
LHFPL3	OTG1EI22	moderate	Genetic Variation	[23]
LHX4	OTVX3J6S	moderate	Genetic Variation	[23]
LINGO2	OT3N88Q1	moderate	Genetic Variation	[23]
LMX1B	OTM8145D	moderate	Genetic Variation	[23]
LRBA	OTOUZN9G	moderate	Genetic Variation	[23]
LRRTM2	OTSBFPUI	moderate	Genetic Variation	[23]
LRRTM4	OTYJ4348	moderate	Genetic Variation	[23]
LTBP1	OTR7Q75L	moderate	Genetic Variation	[23]
MACROD2	OTNQCHC6	moderate	Genetic Variation	[23]
MAP6	OTPUI00F	moderate	Genetic Variation	[23]
MARCKSL1	OT13J2FM	moderate	Altered Expression	[789]
MEGF9	OTDQWTY4	moderate	Genetic Variation	[23]
METAP1D	OT144G80	moderate	Genetic Variation	[23]
MINAR1	OTV1X2R0	moderate	Genetic Variation	[23]
MLIP	OTMT7AII	moderate	Genetic Variation	[23]
MPC2	OT0GHXGG	moderate	Genetic Variation	[23]
MROH7	OTY4H57Y	moderate	Genetic Variation	[23]
MRPL19	OTRBKF6R	moderate	Genetic Variation	[23]
MRPL28	OT4LUTZU	moderate	Posttranslational Modification	[790]
MRPS27	OTN9DA0V	moderate	Genetic Variation	[23]
MSC	OTBRPZL5	moderate	Genetic Variation	[791]
MTMR3	OTBIT23O	moderate	Genetic Variation	[23]
MYCT1	OTZ8A9L3	moderate	Altered Expression	[792]
MYO1D	OTP2RGPN	moderate	Genetic Variation	[23]
MYO3B	OTVD4TNG	moderate	Genetic Variation	[23]
NAB2	OTG4BDF3	moderate	Genetic Variation	[23]
NAV2	OTGAOL01	moderate	Genetic Variation	[23]
NAV3	OT97M1TR	moderate	Genetic Variation	[23]
NDUFA5	OTR848KZ	moderate	Genetic Variation	[23]
NDUFB6	OTIXNT91	moderate	Genetic Variation	[23]
NEDD4L	OT1B19RU	moderate	Genetic Variation	[23]
NEMP1	OTWN3S47	moderate	Genetic Variation	[23]
NEURL3	OTA3ALQO	moderate	Genetic Variation	[23]
NFATC2	OTK5T6HZ	moderate	Genetic Variation	[23]
NFYA	OTWFFOVH	moderate	Genetic Variation	[23]
NLGN1	OTGHRRFQ	moderate	Genetic Variation	[23]
NR2F6	OTNVO2B6	moderate	Altered Expression	[793]
NSD3	OT3677ZG	moderate	Biomarker	[794]
NT5DC2	OTPDRGGN	moderate	Genetic Variation	[23]
NUGGC	OTKQLKWO	moderate	Genetic Variation	[23]
NUP153	OTCAS0AR	moderate	Genetic Variation	[23]
NXT1	OT0VO6AY	moderate	Posttranslational Modification	[790]
OARD1	OTNNWATS	moderate	Genetic Variation	[23]
OAS3	OT6E5FYS	moderate	Genetic Variation	[23]
OR6C1	OTQJ455N	moderate	Genetic Variation	[23]
OR6C75	OT8GMUU7	moderate	Genetic Variation	[23]
OR6P1	OTR1JPLJ	moderate	Genetic Variation	[23]
OR6Y1	OTMHRAGN	moderate	Genetic Variation	[23]
OTUB2	OTZUMPH2	moderate	Genetic Variation	[23]
OVCA2	OT5LSKCS	moderate	Genetic Variation	[23]
P2RX5	OTLBR20R	moderate	Biomarker	[201]
PAFAH1B1	OT9T2TCJ	moderate	Genetic Variation	[795]
PALLD	OTZ2MUJZ	moderate	Genetic Variation	[23]
PALM2AKAP2	OTI618VF	moderate	Genetic Variation	[23]
PCDH15	OTU9C2EH	moderate	Genetic Variation	[23]
PDZD2	OTPPVRGY	moderate	Genetic Variation	[23]
PDZRN3	OTQ891OS	moderate	Genetic Variation	[23]
PGS1	OTHL9ZKS	moderate	Genetic Variation	[23]
PHACTR1	OTAMPX9V	moderate	Genetic Variation	[23]
PHF23	OTVF5VZC	moderate	Altered Expression	[796]
PI16	OTJY2N6U	moderate	Genetic Variation	[23]
PLAC8L1	OTHF4LKX	moderate	Genetic Variation	[23]
PMAIP1	OTXEE550	moderate	Genetic Variation	[115]
POMGNT2	OT0S9Z0J	moderate	Genetic Variation	[23]
PRAM1	OTZN3DWD	moderate	Biomarker	[797]
PRKAA1	OT7TNF0L	moderate	Biomarker	[323]
PRKAA2	OTU1KZPV	moderate	Biomarker	[323]
PRKAB1	OT1OG4QZ	moderate	Biomarker	[323]
PROX2	OTVUW0GJ	moderate	Genetic Variation	[23]
PRSS35	OT09H6WH	moderate	Genetic Variation	[23]
PRSS54	OTZVEVQZ	moderate	Genetic Variation	[23]
PSMD9	OT6Y5CC3	moderate	Altered Expression	[780]
PSMF1	OTX84WLQ	moderate	Genetic Variation	[23]
PTPRA	OTZA82J1	moderate	Biomarker	[207]
PYROXD2	OTJIX22S	moderate	Genetic Variation	[23]
RAB36	OTL30F2P	moderate	Genetic Variation	[23]
RAB3GAP1	OT4DQ8F2	moderate	Genetic Variation	[23]
RAD51C	OTUD6SY5	moderate	Biomarker	[240]
RALGAPB	OTY8CGA3	moderate	Biomarker	[771]
RASGRP3	OTEMEV3P	moderate	Genetic Variation	[23]
RBFOX3	OTL0F3D6	moderate	Genetic Variation	[23]
RIMBP2	OTUNSVUJ	moderate	Genetic Variation	[23]
RITA1	OTUH8IPS	moderate	Biomarker	[798]
RNF187	OTXTN1HP	moderate	Genetic Variation	[23]
RTEL1	OTI3PJCT	Moderate	Autosomal dominant	[185]
RTN4RL1	OTDKKOE7	moderate	Genetic Variation	[23]
S100Z	OTBSHFJR	moderate	Genetic Variation	[23]
SASH1	OTQA8BD4	moderate	Genetic Variation	[23]
SAXO1	OT7M6PLA	moderate	Genetic Variation	[23]
SBK1	OTCO4NEI	moderate	Genetic Variation	[23]
SEC14L6	OTQ190TS	moderate	Genetic Variation	[23]
SEMA5A	OTUOIOJV	moderate	Genetic Variation	[23]
SEMG1	OT6Z4BPQ	moderate	Biomarker	[778]
SEZ6L	OT5Z9CUA	moderate	Genetic Variation	[23]
SFRP1	OT0U9G41	moderate	Altered Expression	[799]
SFRP2	OT8GZ0CA	moderate	Altered Expression	[800]
SGSM3	OTIB1P8A	moderate	Altered Expression	[801]
SH3RF2	OT2IVOK4	moderate	Genetic Variation	[23]
SH3RF3	OTK9VVUU	moderate	Genetic Variation	[23]
SHANK2	OTSQTPFQ	moderate	Genetic Variation	[23]
SHISA6	OTWBCJ8O	moderate	Genetic Variation	[23]
SLC25A44	OTHHPC3C	moderate	Genetic Variation	[23]
SMARCA1	OT0Y6PTU	moderate	Biomarker	[802]
SNX30	OTMGQSAM	moderate	Genetic Variation	[23]
SPINK4	OTHTCW94	moderate	Genetic Variation	[23]
SPSB1	OTGY26U4	moderate	Genetic Variation	[23]
SRP72	OTPV73W7	Moderate	Autosomal dominant	[185]
ST18	OTPRIMTA	moderate	Genetic Variation	[23]
STK32C	OTN4HBAA	moderate	Genetic Variation	[23]
STOX1	OTED3YVO	moderate	Genetic Variation	[23]
SUB1	OTK71JYU	moderate	Posttranslational Modification	[790]
SUN5	OTUVKA6R	moderate	Genetic Variation	[23]
SV2B	OTAO5WIU	moderate	Genetic Variation	[23]
SYCE1	OTTOIXW8	moderate	Genetic Variation	[23]
SYT2	OTJYGTY4	moderate	Genetic Variation	[23]
TBC1D5	OTNHLLAX	moderate	Genetic Variation	[23]
TDRD12	OTP8B2UY	moderate	Genetic Variation	[23]
TENM4	OT91K3FC	moderate	Genetic Variation	[23]
THSD7A	OT7249HH	moderate	Genetic Variation	[23]
TICAM2	OTK7GIJ5	moderate	Altered Expression	[780]
TLE6	OTB84O0U	moderate	Genetic Variation	[23]
TMED7	OTONO8E6	moderate	Altered Expression	[780]
TMEM14A	OTANQA6G	moderate	Genetic Variation	[23]
TMEM161B	OTHVICQS	moderate	Genetic Variation	[23]
TMEM259	OTVH9HD8	moderate	Genetic Variation	[23]
TMOD1	OTTRYF9Y	moderate	Genetic Variation	[23]
TNFSF18	OT3ANRX1	moderate	Altered Expression	[803]
TNR	OTVJGAFN	moderate	Genetic Variation	[23]
TNRC6A	OT493IOM	moderate	Genetic Variation	[23]
TRAK1	OTMQVYNP	moderate	Genetic Variation	[23]
TRIM46	OTFE7WZW	moderate	Genetic Variation	[23]
TTC21A	OTBJ9JKF	moderate	Genetic Variation	[23]
TTLL11	OTWXLE1J	moderate	Genetic Variation	[23]
TTLL5	OTUKOVEM	moderate	Genetic Variation	[23]
TTN	OT0LZ058	moderate	Genetic Variation	[23]
AAAS	OTJT9T23	Strong	Biomarker	[128]
AADAC	OT8VACT2	Strong	Genetic Variation	[804]
ABR	OTZQK8JF	Strong	Altered Expression	[805]
ACER3	OTIVQBG5	Strong	Biomarker	[806]
ACOT7	OT7C68YV	Strong	Altered Expression	[807]
ADAM28	OT3GBVHL	Strong	Altered Expression	[808]
ADAR	OTQNOHR8	Strong	Altered Expression	[809]
ADGRE2	OTUYJVYG	Strong	Biomarker	[810]
ADGRE5	OTTSB84Q	Strong	Biomarker	[810]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[811]
AEBP2	OTOAZJ55	Strong	Genetic Variation	[812]
AFDN	OTTRU341	Strong	Biomarker	[813]
AFF1	OTT2C78E	Strong	Biomarker	[814]
AGRN	OTWJENAZ	Strong	Biomarker	[224]
AK6	OT84OHHP	Strong	Biomarker	[815]
AKAP12	OTCVRDDX	Strong	Genetic Variation	[23]
AKAP13	OTOZAR14	Strong	Genetic Variation	[816]
AKIP1	OT7XPG27	Strong	Biomarker	[278]
ALG3	OTPOL1QW	Strong	Altered Expression	[817]
ALPP	OTZU4G9W	Strong	Biomarker	[495]
ANKRD26	OT2ENKKV	Strong	Autosomal dominant	[185]
ANP32A	OTRHPFO2	Strong	Biomarker	[818]
ANXA3	OTDD8OI7	Strong	Altered Expression	[432]
ANXA4	OTUCRYXL	Strong	Biomarker	[224]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[224]
APAF1	OTJWIVY0	Strong	Biomarker	[819]
APOBEC3A	OTYO6F5P	Strong	Altered Expression	[820]
ARC	OTN2QQPG	Strong	Biomarker	[821]
ARID4A	OT1XKBZ0	Strong	Biomarker	[822]
ARIH2	OTJYJQJ8	Strong	Biomarker	[823]
ARPP19	OTZS3IT6	Strong	Altered Expression	[406]
ASB2	OTF9LV7L	Strong	Genetic Variation	[23]
ASH2L	OT3HG324	Strong	Altered Expression	[824]
ASMTL	OTPUGCZO	Strong	Biomarker	[224]
ASPG	OT5E2EKR	Strong	Biomarker	[825]
ASS1	OT4ZMG0Q	Strong	Biomarker	[826]
ASXL2	OTNG4E2M	Strong	Genetic Variation	[827]
ATF2	OTNIZPEA	Strong	Altered Expression	[828]
ATF5	OT03QCLM	Strong	Biomarker	[829]
ATP1B1	OTTO6ZP4	Strong	Biomarker	[224]
BACH2	OT17GS18	Strong	Biomarker	[830]
BASP1	OTF4VS5G	Strong	Biomarker	[831]
BCAR1	OTKT2C2N	Strong	Altered Expression	[832]
BCL10	OT47MCLI	Strong	Biomarker	[833]
BCL2L10	OTYXQJ3I	Strong	Biomarker	[834]
BCLAF1	OT7T8H6A	Strong	Biomarker	[835]
BCOR	OTG013AX	Strong	Genetic Variation	[836]
BCORL1	OTPTFQN5	Strong	Genetic Variation	[837]
BCS1L	OT5PY5CY	Strong	Biomarker	[838]
BEST2	OT48WOL1	Strong	Genetic Variation	[839]
BEX1	OTBQIF0H	Strong	Altered Expression	[840]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[813]
BLM	OTEJOAJX	Strong	Biomarker	[240]
BMPR1A	OTQOA4ZH	Strong	Altered Expression	[841]
BRCA1	OT5BN6VH	Strong	Biomarker	[240]
BST1	OTAV5SE7	Strong	Biomarker	[842]
C10orf53	OTAPN6SD	Strong	Genetic Variation	[843]
CACUL1	OT6P1ZVP	Strong	Biomarker	[844]
CADM1	OTRWG9QS	Strong	Biomarker	[845]
CAMK1	OTRN55RE	Strong	Biomarker	[357]
CAMK4	OT47RDGV	Strong	Biomarker	[846]
CAPG	OTJ86KI6	Strong	Biomarker	[476]
CARD8	OTXXZYWU	Strong	Altered Expression	[287]
CARTPT	OTTE4V9S	Strong	Biomarker	[847]
CASZ1	OTWJ2OR8	Strong	Posttranslational Modification	[848]
CBFA2T3	OTOJ10S1	Strong	Biomarker	[849]
CBLL2	OTB4AD3V	Strong	Altered Expression	[850]
CCDC50	OTSE1YM5	Strong	Altered Expression	[502]
CCDC6	OTXRQDYG	Strong	Genetic Variation	[568]
CCNT2	OTBDRH1J	Strong	Biomarker	[851]
CCS	OTXHT3QO	Strong	Genetic Variation	[852]
CD177	OTS79FNF	Strong	Altered Expression	[853]
CD226	OT4UG0KB	Strong	Biomarker	[465]
CD300LF	OTQWJGSR	Strong	Biomarker	[854]
CD302	OTX580VU	Strong	Biomarker	[855]
CD48	OT83ZNPP	Strong	Biomarker	[856]
CD53	OT9U5OXJ	Strong	Biomarker	[857]
CD63	OT2UGZA9	Strong	Biomarker	[858]
CD79A	OTOJC8DV	Strong	Altered Expression	[859]
CD81	OTQFXNAZ	Strong	Altered Expression	[860]
CD82	OTH8MC64	Strong	Altered Expression	[861]
CD93	OT6HZT6H	Strong	Altered Expression	[862]
CDCA3	OTUI8QK3	Strong	Altered Expression	[71]
CDK20	OTOLNN68	Strong	Biomarker	[264]
CDK2AP2	OTR99SJ8	Strong	Posttranslational Modification	[863]
CDKN2D	OT2TTZPZ	Strong	Genetic Variation	[864]
CDKN3	OTBE3H07	Strong	Biomarker	[865]
CEBPD	OTNBIPMY	Strong	Biomarker	[866]
CEBPE	OTKZA25M	Strong	Altered Expression	[867]
CENPV	OTPQ0KT9	Strong	Altered Expression	[868]
CHD1	OT9R9G0H	Strong	Genetic Variation	[869]
CHD4	OTBDEHDP	Strong	Biomarker	[870]
CHD8	OTS7A6AF	Strong	Biomarker	[794]
CHMP5	OTQWZL6R	Strong	Genetic Variation	[23]
CHORDC1	OT3W6F1U	Strong	Biomarker	[871]
CIB1	OT4BVCRU	Strong	Biomarker	[872]
CIP2A	OTVS2GXA	Strong	Biomarker	[406]
CIR1	OTKP5JKH	Strong	Biomarker	[349]
CITED2	OT812TV7	Strong	Genetic Variation	[74]
CKMT1A	OTCINHH5	Strong	Biomarker	[873]
CLPB	OT1I0IBK	Strong	Altered Expression	[874]
CLTC	OTBFASMA	Strong	Biomarker	[573]
CNTNAP1	OT5Y03EU	Strong	Altered Expression	[875]
COL12A1	OTHLTV53	Strong	Biomarker	[876]
CP	OTM8JE4Y	Strong	Genetic Variation	[23]
CPNE3	OTCR3WG2	Strong	Altered Expression	[877]
CPT1A	OTI862QH	Strong	Biomarker	[878]
CRIP1	OT0EICG3	Strong	Biomarker	[879]
CRISPLD2	OTVSFHTL	Strong	Altered Expression	[226]
CRYL1	OT0SJSJM	Strong	Biomarker	[880]
CST3	OTNZ6AO4	Strong	Biomarker	[224]
CTC1	OTRJY7QD	Strong	Biomarker	[240]
CTCF	OT8ZB70U	Strong	Genetic Variation	[881]
CTSZ	OTSCX2LL	Strong	Biomarker	[224]
CUEDC2	OTWMOLAJ	Strong	Biomarker	[109]
CUL2	OTPF83PG	Strong	Biomarker	[109]
DAP	OT5YLL7E	Strong	Biomarker	[882]
DAPK1	OTNCNUCO	Strong	Biomarker	[883]
DAPK2	OTWODUQG	Strong	Altered Expression	[884]
DCC	OT2C1SHW	Strong	Genetic Variation	[885]
DCDC2	OTSUFH1H	Strong	Biomarker	[886]
DDA1	OTAZIAIH	Strong	Biomarker	[887]
DDIT3	OTI8YKKE	Strong	Biomarker	[888]
DDT	OTF5HTYL	Strong	Genetic Variation	[889]
DDX18	OTKB9C3S	Strong	Genetic Variation	[890]
DERL1	OTJUS74N	Strong	Genetic Variation	[891]
DGUOK	OT78HUZB	Strong	Altered Expression	[892]
DHDDS	OTVLYBUS	Strong	Genetic Variation	[23]
DIXDC1	OT87DXEG	Strong	Altered Expression	[893]
DKC1	OTX7DJR6	Strong	Biomarker	[894]
DOCK11	OTFSTN6A	Strong	Altered Expression	[895]
DOCK2	OTZTS3PA	Strong	Biomarker	[422]
DOCK5	OT63I0CL	Strong	Altered Expression	[896]
DOCK6	OTPNUVLT	Strong	Genetic Variation	[897]
DOK1	OTGVRLW6	Strong	Biomarker	[898]
DOK2	OTIJ38UF	Strong	Biomarker	[898]
DOK7	OTR2V7HO	Strong	Altered Expression	[899]
DPP6	OTWW3H0K	Strong	Genetic Variation	[23]
DRAM1	OTIJTXEN	Strong	Biomarker	[900]
E2F4	OTB3JFH4	Strong	Genetic Variation	[901]
EBF1	OTZ61YYH	Strong	Genetic Variation	[23]
EBF3	OTB0IWLW	Strong	Posttranslational Modification	[902]
EEF1A1	OT00THXS	Strong	Altered Expression	[903]
EFS	OT06O7XL	Strong	Biomarker	[904]
EGR2	OTAVQ78J	Strong	Altered Expression	[905]
EHD3	OTOKC2G5	Strong	Posttranslational Modification	[224]
EIF1	OTB4GZ0V	Strong	Altered Expression	[454]
EIF2S1	OTM0GDTP	Strong	Altered Expression	[906]
EIF2S2	OTXF0B09	Strong	Altered Expression	[906]
EIF2S3	OTARRES9	Strong	Altered Expression	[906]
EIF3D	OTDOMP80	Strong	Biomarker	[907]
EIF4B	OTE8TXA8	Strong	Biomarker	[428]
ELF5	OTLRU8YF	Strong	Biomarker	[908]
ELK1	OTH9MXD6	Strong	Altered Expression	[828]
ELOC	OT0XHHWP	Strong	Biomarker	[109]
ENO2	OTRODL0T	Strong	Biomarker	[224]
EP400	OTVQ75NX	Strong	Biomarker	[909]
EPC1	OT3Q25ND	Strong	Biomarker	[909]
EPC2	OTTG0W9R	Strong	Biomarker	[909]
EPS8	OTZ6ES6V	Strong	Altered Expression	[910]
ERC1	OTYBGGNO	Strong	Genetic Variation	[23]
ERVW-1	OTWV8DXJ	Strong	Altered Expression	[911]
ESPL1	OTMGEVOK	Strong	Altered Expression	[912]
ETV6	OTCZMG61	Strong	Autosomal dominant	[185]
EXOSC3	OTNCF906	Strong	Genetic Variation	[913]
EXOSC5	OTADUQ7H	Strong	Altered Expression	[914]
FADD	OTV7GFHH	Strong	Biomarker	[915]
FANCC	OTTIDM3P	Strong	Biomarker	[916]
FANCD2	OTVEB5LF	Strong	Biomarker	[240]
FANCE	OTKRPBW1	Strong	Biomarker	[240]
FANCG	OT7MC8TZ	Strong	Biomarker	[240]
FANCI	OTW8E3SC	Strong	Biomarker	[240]
FANCL	OTJC7QPQ	Strong	Biomarker	[240]
FBXL2	OT5EZ7PD	Strong	Altered Expression	[917]
FBXO8	OTZNGJGW	Strong	Altered Expression	[918]
FBXO9	OTW5P5JF	Strong	Biomarker	[850]
FBXW4	OTEGSZOX	Strong	Genetic Variation	[804]
FCGR3B	OTSLSPZG	Strong	Biomarker	[112]
FEZ1	OTWCXPRE	Strong	Biomarker	[919]
FH	OTEQWU6Q	Strong	Altered Expression	[920]
FHL2	OT0OAYWT	Strong	Altered Expression	[921]
FLI1	OT0EV3LX	Strong	Altered Expression	[922]
FLT3LG	OTU0YGC4	Strong	Altered Expression	[923]
FLYWCH1	OTWZVRX2	Strong	Altered Expression	[924]
FOXN3	OTOJYJZP	Strong	Biomarker	[925]
FOXO3	OTHXQG4P	Strong	Altered Expression	[926]
FRYL	OTBN3XHN	Strong	Genetic Variation	[927]
FTL	OTYQA8A6	Strong	Altered Expression	[308]
FUBP1	OT77SC9N	Strong	Biomarker	[928]
FUT6	OTBZUQ7F	Strong	Altered Expression	[88]
FUT7	OTJF6BSN	Strong	Biomarker	[929]
FXYD6	OTHOQXGF	Strong	Biomarker	[224]
FZD1	OTZATHVS	Strong	Altered Expression	[930]
FZD3	OTIWDN78	Strong	Biomarker	[931]
FZD4	OTGLZIE0	Strong	Biomarker	[519]
FZD6	OTBCPII8	Strong	Biomarker	[932]
FZD9	OTTZ9MKK	Strong	Posttranslational Modification	[933]
FZR1	OT0WGWZS	Strong	Altered Expression	[934]
GAS2L1	OTGFPWYN	Strong	Biomarker	[224]
GAS7	OT0M5TNY	Strong	Biomarker	[935]
GATA2	OTBP2QQ2	Strong	Autosomal dominant	[185]
GFI1	OT9HB9H8	Strong	Genetic Variation	[936]
GHRH	OT94U6MO	Strong	Biomarker	[310]
GLI3	OTKDOE94	Strong	Genetic Variation	[23]
GLIS2	OTOUUV1X	Strong	Biomarker	[937]
GNL3	OTILGYO4	Strong	Biomarker	[938]
GOLGA6A	OTHU9MRX	Strong	Biomarker	[192]
GORASP1	OTQS91S7	Strong	Genetic Variation	[23]
GPR42	OTEB0ROY	Strong	Biomarker	[217]
GPR68	OT1NXSMN	Strong	Altered Expression	[245]
GPRC5C	OT45AJT3	Strong	Biomarker	[315]
GSPT1	OT18H1B0	Strong	Biomarker	[939]
GTF2I	OTUYL1TQ	Strong	Biomarker	[476]
GZMA	OT43R33L	Strong	Altered Expression	[226]
H1-0	OTRLJK4Z	Strong	Biomarker	[224]
H1-1	OTSS815G	Strong	Genetic Variation	[940]
H4C1	OTB71W46	Strong	Altered Expression	[941]
HCST	OTILCB4K	Strong	Biomarker	[942]
HERC5	OTZ5PR39	Strong	Biomarker	[586]
HES1	OT8P19W2	Strong	Biomarker	[943]
HEY1	OTJQL0I3	Strong	Biomarker	[385]
HHEX	OTLIUVYX	Strong	Biomarker	[944]
HIC1	OTI9TWY4	Strong	Biomarker	[945]
HIP1	OT7AKCFQ	Strong	Altered Expression	[946]
HLA-C	OTV38BUJ	Strong	Genetic Variation	[947]
HLA-DMB	OT17HGXJ	Strong	Biomarker	[380]
HLA-DOB	OTKADDUB	Strong	Genetic Variation	[386]
HLF	OTTRK9XN	Strong	Biomarker	[865]
HMMR	OT4M0JTZ	Strong	Biomarker	[948]
HNRNPK	OTNPRM8U	Strong	Biomarker	[949]
HOXA2	OT6G6ZIK	Strong	Altered Expression	[950]
HOXA3	OTIX5XFB	Strong	Biomarker	[950]
HOXB2	OTTD6HMV	Strong	Biomarker	[951]
HOXB4	OTH1HRW5	Strong	Altered Expression	[885]
HOXC11	OT8NMHM6	Strong	Genetic Variation	[952]
HOXC13	OT52AVNA	Strong	Genetic Variation	[23]
HOXC4	OT52VJ6V	Strong	Altered Expression	[953]
HOXC5	OTPQTLKZ	Strong	Altered Expression	[953]
HOXC6	OTBCRAZV	Strong	Altered Expression	[953]
HOXD10	OT0NOWU2	Strong	Biomarker	[954]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[23]
HS3ST3B1	OTK53GUD	Strong	Biomarker	[955]
IBTK	OTB2GM4G	Strong	Biomarker	[956]
ICMT	OT8CNKBO	Strong	Biomarker	[957]
ID4	OTPMJ39I	Strong	Posttranslational Modification	[958]
IFI30	OT9DERT1	Strong	Biomarker	[224]
IFITM3	OT2QP8D3	Strong	Altered Expression	[959]
IGF2BP1	OT9G360P	Strong	Biomarker	[960]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[961]
IKBKE	OT5VYOSM	Strong	Biomarker	[457]
IL17B	OTS86H50	Strong	Biomarker	[962]
IL17RB	OT0KDNSF	Strong	Biomarker	[962]
IL18R1	OT83XMPQ	Strong	Biomarker	[290]
INO80C	OTKXHGET	Strong	Biomarker	[73]
IRF7	OTC1A2PQ	Strong	Altered Expression	[963]
IRX3	OTLJ48FG	Strong	Altered Expression	[964]
IST1	OTSFEZ2O	Strong	Genetic Variation	[940]
ITGA2B	OT4Y17PY	Strong	Genetic Variation	[23]
ITGAX	OTOGIMHE	Strong	Genetic Variation	[23]
ITGBL1	OTJDHE17	Strong	Biomarker	[965]
ITPKB	OTSVVPAV	Strong	Biomarker	[966]
JAG1	OT3LGT6K	Strong	Altered Expression	[967]
JUND	OTNKACJD	Strong	Altered Expression	[652]
KAT7	OTUN98IC	Strong	Biomarker	[968]
KAT8	OT5LPQTR	Strong	Altered Expression	[969]
KATNB1	OT7CLZKS	Strong	Biomarker	[178]
KCNH4	OTHJ8WTU	Strong	Altered Expression	[828]
KCNH8	OT3I5FLB	Strong	Altered Expression	[828]
KDM3B	OTZU5J5S	Strong	Altered Expression	[970]
KDM6A	OTZM3MJJ	Strong	Genetic Variation	[971]
KIR2DL5B	OTSV0JL9	Strong	Genetic Variation	[355]
KIR3DS1	OTJWIO4T	Strong	Biomarker	[972]
KLF5	OT1ABI9N	Strong	Altered Expression	[973]
KLHL1	OTAX6SAD	Strong	Altered Expression	[216]
KLRD1	OTMYLOV4	Strong	Biomarker	[974]
KMT2B	OTMMAZQX	Strong	Biomarker	[975]
KMT2C	OTC59BCO	Strong	Genetic Variation	[976]
KRT20	OT4RB40L	Strong	Biomarker	[379]
KRT7	OTLT3JFN	Strong	Altered Expression	[590]
L3MBTL1	OT8M52QY	Strong	Genetic Variation	[977]
L3MBTL2	OTKX1XIX	Strong	Genetic Variation	[977]
LAMP5	OTC672RM	Strong	Altered Expression	[502]
LAMTOR2	OTHEDISB	Strong	Posttranslational Modification	[863]
LARP4B	OT2HI0QE	Strong	Biomarker	[978]
LBH	OT87AT1X	Strong	Biomarker	[178]
LBR	OT1HG3HG	Strong	Genetic Variation	[979]
LCP2	OT57KE22	Strong	Biomarker	[381]
LDOC1	OTWZH4O9	Strong	Biomarker	[70]
LEF1	OTWS5I5H	Strong	Biomarker	[980]
LEO1	OTAPF4PA	Strong	Altered Expression	[981]
LEUTX	OTZV9IH0	Strong	Genetic Variation	[982]
LIG3	OT48SKET	Strong	Altered Expression	[983]
LIN28B	OTVWP0FN	Strong	Altered Expression	[984]
LLGL1	OTAIQSXZ	Strong	Altered Expression	[985]
LPP	OT6TU8SE	Strong	Biomarker	[986]
LRG1	OTLD0KWA	Strong	Biomarker	[987]
LYL1	OTCNOV1M	Strong	Biomarker	[988]
MACROH2A1	OTV2DQDD	Strong	Biomarker	[989]
MAD2L2	OT24ZO59	Strong	Biomarker	[240]
MAFB	OTH2N3T8	Strong	Altered Expression	[990]
MAGEB2	OTAGUVU5	Strong	Altered Expression	[368]
MAK16	OTD546E5	Strong	Biomarker	[417]
MAML2	OT1TSVAR	Strong	Genetic Variation	[991]
MARK1	OTP7KL47	Strong	Altered Expression	[438]
MATK	OTVOJJLJ	Strong	Biomarker	[360]
MBD3	OTRL76H5	Strong	Biomarker	[896]
MBD4	OTWR9YXE	Strong	Biomarker	[992]
MCAT	OTH07FIW	Strong	Altered Expression	[270]
MCF2L2	OTOGFMIH	Strong	Biomarker	[993]
MCTS1	OT7SAOJP	Strong	Altered Expression	[270]
MED12	OTQZ4D2X	Strong	Genetic Variation	[710]
MEF2C	OTZGF1Y5	Strong	Biomarker	[439]
MEFV	OTRJ6S6K	Strong	Genetic Variation	[994]
MEIS2	OTG4ADLM	Strong	Biomarker	[995]
METTL14	OT6TPQMH	Strong	Biomarker	[996]
MIXL1	OT584VOQ	Strong	Biomarker	[423]
MLF1	OTC5BKHU	Strong	Biomarker	[997]
MLLT11	OTG5RVHC	Strong	Genetic Variation	[998]
MLLT6	OTOC9OGX	Strong	Genetic Variation	[999]
MLXIPL	OTR9MLLW	Strong	Altered Expression	[1000]
MNX1	OTXP9FH1	Strong	Genetic Variation	[1001]
MOGS	OT99MBGB	Strong	Genetic Variation	[1002]
MOK	OTQK7M9V	Strong	Altered Expression	[1003]
MORC3	OT81NKVT	Strong	Biomarker	[1004]
MPI	OTBH6ZK1	Strong	Biomarker	[589]
MPST	OTCDPH5D	Strong	Biomarker	[369]
MS4A3	OT0CEJOO	Strong	Biomarker	[1005]
MSTO1	OT37XCNP	Strong	Biomarker	[369]
MSX1	OT5U41ZP	Strong	Altered Expression	[1006]
MT3	OTVCZ7HI	Strong	Posttranslational Modification	[1007]
MTF2	OTNL1O2O	Strong	Biomarker	[1008]
MTHFD2	OT1LQSGX	Strong	Altered Expression	[1009]
MTSS1	OT5DTDO2	Strong	Biomarker	[1010]
MUL1	OT2JC9YR	Strong	Altered Expression	[850]
MX1	OT6X8G5T	Strong	Biomarker	[224]
MYBL2	OTZ3JX8Q	Strong	Genetic Variation	[1011]
MYH8	OT9F350W	Strong	Genetic Variation	[1012]
MYH9	OT94Z706	Strong	Altered Expression	[1013]
MYOF	OTRFC3IJ	Strong	Biomarker	[1014]
MZB1	OT071TET	Strong	Altered Expression	[1015]
NBEAL2	OTMCAXWR	Strong	Biomarker	[966]
NBR1	OTVRL7J9	Strong	Altered Expression	[1016]
NCALD	OTJZ8UEL	Strong	Altered Expression	[1017]
NCOR1	OT04XNOU	Strong	Biomarker	[1018]
NCR3	OT20M764	Strong	Biomarker	[1019]
NDRG2	OT5L6KD7	Strong	Biomarker	[466]
NDUFA2	OTNSTATK	Strong	Biomarker	[1020]
NELL2	OTS4MJZ7	Strong	Biomarker	[388]
NEUROD1	OTZQ7QJ2	Strong	Biomarker	[813]
NF1	OTC29NHH	Strong	Genetic Variation	[1021]
NFATC1	OT4TMERS	Strong	Biomarker	[1022]
NFE2	OTLM94BI	Strong	Genetic Variation	[1023]
NIPA1	OT9ODC8X	Strong	Biomarker	[236]
NKD1	OTY3MO97	Strong	Altered Expression	[1024]
NOL3	OT1K0L0D	Strong	Biomarker	[1025]
NPAS2	OTMRT2TS	Strong	Biomarker	[1026]
NR2C2	OTDZWVOJ	Strong	Biomarker	[118]
NRM	OTK7F9XZ	Strong	Biomarker	[1027]
NRROS	OT9WNOKY	Strong	Biomarker	[1028]
NSMCE2	OTJXLDC9	Strong	Biomarker	[1029]
NT5C3A	OT67KZJA	Strong	Genetic Variation	[1030]
NUDCD1	OT8DS3CX	Strong	Biomarker	[914]
NUP205	OTJKHCY6	Strong	Biomarker	[1031]
NUP214	OTWEA19O	Strong	Biomarker	[1032]
NUP43	OTDF5K8Y	Strong	Biomarker	[264]
ORC5	OTFPW8DE	Strong	Genetic Variation	[1033]
PA2G4	OT7IG7HT	Strong	Altered Expression	[1034]
PAF1	OTDDGUBQ	Strong	Posttranslational Modification	[1035]
PALB2	OT6DNDBG	Strong	Biomarker	[240]
PARP9	OT7K4494	Strong	Genetic Variation	[23]
PBX3	OT8WMVM4	Strong	Altered Expression	[1036]
PCDH17	OTRK0M05	Strong	Altered Expression	[1037]
PDC	OT1UUVYY	Strong	Biomarker	[1038]
PDCD4	OTZ6NXUX	Strong	Biomarker	[1039]
PDIA3	OTHPQ0Q3	Strong	Biomarker	[1040]
PELI1	OTMLBCLC	Strong	Biomarker	[1041]
PER3	OTVKYVJA	Strong	Altered Expression	[609]
PHLPP2	OTXB1OUI	Strong	Altered Expression	[1042]
PIGN	OTHHTJKX	Strong	Altered Expression	[1043]
PIP	OTH719AH	Strong	Biomarker	[1044]
PIP4K2A	OTO9JO9U	Strong	Altered Expression	[1045]
PIP4K2B	OTF1VGJ9	Strong	Altered Expression	[1045]
PIP4K2C	OTHRWR93	Strong	Biomarker	[1045]
PIR	OT8ALXHU	Strong	Biomarker	[1046]
PKD1	OT5ALRZ5	Strong	Biomarker	[1047]
PLAAT4	OTI66SAJ	Strong	Biomarker	[1048]
PLEC	OTU4XDEG	Strong	Biomarker	[1049]
PLS3	OTYBM4PK	Strong	Altered Expression	[1050]
PLSCR1	OTGY9B5T	Strong	Genetic Variation	[1051]
PM20D1	OTXXNQ5K	Strong	Posttranslational Modification	[791]
PNO1	OT010GIS	Strong	Biomarker	[417]
POLR2A	OTHJQ1DZ	Strong	Biomarker	[1052]
POT1	OTNBXJCQ	Strong	Genetic Variation	[1053]
POTEF	OTV3WXYE	Strong	Altered Expression	[1054]
POU5F1B	OT0FKQ51	Strong	Biomarker	[1055]
PPP1R13B	OTC88VQO	Strong	Biomarker	[1056]
PPP1R13L	OTNCPLWE	Strong	Altered Expression	[921]
PPP1R1A	OTGTAGCV	Strong	Genetic Variation	[1057]
PPP2R2A	OT9297OG	Strong	Altered Expression	[1058]
PRC1	OTHD0XS0	Strong	Biomarker	[1059]
PRDM1	OTQLSVBS	Strong	Altered Expression	[1060]
PRDM16	OT0BGA27	Strong	Biomarker	[1061]
PRDM5	OTU1GB68	Strong	Biomarker	[119]
PRDM6	OTKY12D9	Strong	Biomarker	[1041]
PRDX3	OTLB2WEU	Strong	Biomarker	[1062]
PREX1	OTUTPVA9	Strong	Biomarker	[1063]
PRKACB	OT6RMDCE	Strong	Biomarker	[1064]
PRKD2	OTIFSVI8	Strong	Altered Expression	[1065]
PRKN	OTJBN41W	Strong	Altered Expression	[850]
PRM3	OT6574BF	Strong	Biomarker	[1066]
PRPF31	OTSJ0Z1Y	Strong	Altered Expression	[1067]
PRPF8	OTU39JZI	Strong	Genetic Variation	[1068]
PRRT2	OTCJUBDO	Strong	Biomarker	[410]
PRSS27	OTC4G4UF	Strong	Biomarker	[1069]
PSMA7	OTPHI6ST	Strong	Biomarker	[1070]
PSMC6	OTG8997V	Strong	Biomarker	[264]
PTPRR	OT790UA2	Strong	Genetic Variation	[843]
PTPRU	OTHDO0QG	Strong	Altered Expression	[569]
PVR	OT3N91T7	Strong	Biomarker	[465]
PXDN	OTFGGM9R	Strong	Biomarker	[224]
QRSL1	OTJDU2UG	Strong	Altered Expression	[1071]
RAB27A	OT9SQRWY	Strong	Biomarker	[1072]
RAB27B	OTPF9D0K	Strong	Biomarker	[1073]
RAB40B	OTCA9ZF5	Strong	Biomarker	[1074]
RABGEF1	OTWC3Z3R	Strong	Genetic Variation	[23]
RALB	OTFH203X	Strong	Biomarker	[1075]
RAMAC	OTAFAKPR	Strong	Biomarker	[1072]
RAP1GDS1	OTH70UHD	Strong	Biomarker	[1076]
RASGRP1	OTX9WN2E	Strong	Biomarker	[605]
RBM25	OTVOUOAG	Strong	Altered Expression	[1077]
RBM39	OTCMPTF9	Strong	Biomarker	[417]
RBMS3	OTFSC9MR	Strong	Biomarker	[417]
RCBTB1	OTAYELI8	Strong	Biomarker	[192]
REM1	OTUXL0HC	Strong	Biomarker	[1078]
RFC3	OT1MS7AO	Strong	Altered Expression	[1079]
RIPK3	OTL1D484	Strong	Biomarker	[543]
RMDN1	OTE1NB6U	Strong	Altered Expression	[767]
RMDN2	OTK5WSFI	Strong	Altered Expression	[767]
RMI1	OT1ZVTFL	Strong	Genetic Variation	[1080]
RNASE3	OTVE2XD1	Strong	Biomarker	[1081]
RNF2	OTFPLOIN	Strong	Biomarker	[1082]
ROBO2	OTFJ9FQW	Strong	Altered Expression	[1083]
RPP14	OT4OYFSK	Strong	Posttranslational Modification	[863]
RPRM	OTNNBAS1	Strong	Posttranslational Modification	[1084]
RPS14	OTB90KV5	Strong	Biomarker	[1085]
RPS15A	OT0BUA12	Strong	Biomarker	[1086]
RPS19	OTBKGP48	Strong	Biomarker	[1087]
RRAS	OTBBF28C	Strong	Genetic Variation	[1088]
RREB1	OT62460U	Strong	Altered Expression	[1089]
RRM2B	OTE8GBUR	Strong	Biomarker	[1090]
RTL1	OTOT33IM	Strong	Biomarker	[405]
RUNX1	OTU7J84H	Strong	Autosomal dominant	[185]
RUVBL2	OTGWJ4T4	Strong	Biomarker	[128]
SALL1	OTYYZGLH	Strong	Biomarker	[1091]
SARDH	OTQ49Q27	Strong	Biomarker	[520]
SBDS	OTHDCCIB	Strong	Biomarker	[240]
SCIN	OT6U09OL	Strong	Altered Expression	[1092]
SCPEP1	OT43LYEZ	Strong	Biomarker	[275]
SDS	OT5WTJ2M	Strong	Biomarker	[573]
SEPTIN2	OT3G33TM	Strong	Altered Expression	[437]
SETBP1	OTKGCOSR	Strong	Genetic Variation	[1093]
SETD1A	OTVVWRIC	Strong	Biomarker	[1094]
SETMAR	OTE2MIMZ	Strong	Genetic Variation	[1095]
SF3B2	OTNW2U4Y	Strong	Genetic Variation	[1096]
SF3B6	OTPRKS6S	Strong	Posttranslational Modification	[863]
SGCZ	OTVGTEOD	Strong	Genetic Variation	[23]
SGK3	OTQ6QO99	Strong	Biomarker	[1097]
SH3BGRL	OTUOCTMT	Strong	Biomarker	[1098]
SH3BP5	OTOOEGUJ	Strong	Biomarker	[1099]
SHB	OTF2HSC0	Strong	Altered Expression	[1100]
SIPA1L3	OTNYFUM3	Strong	Genetic Variation	[1101]
SIX1	OT70YYWM	Strong	Biomarker	[1102]
SKI	OT4KJ8F6	Strong	Altered Expression	[1103]
SLC12A9	OTR7VRAK	Strong	Biomarker	[1104]
SLU7	OTZUUICN	Strong	Genetic Variation	[1068]
SLX4	OTF6236I	Strong	Biomarker	[240]
SMAD5	OTQNSVCQ	Strong	Genetic Variation	[1105]
SMARCA5	OT5GR4Z2	Strong	Altered Expression	[1106]
SMARCC1	OTUOMBE7	Strong	Biomarker	[802]
SMC3	OTWGFRHD	Strong	Genetic Variation	[1107]
SMC4	OTEJE6AG	Strong	Biomarker	[1108]
SMG1	OTTS3SXE	Strong	Biomarker	[1109]
SNAI1	OTDPYAMC	Strong	Biomarker	[1110]
SNAP91	OTE3EXWZ	Strong	Biomarker	[711]
SNF8	OTRQA2AI	Strong	Altered Expression	[1111]
SNRNP200	OTSAU864	Strong	Biomarker	[1112]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[1113]
SOCS2	OTBPNKJQ	Strong	Altered Expression	[1078]
SOS1	OTTCWXC3	Strong	Genetic Variation	[1114]
SOX12	OT93P8C9	Strong	Altered Expression	[1115]
SOX17	OT9H4WWE	Strong	Altered Expression	[1116]
SOX18	OTPUMHWA	Strong	Altered Expression	[1117]
SOX6	OTT0W0LE	Strong	Altered Expression	[1118]
SOX7	OTOZOFAG	Strong	Biomarker	[1119]
SPACA3	OTM1JKTC	Strong	Altered Expression	[1120]
SPANXA1	OTMK3QIS	Strong	Altered Expression	[1121]
SPI1	OTVCA1D0	Strong	Altered Expression	[222]
SPINK1	OTSUVAL2	Strong	Biomarker	[1122]
SPINK2	OTSFBT0G	Strong	Biomarker	[1123]
SRI	OT4R3EAC	Strong	Biomarker	[1124]
SRL	OT7IEBWZ	Strong	Biomarker	[520]
SRRM2	OTSIMMC9	Strong	Biomarker	[417]
SRSF1	OTF61HOV	Strong	Biomarker	[843]
SSX2	OT2Z6RLL	Strong	Altered Expression	[1003]
ST3GAL4	OTNENJZQ	Strong	Altered Expression	[929]
STK3	OTLNSCQD	Strong	Biomarker	[1125]
STUB1	OTSUYI9A	Strong	Biomarker	[888]
STX11	OTHFRSFP	Strong	Biomarker	[1126]
SYBU	OT3FQV7N	Strong	Altered Expression	[767]
SYCE1L	OTXU44F3	Strong	Altered Expression	[216]
SYCP1	OTWFV4KA	Strong	Biomarker	[275]
SYCP3	OTKOF54H	Strong	Altered Expression	[1127]
SYNE1	OTSBSLUH	Strong	Genetic Variation	[518]
SYNE2	OTBUXGQ0	Strong	Genetic Variation	[1128]
SYNGR1	OT0MBUK5	Strong	Biomarker	[224]
SYT1	OTVTPOI6	Strong	Biomarker	[490]
TAF1	OTDYS5G4	Strong	Biomarker	[1129]
TAF12	OTQZII5O	Strong	Biomarker	[1130]
TAF4	OTPIRFEF	Strong	Altered Expression	[1130]
TAL1	OTX4K6QZ	Strong	Altered Expression	[590]
TAP2	OTWSYFI7	Strong	Altered Expression	[1131]
TAT	OT2CJ91O	Strong	Biomarker	[1132]
TBCE	OTGBSTKS	Strong	Biomarker	[1133]
TBP	OT6C0S52	Strong	Biomarker	[1130]
TCEA2	OT1OS9TY	Strong	Biomarker	[224]
TCF21	OT393IMA	Strong	Biomarker	[1134]
TCIM	OTARUXQF	Strong	Genetic Variation	[1135]
TERT	OT085VVA	Strong	Autosomal dominant	[185]
TFE3	OTM99ZWH	Strong	Genetic Variation	[1136]
TFPI2	OTZCRWOR	Strong	Altered Expression	[1137]
TFR2	OTMYCCEO	Strong	Genetic Variation	[1138]
TGIF1	OTN9VHAG	Strong	Biomarker	[1139]
THAP10	OTCMT4L7	Strong	Biomarker	[1140]
TIFA	OTIRCVG7	Strong	Biomarker	[1141]
TIGAR	OTR7NMRJ	Strong	Biomarker	[1142]
TIMM8A	OTDX9687	Strong	Genetic Variation	[1143]
TIMP2	OT8S1RRP	Strong	Genetic Variation	[1144]
TIMP3	OTDGQAD1	Strong	Biomarker	[1145]
TLE1	OT50MRZ1	Strong	Biomarker	[1146]
TLE4	OT4QEH6T	Strong	Genetic Variation	[23]
TLE5	OTEH0BFG	Strong	Biomarker	[1147]
TMEM11	OTL9HDEY	Strong	Biomarker	[589]
TMEM18	OT05YQ1E	Strong	Altered Expression	[1148]
TMPRSS11F	OTRUQ164	Strong	Altered Expression	[1149]
TNFSF9	OTV9L89D	Strong	Altered Expression	[257]
TPD52	OTPKSK43	Strong	Altered Expression	[1150]
TPD52L2	OTTOG0NK	Strong	Biomarker	[928]
TPM3	OT5RU5G6	Strong	Biomarker	[1151]
TRADD	OTBOSJHO	Strong	Biomarker	[1152]
TRAF2	OT1MEZZN	Strong	Biomarker	[1153]
TRAF3	OT5TQBGV	Strong	Genetic Variation	[212]
TRAF7	OTW8Q5TF	Strong	Biomarker	[1154]
TRAIP	OTMPT9Y2	Strong	Biomarker	[1141]
TREML1	OTMJD2HI	Strong	Genetic Variation	[528]
TRIM62	OT15YO6N	Strong	Altered Expression	[1155]
TRIO	OT71X1AK	Strong	Biomarker	[476]
TSC22D1	OTN4GFWD	Strong	Altered Expression	[1156]
TSGA10	OTIF1O1T	Strong	Biomarker	[1157]
TSPAN3	OT7WS6ZI	Strong	Altered Expression	[530]
TSTD1	OT5DMKFX	Strong	Biomarker	[178]
TTC4	OTAPMYXU	Strong	Biomarker	[1158]
AIFM1	OTKPWB7Q	Definitive	Biomarker	[1159]
AP2A1	OTEFZB21	Definitive	Altered Expression	[1160]
AP5M1	OTDLWEBL	Definitive	Genetic Variation	[1161]
ARID5B	OTUQ4CQY	Definitive	Genetic Variation	[670]
ASXL1	OTX931AW	Definitive	Genetic Variation	[795]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[1162]
ATXN1	OTQF0HNR	Definitive	Biomarker	[1163]
BAALC	OTUZSRVF	Definitive	Altered Expression	[1164]
BAD	OT63ERYM	Definitive	Biomarker	[1165]
BAG1	OTRQNIA4	Definitive	Genetic Variation	[23]
BARD1	OTTC0Z9Y	Definitive	Altered Expression	[1166]
BCAS3	OTDVAX6B	Definitive	Biomarker	[1167]
BCL11B	OT8KKCVJ	Definitive	Genetic Variation	[1168]
BCL2L12	OTS6IFZY	Definitive	Altered Expression	[1169]
BIRC6	OTCQJAB0	Definitive	Biomarker	[1170]
BSPH1	OTLLM5JY	Definitive	Biomarker	[1171]
BUB1B	OT8KME51	Definitive	Altered Expression	[1172]
CALM2	OTNYA92F	Definitive	Biomarker	[711]
CD200R1	OT65Q9M6	Definitive	Altered Expression	[1173]
CD72	OTPOJID2	Definitive	Biomarker	[1174]
CDC73	OT6JASZ1	Definitive	Biomarker	[1035]
CEBPA	OTOM9OE4	Definitive	Autosomal dominant	[504]
CEBPG	OTGNAX3H	Definitive	Biomarker	[1175]
CETN1	OTGQ8JOZ	Definitive	Biomarker	[1176]
CHFR	OTRAD2TT	Definitive	Altered Expression	[1177]
CIITA	OTRJNZFO	Definitive	Altered Expression	[1178]
CLEC4D	OTT7X1UC	Definitive	Biomarker	[855]
CLEC7A	OTRTBH27	Definitive	Genetic Variation	[211]
CNDP2	OTJR9436	Definitive	Genetic Variation	[23]
COP1	OT6J2K12	Definitive	Altered Expression	[1179]
CPQ	OTTNZNLD	Definitive	Altered Expression	[1180]
DAXX	OTX6O7PL	Definitive	Biomarker	[1181]
DEXI	OT60W9CN	Definitive	Biomarker	[1178]
DOCK1	OTCFV3ON	Definitive	Biomarker	[895]
DOCK4	OTH3XY8B	Definitive	Genetic Variation	[1182]
DTX2	OT7QLDU4	Definitive	Genetic Variation	[1183]
E2F7	OTWW358N	Definitive	Altered Expression	[1184]
EIF3A	OTFABY9G	Definitive	Altered Expression	[1185]
ELOVL6	OTB26UJJ	Definitive	Genetic Variation	[1186]
EOMES	OTB9VQFA	Definitive	Biomarker	[1187]
ERG	OTOTX9VU	Definitive	Altered Expression	[1188]
FCHSD2	OTKXLIJ6	Definitive	Altered Expression	[1189]
FXYD5	OT81DIOD	Definitive	Biomarker	[1190]
FZD5	OTXFFY56	Definitive	Biomarker	[930]
GABARAP	OTAQUX6E	Definitive	Biomarker	[1191]
GNA15	OTFYRZGV	Definitive	Biomarker	[505]
GNMT	OT0O2OQO	Definitive	Posttranslational Modification	[1192]
GPR151	OT7EACU6	Definitive	Biomarker	[519]
GPX3	OT6PK94R	Definitive	Posttranslational Modification	[1193]
GRB10	OTCKXGRC	Definitive	Biomarker	[1194]
H1-2	OT0AVI4M	Definitive	Genetic Variation	[23]
HLTF	OTRX2OSF	Definitive	Genetic Variation	[1195]
HOMER3	OTQ6D9X1	Definitive	Biomarker	[1196]
HOXA1	OTMSOJ7D	Definitive	Altered Expression	[950]
HS3ST2	OTWFA0GJ	Definitive	Biomarker	[494]
IER5	OTJPTXMD	Definitive	Altered Expression	[1197]
IRF9	OTK4MYQJ	Definitive	Altered Expression	[1198]
JAM3	OTX0F9QL	Definitive	Genetic Variation	[1199]
KDM2B	OTDMCVW7	Definitive	Biomarker	[1200]
KIAA1549L	OT80HUVY	Definitive	Biomarker	[1201]
LGALS9	OT7MF91K	Definitive	Biomarker	[1202]
LGR6	OTPZ1PWR	Definitive	Biomarker	[519]
MAGT1	OTQSAV5C	Definitive	Biomarker	[495]
MAP2K4	OTZPZX11	Definitive	Genetic Variation	[1203]
MCC	OTQVI1EM	Definitive	Biomarker	[1204]
METTL3	OTSXP1M3	Definitive	Altered Expression	[1205]
MN1	OTVQR4R9	Definitive	Biomarker	[1206]
MPP1	OTA2ENZQ	Definitive	Genetic Variation	[492]
MPRIP	OT5FV5NS	Definitive	Biomarker	[543]
MRGPRX3	OTRKCCDS	Definitive	Biomarker	[519]
MRGPRX4	OTOBHZVA	Definitive	Biomarker	[519]
MT1E	OTXJKU4Y	Definitive	Biomarker	[1207]
MXD1	OTS5CTHX	Definitive	Altered Expression	[532]
MYH10	OTXN2WXS	Definitive	Biomarker	[1208]
MYO18A	OT2YPT7O	Definitive	Genetic Variation	[1209]
NANOG	OTUEY1FM	Definitive	Altered Expression	[1210]
ND4	OT4RQVAA	Definitive	Genetic Variation	[1211]
NEBL	OT2WH1NC	Definitive	Biomarker	[1212]
NECTIN2	OTIE0W6O	Definitive	Biomarker	[465]
NFYB	OTXSE7KW	Definitive	Biomarker	[1197]
NMS	OTFYS4LO	Definitive	Biomarker	[1213]
NUMB	OTMB586Q	Definitive	Altered Expression	[1214]
OIP5	OTI5C2DE	Definitive	Altered Expression	[580]
OLIG2	OTMCN6D3	Definitive	Biomarker	[1215]
PBX1	OTORABGO	Definitive	Genetic Variation	[23]
PBX2	OTEBYCAW	Definitive	Biomarker	[1216]
PDCD7	OTK5YO7J	Definitive	Altered Expression	[222]
PGP	OT6QQ7OR	Definitive	Biomarker	[1217]
PLCB4	OTPA0QHW	Definitive	Biomarker	[1218]
POU1F1	OTXT8A5C	Definitive	Genetic Variation	[1219]
POU2F1	OTK7ELJ0	Definitive	Biomarker	[552]
PRDM2	OT8L7CGX	Definitive	Posttranslational Modification	[1220]
PRIMA1	OT9ITT3P	Definitive	Genetic Variation	[115]
PRPF40B	OTBPUXVD	Definitive	Genetic Variation	[1221]
PTPRE	OTOD5NID	Definitive	Altered Expression	[1222]
PTPRT	OTV5TXNN	Definitive	Genetic Variation	[23]
PURA	OT975ELW	Definitive	Genetic Variation	[1223]
PURB	OTCDDKYB	Definitive	Biomarker	[1224]
RAC2	OTAOHFNH	Definitive	Biomarker	[1225]
RAP1A	OT5RH6TI	Definitive	Biomarker	[1226]
RAP1GAP	OTC31ONQ	Definitive	Altered Expression	[1227]
RASGRF1	OTNWJ7EN	Definitive	Biomarker	[259]
RBM45	OTWTHD77	Definitive	Biomarker	[1228]
RCOR1	OTREADPC	Definitive	Biomarker	[1229]
RHEBL1	OTPOMM5J	Definitive	Altered Expression	[1230]
RHOH	OT1J9SEB	Definitive	Altered Expression	[1231]
RING1	OTCWTAX0	Definitive	Genetic Variation	[386]
ROBO3	OTPVG40S	Definitive	Biomarker	[508]
RPS6	OTT4D1LN	Definitive	Altered Expression	[232]
S100A10	OTI71243	Definitive	Genetic Variation	[913]
SDF4	OTQ7WFYW	Definitive	Biomarker	[1176]
SF3A1	OTI733D7	Definitive	Genetic Variation	[1221]
SHKBP1	OTJXWLEH	Definitive	Genetic Variation	[1232]
SIGLEC5	OTYC440J	Definitive	Biomarker	[1233]
SIN3A	OTM8OZWV	Definitive	Altered Expression	[843]
SMARCA2	OTSGJ8SV	Definitive	Genetic Variation	[1234]
SMARCD2	OTQTBWHW	Definitive	Biomarker	[802]
SMC1A	OT9ZMRK9	Definitive	Biomarker	[1235]
SORL1	OTQ8FFNS	Definitive	Altered Expression	[1236]
SPHKAP	OT5RHUYJ	Definitive	Altered Expression	[1237]
SPRED1	OTKX7P8G	Definitive	Posttranslational Modification	[1238]
SPRY4	OT2VK9N0	Definitive	Biomarker	[1239]
SRXN1	OTYDBO4L	Definitive	Biomarker	[1167]
SRY	OT516T6D	Definitive	Altered Expression	[1117]
TAF7L	OTPDZ6XV	Definitive	Altered Expression	[580]
TANK	OTZSGFIK	Definitive	Biomarker	[1141]
TAOK2	OTNUMOZ1	Definitive	Biomarker	[1240]
TCL1B	OT4CSO39	Definitive	Genetic Variation	[556]
TERF2IP	OT3M5P3G	Definitive	Biomarker	[1226]
TMEM132D	OTV6I4Z0	Definitive	Genetic Variation	[23]
TPR	OTUBBA4W	Definitive	Biomarker	[1241]
TTC5	OTWW9ME0	Definitive	Biomarker	[1242]

References

• [1] Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep;46(3):446-514.
• [2] Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May;15(5):610-7.
• [3] Azacitidine FDA Label
• [4] Clofarabine FDA Label
• [5] Cytarabine FDA Label
• [6] Daunorubicin FDA Label
• [7] Decitabine FDA Label
• [8] Doxorubicin FDA Label
• [9] Etoposide FDA Label
• [10] Fludarabine FDA Label
• [11] Idarubicin FDA Label
• [12] Mitoxantrone FDA Label
• [13] Sulindac FDA Label
• [14] Thioguanine FDA Label
• [15] Tretinoin FDA Label
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] ClinicalTrials.gov (NCT03059615) A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT04278768) Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT03081780) Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML). U.S.National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03038230) MCLA-117 in Acute Myelogenous Leukemia. U.S. National Institutes of Health.
• [22] Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line.Br J Haematol. 2002 Nov;119(2):454-8. doi: 10.1046/j.1365-2141.2002.03850.x.
• [23] Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.Oncotarget. 2017 Jan 31;8(5):7891-7899. doi: 10.18632/oncotarget.13631.
• [24] A novel MLL-AF10 fusion mRNA variant in a patient with acute myeloid leukemia detected by a new asymmetric reverse transcription PCR method.Leukemia. 1997 Sep;11(9):1588-93. doi: 10.1038/sj.leu.2400758.
• [25] Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.Blood. 2009 Sep 24;114(13):2733-43. doi: 10.1182/blood-2009-03-213496. Epub 2009 Jul 28.
• [26] Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.J Med Chem. 2019 Apr 11;62(7):3590-3616. doi: 10.1021/acs.jmedchem.9b00090. Epub 2019 Mar 25.
• [27] Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia.Int J Cancer. 2002 Sep 1;101(1):86-94. doi: 10.1002/ijc.10566.
• [28] CML with Megakaryocytic Blast Crisis: Report of 3 Cases.Pathol Oncol Res. 2019 Jul;25(3):1253-1258. doi: 10.1007/s12253-018-0484-7. Epub 2018 Oct 25.
• [29] Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.Blood. 1997 Sep 1;90(5):1968-76.
• [30] Acute myeloid leukaemia niche regulates response to L-asparaginase.Br J Haematol. 2019 Aug;186(3):420-430. doi: 10.1111/bjh.15920. Epub 2019 May 1.
• [31] Evaluation of ATG7 and Light Chain 3 (LC3) Autophagy Genes Expression in AML Patients.Iran J Pharm Res. 2019 Spring;18(2):1060-1066. doi: 10.22037/ijpr.2019.1100682.
• [32] Gilteritinib Likely New Standard Care for AML.Cancer Discov. 2019 Jun;9(6):OF6. doi: 10.1158/2159-8290.CD-NB2019-046. Epub 2019 Apr 1.
• [33] Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.Cell Death Dis. 2019 Dec 4;10(12):917. doi: 10.1038/s41419-019-2156-2.
• [34] BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy.Pharmacogenomics. 2018 Mar;19(4):343-348. doi: 10.2217/pgs-2017-0157. Epub 2018 Feb 22.
• [35] The Study of SALL4 Gene and BMI-1 Gene Expression in Acute Myeloid Leukemia Patients.Lab Med. 2020 May 6;51(3):265-270. doi: 10.1093/labmed/lmz056.
• [36] Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study.Br J Haematol. 2003 Jan;120(1):56-62. doi: 10.1046/j.1365-2141.2003.03981.x.
• [37] Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia.Proteomics. 2004 Nov;4(11):3456-63. doi: 10.1002/pmic.200400968.
• [38] Expression of hBUB1 in acute myeloid leukemia.Leuk Lymphoma. 2002 Feb;43(2):385-91. doi: 10.1080/10428190290006206.
• [39] Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.Haematologica. 2020 Jul;105(7):1868-1878. doi: 10.3324/haematol.2019.223933. Epub 2019 Oct 3.
• [40] Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.Clin Cancer Res. 1999 Dec;5(12):4041-7.
• [41] Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense.Cancer Manag Res. 2019 Jan 22;11:1023-1032. doi: 10.2147/CMAR.S187597. eCollection 2019.
• [42] CAR-T cells beyond CD19, UnCAR-Ted territory.Am J Hematol. 2019 May;94(S1):S34-S41. doi: 10.1002/ajh.25398. Epub 2019 Jan 23.
• [43] In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.J Interferon Cytokine Res. 2008 May;28(5):297-310. doi: 10.1089/jir.2007.0052.
• [44] Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.Br J Haematol. 2005 Feb;128(3):318-23. doi: 10.1111/j.1365-2141.2004.05324.x.
• [45] Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.Cancer Res. 2001 Jan 15;61(2):647-53.
• [46] Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and TP53 mutations.J Clin Pathol. 2018 Dec;71(12):1051-1059. doi: 10.1136/jclinpath-2018-205348. Epub 2018 Aug 31.
• [47] CD1-reactive leukemic cells in bone marrow: presence of Langerhans cell marker on leukemic monocytic cells.Eur J Haematol. 1992 Jan;48(1):27-32. doi: 10.1111/j.1600-0609.1992.tb01789.x.
• [48] Molecular analysis of CD2 gene expression in acute myeloblastic leukemia expressing T-lineage associated surface antigens.Leuk Lymphoma. 1995 Jan;16(3-4):281-8. doi: 10.3109/10428199509049767.
• [49] Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.Cancer Biomark. 2018;22(3):587-595. doi: 10.3233/CBM-181368.
• [50] Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.Nat Med. 2019 Apr;25(4):603-611. doi: 10.1038/s41591-019-0400-z. Epub 2019 Mar 25.
• [51] Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.Transfusion. 2008 May;48(5):861-70. doi: 10.1111/j.1537-2995.2007.01616.x. Epub 2008 Jan 15.
• [52] Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.Leukemia. 2019 Apr;33(4):931-944. doi: 10.1038/s41375-018-0279-6. Epub 2018 Oct 5.
• [53] Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission.Br J Haematol. 2003 Feb;120(3):442-51. doi: 10.1046/j.1365-2141.2003.04085.x.
• [54] Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome.Int J Hematol. 2001 Feb;73(2):206-12. doi: 10.1007/BF02981939.
• [55] IL-15/IL-15R/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.Blood Adv. 2018 Nov 27;2(22):3177-3192. doi: 10.1182/bloodadvances.2018019026.
• [56] CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126.
• [57] CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.
• [58] Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.Br J Haematol. 2014 Jan;164(2):200-11. doi: 10.1111/bjh.12611. Epub 2013 Oct 23.
• [59] CDK1 interacts with RAR and plays an important role in treatment response of acute myeloid leukemia.Cell Cycle. 2013 Apr 15;12(8):1251-66. doi: 10.4161/cc.24313. Epub 2013 Mar 21.
• [60] del(2)(p23) as a sole abnormality in a case of acute myeloid leukemia.Cancer Genet Cytogenet. 2002 Apr 15;134(2):172-4. doi: 10.1016/s0165-4608(01)00631-8.
• [61] A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia.Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x.
• [62] Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia.Transl Oncol. 2019 Apr;12(4):602-613. doi: 10.1016/j.tranon.2019.01.001. Epub 2019 Jan 27.
• [63] JMJD3 facilitates C/EBP-centered transcriptional program to exert oncorepressor activity in AML.Nat Commun. 2018 Aug 22;9(1):3369. doi: 10.1038/s41467-018-05548-z.
• [64] Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.J Leukoc Biol. 2004 Sep;76(3):623-33. doi: 10.1189/jlb.1103581. Epub 2004 Jun 14.
• [65] CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.Blood. 2019 Feb 7;133(6):588-599. doi: 10.1182/blood-2018-03-838946. Epub 2018 Nov 13.
• [66] Higher frequency of the CTLA-4(+) LAG-3(+) T-cell subset in patients with newly diagnosed acute myeloid leukemia.Asia Pac J Clin Oncol. 2020 Apr;16(2):e12-e18. doi: 10.1111/ajco.13236. Epub 2019 Oct 15.
• [67] Defining the invivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.Immunol Cell Biol. 2019 Feb;97(2):229-235. doi: 10.1111/imcb.12216. Epub 2018 Dec 13.
• [68] The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia.Haematologica. 2005 Jul;90(7):982-4.
• [69] RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.Exp Hematol. 2007 Apr;35(4):572-8. doi: 10.1016/j.exphem.2007.01.049.
• [70] Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway.Stem Cell Res Ther. 2019 Dec 16;10(1):384. doi: 10.1186/s13287-019-1475-7.
• [71] A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.BMC Cancer. 2018 Feb 13;18(1):182. doi: 10.1186/s12885-018-4097-z.
• [72] Regulation of Trib2 by an E2F1-C/EBP feedback loop in AML cell proliferation.Blood. 2014 Apr 10;123(15):2389-400. doi: 10.1182/blood-2013-07-511683. Epub 2014 Feb 10.
• [73] Identifying functions and prognostic biomarkers of network motifs marked by diverse chromatin states in human cell lines.Oncogene. 2020 Jan;39(3):677-689. doi: 10.1038/s41388-019-1005-1. Epub 2019 Sep 19.
• [74] Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.Exp Hematol. 2019 May;73:38-49.e7. doi: 10.1016/j.exphem.2019.03.003. Epub 2019 Apr 13.
• [75] Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Cytometry A. 2015 Apr;87(4):346-56. doi: 10.1002/cyto.a.22628. Epub 2015 Jan 16.
• [76] Reduced Neutrophil Elastase Activity and Neutrophil Extracellular Traps in Pediatric Acute Myeloid Leukemia May Increase the Rate of Infections.J Pediatr Hematol Oncol. 2018 May;40(4):e248-e252. doi: 10.1097/MPH.0000000000001015.
• [77] T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors.Cancer Immunol Res. 2019 Apr;7(4):683-692. doi: 10.1158/2326-6066.CIR-18-0748. Epub 2019 Feb 19.
• [78] Cell Cycle Arrest and Apoptosis Induction Activity of Nitidine Chloride on Acute Myeloid Leukemia Cells.Med Chem. 2018;14(1):60-66. doi: 10.2174/1573406413666170620091543.
• [79] High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.J Transl Med. 2017 Jul 19;15(1):159. doi: 10.1186/s12967-017-1260-2.
• [80] EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.J Cell Mol Med. 2020 Jan;24(2):1640-1649. doi: 10.1111/jcmm.14855. Epub 2019 Dec 3.
• [81] Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts.Leuk Res. 1998 Apr;22(4):329-39. doi: 10.1016/s0145-2126(97)00178-1.
• [82] Construction of a yeast artificial chromosome contig encompassing the human acidic fibroblast growth factor (FGF1) gene: toward the cloning of the ANLL/MDS tumor-suppressor gene.Genomics. 1994 Feb;19(3):552-60. doi: 10.1006/geno.1994.1105.
• [83] Differential effects of fibroblast growth factor-4, epidermal growth factor and transforming growth factor-beta1 on functional development of stromal layers in acute myeloid leukemia.Leuk Res. 2002 Oct;26(10):933-8. doi: 10.1016/s0145-2126(02)00033-4.
• [84] t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF).Cancer Res. 2000 Nov 15;60(22):6227-9.
• [85] Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.Eur J Med Chem. 2019 Feb 1;163:195-206. doi: 10.1016/j.ejmech.2018.11.063. Epub 2018 Nov 27.
• [86] Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia.Leukemia. 2007 Oct;21(10):2233-5. doi: 10.1038/sj.leu.2404786. Epub 2007 Jun 7.
• [87] Low Expression of FUS1 Is Negatively Correlated with miR-378 and May Predict Adverse Prognoses in Acute Myeloid Leukemia.Acta Haematol. 2018;139(2):89-95. doi: 10.1159/000486663. Epub 2018 Feb 1.
• [88] Prognostic value of the FUT family in acute myeloid leukemia.Cancer Gene Ther. 2020 Feb;27(1-2):70-80. doi: 10.1038/s41417-019-0115-9. Epub 2019 Jun 17.
• [89] FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.Oncotarget. 2016 Mar 1;7(9):9964-74. doi: 10.18632/oncotarget.7128.
• [90] High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.
• [91] Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias.Clin Chim Acta. 2006 Mar;365(1-2):342-5. doi: 10.1016/j.cca.2005.09.012. Epub 2005 Oct 18.
• [92] Mutation analysis of the N-ras proto-oncogene in active and remission phase of human acute leukemias.Int J Cancer. 1988 Jan 15;41(1):59-64. doi: 10.1002/ijc.2910410112.
• [93] Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.Oncogene. 2019 Jan;38(5):687-698. doi: 10.1038/s41388-018-0431-9. Epub 2018 Aug 31.
• [94] LncRNA ANRIL promotes cell proliferation, migration and invasion during acute myeloid leukemia pathogenesis via negatively regulating miR-34a.Int J Biochem Cell Biol. 2020 Feb;119:105666. doi: 10.1016/j.biocel.2019.105666. Epub 2019 Dec 9.
• [95] Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.Cells. 2019 Nov 21;8(12):1480. doi: 10.3390/cells8121480.
• [96] Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription.J Mol Biol. 2008 Apr 25;378(2):302-17. doi: 10.1016/j.jmb.2008.02.055. Epub 2008 Mar 4.
• [97] HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.Leuk Res. 2011 Oct;35(10):1350-4. doi: 10.1016/j.leukres.2011.05.036. Epub 2011 Jun 21.
• [98] The chromosome translocation t(7;11)(p15;p15) in acute myeloid leukemia results in fusion of the NUP98 gene with a HOXA cluster gene, HOXA13, but not HOXA9.Genes Chromosomes Cancer. 2002 Aug;34(4):437-43. doi: 10.1002/gcc.10077.
• [99] Genetic variants of glutathione S-transferase and the risk of acute myeloid leukemia in a Saudi population.Saudi J Biol Sci. 2019 Nov;26(7):1525-1530. doi: 10.1016/j.sjbs.2018.12.011. Epub 2018 Dec 21.
• [100] Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia.Transl Oncol. 2019 Jun;12(6):801-809. doi: 10.1016/j.tranon.2019.02.016. Epub 2019 Apr 4.
• [101] A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.Sci Rep. 2017 Oct 16;7(1):12892. doi: 10.1038/s41598-017-12940-0.
• [102] Correlation between acute myeloid leukemia and IL-17A, IL-17F, and IL-23R gene polymorphism.Int J Clin Exp Pathol. 2015 May 1;8(5):5739-43. eCollection 2015.
• [103] Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.Hum Vaccin Immunother. 2020;16(1):109-111. doi: 10.1080/21645515.2019.1636598. Epub 2019 Jul 24.
• [104] Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blasts.Leukemia. 1993 Mar;7(3):418-25.
• [105] Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells.Cell Signal. 2018 Sep;49:87-94. doi: 10.1016/j.cellsig.2018.05.006. Epub 2018 May 28.
• [106] Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.Blood. 2001 Apr 1;97(7):2121-9. doi: 10.1182/blood.v97.7.2121.
• [107] A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers.Mol Cell Proteomics. 2013 Mar;12(3):626-37. doi: 10.1074/mcp.M112.021931. Epub 2012 Dec 11.
• [108] Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.Haematologica. 2018 Nov;103(11):1843-1852. doi: 10.3324/haematol.2018.190231. Epub 2018 Jul 12.
• [109] CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia.Cell Death Dis. 2018 Jul 10;9(7):774. doi: 10.1038/s41419-018-0812-6.
• [110] CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models.Eur J Pharmacol. 2019 Jun 15;853:193-200. doi: 10.1016/j.ejphar.2019.03.041. Epub 2019 Mar 27.
• [111] Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.J Clin Oncol. 2013 Oct 20;31(30):3782-90. doi: 10.1200/JCO.2012.47.4007. Epub 2013 Sep 16.
• [112] Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.J Immunother Cancer. 2019 May 29;7(1):143. doi: 10.1186/s40425-019-0606-0.
• [113] LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.EBioMedicine. 2019 Jun;44:126-137. doi: 10.1016/j.ebiom.2019.05.025. Epub 2019 May 16.
• [114] Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.Leuk Res. 1995 Jan;19(1):23-34. doi: 10.1016/0145-2126(94)00059-j.
• [115] Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.Haematologica. 2020 Jun;105(6):1539-1551. doi: 10.3324/haematol.2019.218453. Epub 2019 Sep 5.
• [116] Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.
• [117] Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Haematologica. 2000 Jul;85(7):711-21.
• [118] The TAK1-NF-B axis as therapeutic target for AML.Blood. 2014 Nov 13;124(20):3130-40. doi: 10.1182/blood-2014-04-569780. Epub 2014 Oct 6.
• [119] Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway.Cancer Med. 2019 Jul;8(8):3905-3917. doi: 10.1002/cam4.2261. Epub 2019 May 23.
• [120] Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.Exp Hematol. 2000 Dec;28(12):1413-22. doi: 10.1016/s0301-472x(00)00550-6.
• [121] Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.Mol Cancer Res. 2020 Mar;18(3):352-363. doi: 10.1158/1541-7786.MCR-19-0619. Epub 2019 Nov 19.
• [122] Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation.Anticancer Res. 2018 Jul;38(7):3961-3966. doi: 10.21873/anticanres.12682.
• [123] Expression of MDM2 and p16 in angiomyolipoma.Hum Pathol. 2018 May;75:34-40. doi: 10.1016/j.humpath.2018.01.022. Epub 2018 Feb 10.
• [124] Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.Nat Commun. 2019 Jun 19;10(1):2691. doi: 10.1038/s41467-019-10523-3.
• [125] Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.Eur J Haematol. 2007 Oct;79(4):281-6. doi: 10.1111/j.1600-0609.2007.00928.x. Epub 2007 Sep 4.
• [126] AEG-1 regulates retinoid X receptor and inhibits retinoid signaling.Cancer Res. 2014 Aug 15;74(16):4364-77. doi: 10.1158/0008-5472.CAN-14-0421.
• [127] Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.Br J Haematol. 2011 Mar;152(6):677-87. doi: 10.1111/j.1365-2141.2010.08525.x.
• [128] The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.Leukemia. 2019 Dec;33(12):2817-2829. doi: 10.1038/s41375-019-0495-8. Epub 2019 May 28.
• [129] NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.
• [130] Associations of NQO1 C609T and NQO1 C465T polymorphisms with acute leukemia risk: a PRISMA-compliant meta-analysis.Onco Targets Ther. 2017 Mar 23;10:1793-1801. doi: 10.2147/OTT.S132503. eCollection 2017.
• [131] Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells.Exp Hematol. 2006 May;34(5):622-30. doi: 10.1016/j.exphem.2006.01.020.
• [132] Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.Oncol Lett. 2019 Feb;17(2):2543-2550. doi: 10.3892/ol.2018.9841. Epub 2018 Dec 17.
• [133] Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.Leuk Res. 2016 Nov;50:85-94. doi: 10.1016/j.leukres.2016.09.018. Epub 2016 Sep 26.
• [134] Downregulation of CD73 associates with T cell exhaustion in AML patients.J Hematol Oncol. 2019 Apr 24;12(1):40. doi: 10.1186/s13045-019-0728-3.
• [135] Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25).Blood. 1999 Feb 15;93(4):1355-63.
• [136] Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.Biochem Pharmacol. 2019 Sep;167:133-148. doi: 10.1016/j.bcp.2019.04.019. Epub 2019 Apr 24.
• [137] Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.Chembiochem. 2019 Jul 15;20(14):1783-1788. doi: 10.1002/cbic.201900067. Epub 2019 Jul 3.
• [138] Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission.Mol Cell Proteomics. 2008 Feb;7(2):431-41. doi: 10.1074/mcp.M700194-MCP200. Epub 2007 Nov 12.
• [139] The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.Sci Rep. 2019 Aug 21;9(1):12209. doi: 10.1038/s41598-019-48687-z.
• [140] Alpha-1-antitrypsin phenotypes in leukaemia and lymphoma.Dis Markers. 1990 Mar-Apr;8(2):93-7.
• [141] Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.Biochem Biophys Res Commun. 2020 Jan 22;521(4):833-839. doi: 10.1016/j.bbrc.2019.11.007. Epub 2019 Nov 7.
• [142] Polo-like kinases in AML.Expert Opin Investig Drugs. 2012 Aug;21(8):1069-74. doi: 10.1517/13543784.2012.691163. Epub 2012 Jun 6.
• [143] Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity.Blood. 1987 Aug;70(2):372-8.
• [144] Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN.Exp Hematol. 2009 Oct;37(10):1176-1185.e21. doi: 10.1016/j.exphem.2009.07.002. Epub 2009 Jul 15.
• [145] Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.Blood Rev. 2018 May;32(3):235-248. doi: 10.1016/j.blre.2017.11.006. Epub 2017 Dec 2.
• [146] Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.Leukemia. 2019 Jul;33(7):1635-1649. doi: 10.1038/s41375-018-0368-6. Epub 2019 Jan 28.
• [147] Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia.Genes Chromosomes Cancer. 2004 Apr;39(4):324-34. doi: 10.1002/gcc.20004.
• [148] Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).J Transl Med. 2018 Apr 10;16(1):90. doi: 10.1186/s12967-018-1463-1.
• [149] Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia.Mol Ther Oncolytics. 2018 Dec 18;12:103-111. doi: 10.1016/j.omto.2018.12.008. eCollection 2019 Mar 29.
• [150] Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes.Leukemia. 1989 Jun;3(6):423-30.
• [151] S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.Blood. 2017 Apr 6;129(14):1980-1990. doi: 10.1182/blood-2016-09-738005. Epub 2017 Jan 30.
• [152] Decreased SATB1 expression promotes AML cell proliferation through NF-B activation.Cancer Cell Int. 2019 May 17;19:134. doi: 10.1186/s12935-019-0850-x. eCollection 2019.
• [153] Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.Blood. 2008 Aug 15;112(4):1366-73. doi: 10.1182/blood-2007-11-126227. Epub 2008 Jun 3.
• [154] Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells.Int J Oncol. 2001 Mar;18(3):593-8. doi: 10.3892/ijo.18.3.593.
• [155] Mapping of chromosome 17 breakpoints in acute myeloid leukemias.Oncogene. 1990 Oct;5(10):1557-63.
• [156] High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.Leuk Lymphoma. 2001 Jul;42(3):511-6. doi: 10.3109/10428190109064609.
• [157] Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.Leukemia. 1997 Oct;11(10):1605-9. doi: 10.1038/sj.leu.2400812.
• [158] Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.Leukemia. 2009 Oct;23(10):1818-24. doi: 10.1038/leu.2009.138. Epub 2009 Jul 16.
• [159] Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.Curr Drug Metab. 2007 May;8(4):395-403. doi: 10.2174/138920007780655432.
• [160] A t(11;20)(p15;q11) may identify a subset of nontherapy-related acute myelocytic leukemia.Cancer Genet Cytogenet. 2004 Mar;149(2):164-8. doi: 10.1016/j.cancergencyto.2003.07.002.
• [161] Significant expression of G-CSF-induced gene-1 (GIG-1) protein in myeloid cells and NK cells.J Leukoc Biol. 1999 Jan;65(1):109-16. doi: 10.1002/jlb.65.1.109.
• [162] Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia.Blood. 2001 Oct 1;98(7):2200-9. doi: 10.1182/blood.v98.7.2200.
• [163] Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML.Leukemia. 2002 May;16(5):886-93. doi: 10.1038/sj.leu.2402452.
• [164] X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.Mol Oncol. 2018 Jan;12(1):33-47. doi: 10.1002/1878-0261.12146. Epub 2017 Dec 1.
• [165] Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells.Elife. 2019 Nov 22;8:e46667. doi: 10.7554/eLife.46667.
• [166] GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.J Hematol Oncol. 2016 Jan 27;9:5. doi: 10.1186/s13045-016-0235-8.
• [167] Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.Clin Transl Oncol. 2019 Sep;21(9):1186-1196. doi: 10.1007/s12094-019-02045-7. Epub 2019 Jan 29.
• [168] Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.Expert Opin Investig Drugs. 2019 Nov;28(11):989-1001. doi: 10.1080/13543784.2019.1678583. Epub 2019 Oct 22.
• [169] The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner.Blood. 2004 Jul 15;104(2):526-34. doi: 10.1182/blood-2003-12-4357. Epub 2004 Mar 23.
• [170] Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.Br J Haematol. 2009 Feb;144(3):376-87. doi: 10.1111/j.1365-2141.2008.07491.x. Epub 2008 Nov 13.
• [171] Targeting of folate receptor on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.Blood. 2015 May 28;125(22):3466-76. doi: 10.1182/blood-2014-11-612721. Epub 2015 Apr 17.
• [172] miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia.Oncol Res. 2016;24(2):109-16. doi: 10.3727/096504016X14611963142254.
• [173] Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.Leuk Res. 2017 Dec;63:41-46. doi: 10.1016/j.leukres.2017.10.012. Epub 2017 Oct 28.
• [174] IRF3 is involved in human acute myeloid leukemia through regulating the expression of miR-155.Biochem Biophys Res Commun. 2016 Sep 23;478(3):1130-5. doi: 10.1016/j.bbrc.2016.08.080. Epub 2016 Aug 13.
• [175] NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.Cell Death Differ. 2015 Apr;22(4):654-64. doi: 10.1038/cdd.2014.152. Epub 2014 Oct 17.
• [176] The oncometabolite R-2-hydroxyglutarate activates NF-B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.Sci Rep. 2016 Aug 31;6:32428. doi: 10.1038/srep32428.
• [177] SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.Int J Oncol. 2016 Feb;48(2):613-23. doi: 10.3892/ijo.2015.3275. Epub 2015 Dec 7.
• [178] Panobinostat for the treatment of acute myelogenous leukemia.Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8.
• [179] Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Biochim Biophys Acta. 2016 Apr;1863(4):562-71. doi: 10.1016/j.bbamcr.2015.12.008. Epub 2015 Dec 17.
• [180] Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation.J Cell Physiol. 2020 Jan;235(1):573-586. doi: 10.1002/jcp.28996. Epub 2019 Jun 27.
• [181] Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.Leuk Res. 2008 Jun;32(6):919-29. doi: 10.1016/j.leukres.2007.10.011. Epub 2008 Jan 18.
• [182] The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin. 2017 Mar;38(3):382-391.
• [183] CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.Int J Mol Sci. 2019 Nov 20;20(23):5826. doi: 10.3390/ijms20235826.
• [184] The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.Haematologica. 2020 Mar;105(3):687-696. doi: 10.3324/haematol.2018.212886. Epub 2019 May 23.
• [185] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [186] T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.Cancer Manag Res. 2019 Jul 16;11:6467-6476. doi: 10.2147/CMAR.S205296. eCollection 2019.
• [187] Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.
• [188] Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.J Cell Mol Med. 2019 Jun;23(6):4111-4117. doi: 10.1111/jcmm.14298. Epub 2019 Mar 28.
• [189] Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.
• [190] Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival.Clin Epigenetics. 2019 Mar 15;11(1):50. doi: 10.1186/s13148-019-0643-z.
• [191] Copy number variations of EphA3 are associated with multiple types of hematologic malignancies.Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):50-3. doi: 10.3816/CLML.2011.n.006.
• [192] Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.PLoS One. 2017 Mar 16;12(3):e0173723. doi: 10.1371/journal.pone.0173723. eCollection 2017.
• [193] HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia.ACS Appl Mater Interfaces. 2018 May 2;10(17):14454-14462. doi: 10.1021/acsami.8b01696. Epub 2018 Apr 18.
• [194] Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.Cancer Cell. 2019 Apr 15;35(4):677-691.e10. doi: 10.1016/j.ccell.2019.03.006.
• [195] Low expression of GFI-1 Gene is associated with Panobinostat-resistance in acute myeloid leukemia through influencing the level of HO-1.Biomed Pharmacother. 2018 Apr;100:509-520. doi: 10.1016/j.biopha.2018.02.039. Epub 2018 Feb 23.
• [196] Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z.
• [197] IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells.J Hematol Oncol. 2013 Oct 8;6(1):72. doi: 10.1186/1756-8722-6-72.
• [198] Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.Front Immunol. 2018 Apr 10;9:658. doi: 10.3389/fimmu.2018.00658. eCollection 2018.
• [199] Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.Leukemia. 2002 May;16(5):874-85. doi: 10.1038/sj.leu.2402465.
• [200] Targeted signal transduction therapies in myeloid malignancies.Curr Oncol Rep. 2010 Nov;12(6):358-65. doi: 10.1007/s11912-010-0126-z.
• [201] Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.
• [202] Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.Br J Haematol. 2019 May;185(4):679-690. doi: 10.1111/bjh.15818. Epub 2019 Mar 3.
• [203] RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.Int J Mol Sci. 2019 Nov 16;20(22):5756. doi: 10.3390/ijms20225756.
• [204] Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.J Hematol Oncol. 2018 May 30;11(1):73. doi: 10.1186/s13045-018-0611-7.
• [205] Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.
• [206] A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.Br J Cancer. 2019 May;120(11):1023-1025. doi: 10.1038/s41416-019-0456-z. Epub 2019 Apr 18.
• [207] MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.Eur J Haematol. 2017 Nov;99(5):415-422. doi: 10.1111/ejh.12938. Epub 2017 Sep 29.
• [208] S100A3 a partner protein regulating the stability/activity of RAR and PML-RAR in cellular models of breast/lung cancer and acute myeloid leukemia.Oncogene. 2019 Apr;38(14):2482-2500. doi: 10.1038/s41388-018-0599-z. Epub 2018 Dec 7.
• [209] Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.Exp Hematol. 2008 Apr;36(4):451-63. doi: 10.1016/j.exphem.2007.12.011. Epub 2008 Feb 8.
• [210] Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.Cancer Discov. 2020 Feb;10(2):214-231. doi: 10.1158/2159-8290.CD-19-0209. Epub 2019 Nov 26.
• [211] Dectin-1 rs3901533 and rs7309123 Polymorphisms Increase Susceptibility to Pulmonary Invasive Fungal Disease in Patients with Acute Myeloid Leukemia from a Chinese Han Population.Curr Med Sci. 2019 Dec;39(6):906-912. doi: 10.1007/s11596-019-2122-3. Epub 2019 Dec 16.
• [212] Variations in genes involved in regulation of the nuclear factor - B pathway and the risk of acute myeloid leukaemia.Int J Immunogenet. 2016 Apr;43(2):101-6. doi: 10.1111/iji.12255. Epub 2016 Feb 25.
• [213] Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.
• [214] Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase II downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.Mol Pharmacol. 2013 Aug;84(2):236-43. doi: 10.1124/mol.113.086140. Epub 2013 May 21.
• [215] A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.
• [216] Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia.Sci Rep. 2019 Jan 23;9(1):378. doi: 10.1038/s41598-018-36780-8.
• [217] An Overview on G Protein-coupled Receptor-induced Signal Transduction in Acute Myeloid Leukemia.Curr Med Chem. 2019;26(28):5293-5316. doi: 10.2174/0929867326666190429153247.
• [218] Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia.J Transl Med. 2019 May 10;17(1):149. doi: 10.1186/s12967-019-1884-5.
• [219] Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1.Gen Physiol Biophys. 2018 May;37(3):353-357. doi: 10.4149/gpb_2018008.
• [220] Correlation between IL-7 genomic protein methylation level and acute myeloid leukemia.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1196-1202. doi: 10.26355/eurrev_201902_17012.
• [221] Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.Br J Haematol. 2009 Jan;144(1):53-68. doi: 10.1111/j.1365-2141.2008.07411.x. Epub 2008 Oct 30.
• [222] The clinical and prognostic significance of FIS1, SPI1, PDCD7 and Ang2 expression levels in acute myeloid leukemia.Cancer Genet. 2019 Apr;233-234:84-95. doi: 10.1016/j.cancergen.2018.12.001. Epub 2018 Dec 7.
• [223] MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.Blood. 2015 Feb 19;125(8):1292-301. doi: 10.1182/blood-2014-06-581892. Epub 2014 Dec 22.
• [224] Discovery of epigenetically silenced genes in acute myeloid leukemias.Leukemia. 2007 May;21(5):1026-34. doi: 10.1038/sj.leu.2404611. Epub 2007 Mar 1.
• [225] Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines.Leuk Res. 1993 Nov;17(11):949-57. doi: 10.1016/0145-2126(93)90042-j.
• [226] Serum proteomic spectral characteristics of acute myeloid leukemia and their clinical significance.Genet Mol Res. 2017 Apr 13;16(2). doi: 10.4238/gmr16029172.
• [227] Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007 Jan 15;109(2):740-6. doi: 10.1182/blood-2006-04-019588. Epub 2006 Sep 12.
• [228] ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.Epigenetics. 2015;10(1):6-18. doi: 10.4161/15592294.2014.988035. Epub 2015 Jan 27.
• [229] Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214.
• [230] Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.Ann Hematol. 2018 Aug;97(8):1375-1389. doi: 10.1007/s00277-018-3315-8. Epub 2018 Apr 13.
• [231] Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.
• [232] Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.PLoS One. 2018 May 3;13(5):e0196805. doi: 10.1371/journal.pone.0196805. eCollection 2018.
• [233] BCAT1 restricts KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8.
• [234] Genetic characterization of ABT-199 sensitivity in human AML.Leukemia. 2020 Jan;34(1):63-74. doi: 10.1038/s41375-019-0485-x. Epub 2019 Jul 12.
• [235] Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.J Interferon Cytokine Res. 2002 Feb;22(2):269-79. doi: 10.1089/107999002753536248.
• [236] SPG6 supports development of acute myeloid leukemia by regulating BMPR2-Smad-Bcl-2/Bcl-xl signaling.Biochem Biophys Res Commun. 2018 Jun 18;501(1):220-225. doi: 10.1016/j.bbrc.2018.04.220. Epub 2018 May 3.
• [237] Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.J Clin Invest. 2018 Jan 2;128(1):369-380. doi: 10.1172/JCI91893. Epub 2017 Dec 11.
• [238] Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
• [239] BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.Cell Death Dis. 2019 Apr 18;10(5):338. doi: 10.1038/s41419-019-1570-9.
• [240] Germline Genetic Predisposition to Hematologic Malignancy.J Clin Oncol. 2017 Mar 20;35(9):1018-1028. doi: 10.1200/JCO.2016.70.8644. Epub 2017 Feb 13.
• [241] Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.Anticancer Res. 2019 Oct;39(10):5531-5539. doi: 10.21873/anticanres.13746.
• [242] LukS-PV induces apoptosis in acute myeloid leukemia cells mediated by C5a receptor.Cancer Med. 2019 May;8(5):2474-2483. doi: 10.1002/cam4.2137. Epub 2019 Apr 6.
• [243] Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5' CpG island in human tumors.Cancer Res. 1999 Sep 15;59(18):4535-41.
• [244] CGRP-CRLR/RAMP1 signal is important for stress-induced hematopoiesis.Sci Rep. 2019 Jan 23;9(1):429. doi: 10.1038/s41598-018-36796-0.
• [245] A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.Nat Med. 2016 Jul;22(7):727-34. doi: 10.1038/nm.4127. Epub 2016 Jun 13.
• [246] CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5. doi: 10.1016/j.ccell.2018.05.007.
• [247] Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.Br J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15.
• [248] Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.Blood. 2003 Feb 15;101(4):1551-7. doi: 10.1182/blood-2002-07-2337. Epub 2002 Oct 17.
• [249] Osteolineage cells and regulation of the hematopoietic stem cell.Best Pract Res Clin Haematol. 2013 Sep;26(3):249-52. doi: 10.1016/j.beha.2013.10.004. Epub 2013 Oct 16.
• [250] Polymorphisms of the CYR61 gene in patients with acute myeloid leukemia in a Han Chinese population.Medicine (Baltimore). 2018 Aug;97(34):e11963. doi: 10.1097/MD.0000000000011963.
• [251] CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.J Exp Med. 2017 Feb;214(2):359-380. doi: 10.1084/jem.20152008. Epub 2016 Dec 28.
• [252] B7-H3 protein expression in acute myeloid leukemia.Cancer Med. 2015 Dec;4(12):1879-83. doi: 10.1002/cam4.522. Epub 2015 Sep 17.
• [253] CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget. 2018 Jan 11;9(44):27574-27584.
• [254] Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.Clin Cancer Res. 2014 Jul 1;20(13):3589-602. doi: 10.1158/1078-0432.CCR-13-2811. Epub 2014 May 5.
• [255] Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.Eur J Haematol. 2000 Jan;64(1):3-9. doi: 10.1034/j.1600-0609.2000.80097.x.
• [256] CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.Mol Ther. 2019 Jan 2;27(1):272-280. doi: 10.1016/j.ymthe.2018.10.001. Epub 2018 Oct 4.
• [257] Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.J Investig Med. 2016 Dec;64(8):1252-1260. doi: 10.1136/jim-2016-000081. Epub 2016 Jul 7.
• [258] FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.Ann Hematol. 2014 Apr;93(4):577-93. doi: 10.1007/s00277-013-1898-7. Epub 2013 Sep 13.
• [259] CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.Molecules. 2017 Mar 11;22(3):446. doi: 10.3390/molecules22030446.
• [260] Tuberin-deficiency downregulates N-cadherin and upregulates vimentin in kidney tumor of TSC patients.Oncotarget. 2014 Aug 30;5(16):6936-46. doi: 10.18632/oncotarget.2206.
• [261] Mediator kinase inhibition further activates super-enhancer-associated genes in AML.Nature. 2015 Oct 8;526(7572):273-276. doi: 10.1038/nature14904. Epub 2015 Sep 28.
• [262] Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib.Int J Mol Sci. 2018 Dec 11;19(12):3987. doi: 10.3390/ijms19123987.
• [263] Small Molecules Co-targeting CKI and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.Cell. 2018 Sep 20;175(1):171-185.e25. doi: 10.1016/j.cell.2018.07.045. Epub 2018 Aug 23.
• [264] The presence of C/EBP and its degradation are both required for TRIB2-mediated leukaemia.Oncogene. 2016 Oct 6;35(40):5272-5281. doi: 10.1038/onc.2016.66. Epub 2016 Mar 21.
• [265] Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML.Leuk Res. 2005 Nov;29(11):1357-60. doi: 10.1016/j.leukres.2005.04.012.
• [266] Clinical and laboratory features of adult biphenotypic acute leukemia.Asia Pac J Clin Oncol. 2013 Jun;9(2):146-54. doi: 10.1111/j.1743-7563.2012.01571.x. Epub 2012 Jul 9.
• [267] Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.Br J Haematol. 2013 Jan;160(2):188-98. doi: 10.1111/bjh.12108. Epub 2012 Nov 20.
• [268] Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.Leuk Lymphoma. 2015 Jan;56(1):141-6. doi: 10.3109/10428194.2014.910774. Epub 2014 Jun 16.
• [269] Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms.Eur J Haematol. 2010 Jul;85(1):58-64. doi: 10.1111/j.1600-0609.2010.01443.x. Epub 2010 Mar 12.
• [270] Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells.Oncotarget. 2017 Aug 16;8(47):82803-82823. doi: 10.18632/oncotarget.20294. eCollection 2017 Oct 10.
• [271] microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling.Yonsei Med J. 2019 Oct;60(10):924-934. doi: 10.3349/ymj.2019.60.10.924.
• [272] Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.Ann Hematol. 2019 May;98(5):1149-1157. doi: 10.1007/s00277-019-03637-7. Epub 2019 Feb 13.
• [273] Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency.Blood Adv. 2017 Feb 27;1(7):443-448. doi: 10.1182/bloodadvances.2016002311. eCollection 2017 Feb 28.
• [274] Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.Mol Med Rep. 2017 Jul;16(1):281-287. doi: 10.3892/mmr.2017.6581. Epub 2017 May 12.
• [275] Expression of testicular genes in haematological malignancies.Br J Cancer. 1999 Dec;81(7):1162-4. doi: 10.1038/sj.bjc.6690824.
• [276] Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. eCollection 2017.
• [277] PNL2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours.Histopathology. 2018 Feb;72(3):441-448. doi: 10.1111/his.13369. Epub 2017 Nov 21.
• [278] A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia.J Clin Lab Anal. 2020 Feb;34(2):e23052. doi: 10.1002/jcla.23052. Epub 2019 Oct 16.
• [279] Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5.
• [280] Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment.Blood. 2019 Jan 31;133(5):446-456. doi: 10.1182/blood-2018-04-845420. Epub 2018 Nov 6.
• [281] Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.Clin Pharmacol Ther. 2020 Mar;107(3):563-570. doi: 10.1002/cpt.1641. Epub 2019 Nov 1.
• [282] Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.Eur J Cancer Prev. 2008 Jun;17(3):251-8. doi: 10.1097/CEJ.0b013e3282b72093.
• [283] Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study.Br J Haematol. 2018 Nov;183(4):618-628. doi: 10.1111/bjh.15587. Epub 2018 Nov 8.
• [284] The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.Leukemia. 2019 Oct;33(10):2403-2415. doi: 10.1038/s41375-019-0461-5. Epub 2019 Apr 2.
• [285] DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.Leuk Res. 2017 Dec;63:62-71. doi: 10.1016/j.leukres.2017.10.006. Epub 2017 Oct 31.
• [286] MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.
• [287] DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia.Nat Med. 2018 Aug;24(8):1151-1156. doi: 10.1038/s41591-018-0082-y. Epub 2018 Jul 2.
• [288] Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.PLoS One. 2014 Jun 5;9(6):e98853. doi: 10.1371/journal.pone.0098853. eCollection 2014.
• [289] C/EBP regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.Blood. 2010 Dec 16;116(25):5638-49. doi: 10.1182/blood-2010-04-281600. Epub 2010 Oct 1.
• [290] Cytokine receptor splice variants in hematologic diseases.Cytokine. 2020 Mar;127:154919. doi: 10.1016/j.cyto.2019.154919. Epub 2019 Dec 6.
• [291] EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia.Clin Cancer Res. 2020 Feb 1;26(3):669-678. doi: 10.1158/1078-0432.CCR-19-2479. Epub 2019 Oct 31.
• [292] The methyltransferase G9a regulates HoxA9-dependent transcription in AML.Genes Dev. 2014 Feb 15;28(4):317-27. doi: 10.1101/gad.236794.113.
• [293] Nuclear, not cytoplasmic, PKR maneuvers in AML.Blood. 2015 Sep 24;126(13):1523-4. doi: 10.1182/blood-2015-08-661421.
• [294] The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.Nat Genet. 2015 Sep;47(9):1030-7. doi: 10.1038/ng.3371. Epub 2015 Aug 3.
• [295] A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.PLoS One. 2013;8(2):e55481. doi: 10.1371/journal.pone.0055481. Epub 2013 Feb 4.
• [296] Expression of Eph A4, Eph B2 and Eph B4 receptors in AML.Pathol Oncol Res. 2014 Oct;20(4):901-7. doi: 10.1007/s12253-014-9767-9. Epub 2014 Apr 25.
• [297] EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.Blood Adv. 2017 Aug 28;1(20):1635-1644. doi: 10.1182/bloodadvances.2017005694. eCollection 2017 Sep 12.
• [298] Inhibition of ER stress-related IRE1/CREB/NLRP1 pathway promotes the apoptosis of human chronic myelogenous leukemia cell.Mol Immunol. 2018 Sep;101:377-385. doi: 10.1016/j.molimm.2018.07.002. Epub 2018 Jul 26.
• [299] Ginsenoside 20(S)-Rh2 Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells: Role of Orphan Nuclear Receptor Nur77.J Agric Food Chem. 2017 Sep 6;65(35):7687-7697. doi: 10.1021/acs.jafc.7b02299. Epub 2017 Aug 23.
• [300] Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.Mol Cell Biol. 2017 Jun 15;37(13):e00585-16. doi: 10.1128/MCB.00585-16. Print 2017 Jul 1.
• [301] Immunotoxins in cancer therapy: Review and update.Int Rev Immunol. 2017 Jul 4;36(4):207-219. doi: 10.1080/08830185.2017.1284211. Epub 2017 Mar 1.
• [302] The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-B activation.Cancer Lett. 2018 Jun 1;423:127-138. doi: 10.1016/j.canlet.2018.03.008. Epub 2018 Mar 8.
• [303] CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells.Biomaterials. 2020 Feb;230:119651. doi: 10.1016/j.biomaterials.2019.119651. Epub 2019 Nov 22.
• [304] Human GM-CSF receptor alpha-chain gene is highly polymorphic but not rearranged in AML.Leukemia. 1992 Sep;6(9):893-7.
• [305] FLT3/ITD regulates leukaemia cell adhesion through 41 integrin and Pyk2 signalling.Eur J Haematol. 2011 Mar;86(3):191-8. doi: 10.1111/j.1600-0609.2010.01556.x. Epub 2011 Jan 25.
• [306] Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.Genet Mol Res. 2015 May 18;14(2):5181-7. doi: 10.4238/2015.May.18.8.
• [307] FOXM1 contributes to treatment failure in acute myeloid leukemia.JCI Insight. 2018 Aug 9;3(15):e121583. doi: 10.1172/jci.insight.121583. eCollection 2018 Aug 9.
• [308] Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.
• [309] ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.Biosci Rep. 2019 May 21;39(5):BSR20190389. doi: 10.1042/BSR20190389. Print 2019 May 31.
• [310] A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.Br J Haematol. 2018 May;181(4):476-485. doi: 10.1111/bjh.15207. Epub 2018 Apr 16.
• [311] Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.Int J Nanomedicine. 2017 Nov 23;12:8427-8442. doi: 10.2147/IJN.S147659. eCollection 2017.
• [312] Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.Oncol Rep. 2013 Nov;30(5):2254-62. doi: 10.3892/or.2013.2716. Epub 2013 Sep 4.
• [313] Hepatic angiomyolipoma: mutation analysis and immunohistochemical pitfalls in diagnosis.Histopathology. 2018 Jul;73(1):101-108. doi: 10.1111/his.13509. Epub 2018 Apr 19.
• [314] Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3761-3765. doi: 10.1016/j.bmcl.2018.10.013. Epub 2018 Oct 11.
• [315] Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.Leukemia. 2019 Dec;33(12):2805-2816. doi: 10.1038/s41375-019-0491-z. Epub 2019 May 24.
• [316] GPR84 sustains aberrant -catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.Blood. 2014 Nov 20;124(22):3284-94. doi: 10.1182/blood-2013-10-532523. Epub 2014 Oct 7.
• [317] Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.Haematologica. 2004 Aug;89(8):926-33.
• [318] DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.Cancer Biomark. 2019;25(1):43-51. doi: 10.3233/CBM-182176.
• [319] Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):450-461. doi: 10.1016/j.bbadis.2016.11.013. Epub 2016 Nov 11.
• [320] HDAC2-dependent miRNA signature in acute myeloid leukemia.FEBS Lett. 2019 Sep;593(18):2574-2584. doi: 10.1002/1873-3468.13521. Epub 2019 Jul 19.
• [321] HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.Cell Stem Cell. 2015 Nov 5;17(5):597-610. doi: 10.1016/j.stem.2015.08.004. Epub 2015 Sep 18.
• [322] The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.
• [323] LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4/AMPK/WNT5A signaling pathway.Hematol Oncol. 2019 Oct;37(4):474-482. doi: 10.1002/hon.2651. Epub 2019 Aug 5.
• [324] microRNA-451-modulated hnRNP A1 takes a part in granulocytic differentiation regulation and acute myeloid leukemia.Oncotarget. 2017 Jul 18;8(33):55453-55466. doi: 10.18632/oncotarget.19325. eCollection 2017 Aug 15.
• [325] Correlation of miR-181a and three HOXA genes as useful biomarkers in acute myeloid leukemia.Int J Lab Hematol. 2020 Feb;42(1):16-22. doi: 10.1111/ijlh.13116. Epub 2019 Oct 31.
• [326] Silencing long non-coding RNA HOTAIR exerts anti-oncogenic effect on human acute myeloid leukemia via demethylation of HOXA5 by inhibiting Dnmt3b.Cancer Cell Int. 2019 Apr 29;19:114. doi: 10.1186/s12935-019-0808-z. eCollection 2019.
• [327] All-trans retinoic acid inhibits HOXA7 expression in leukemia cell NB4.Cell Mol Biol (Noisy-le-grand). 2016 Jan 22;62(1):63-6.
• [328] Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood. 2011 Feb 3;117(5):1530-9. doi: 10.1182/blood-2010-06-293167. Epub 2010 Dec 1.
• [329] Hsp27: a novel therapeutic target for pediatric M4/M5 acute myeloid leukemia.Oncol Rep. 2013 Apr;29(4):1459-66. doi: 10.3892/or.2013.2274. Epub 2013 Feb 5.
• [330] Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.Leukemia. 2017 Nov;31(11):2288-2302. doi: 10.1038/leu.2017.52. Epub 2017 Feb 14.
• [331] The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.
• [332] Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.Blood. 2016 May 12;127(19):2322-6. doi: 10.1182/blood-2015-11-677708. Epub 2016 Mar 4.
• [333] Differential requirements for myeloid leukemia IFN- conditioning determine graft-versus-leukemia resistance and sensitivity.J Clin Invest. 2017 Jun 30;127(7):2765-2776. doi: 10.1172/JCI85736. Epub 2017 Jun 12.
• [334] IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.Cell Rep. 2018 Dec 11;25(11):3021-3035.e5. doi: 10.1016/j.celrep.2018.11.062.
• [335] IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.Cell Stem Cell. 2019 Jan 3;24(1):153-165.e7. doi: 10.1016/j.stem.2018.10.016. Epub 2018 Nov 21.
• [336] Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.
• [337] IL1RAP potentiates multiple oncogenic signaling pathways in AML.J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17.
• [338] IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia.J Leukoc Biol. 2016 Jan;99(1):131-41. doi: 10.1189/jlb.2A0414-228RR. Epub 2015 Sep 4.
• [339] Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2. Epub 2018 Mar 29.
• [340] U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22.
• [341] Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.J Hematol Oncol. 2014 Jun 2;7:43. doi: 10.1186/1756-8722-7-43.
• [342] Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):370-8. doi: 10.1002/cyto.b.21082. Epub 2013 Feb 28.
• [343] The Possible Importance of 3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.Int J Mol Sci. 2018 Jan 15;19(1):251. doi: 10.3390/ijms19010251.
• [344] CD18 deficiency evolving to megakaryocytic (M7) acute myeloid leukemia: case report.Blood Cells Mol Dis. 2014 Dec;53(4):180-4. doi: 10.1016/j.bcmd.2014.07.005. Epub 2014 Aug 5.
• [345] PLSCR1/IP3R1/Ca(2+) axis contributes to differentiation of primary AML cells induced by wogonoside.Cell Death Dis. 2017 May 11;8(5):e2768. doi: 10.1038/cddis.2017.175.
• [346] JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.Leukemia. 2017 May;31(5):1196-1205. doi: 10.1038/leu.2016.329. Epub 2016 Nov 14.
• [347] MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.Mol Cell Biol. 2005 Feb;25(3):988-1002. doi: 10.1128/MCB.25.3.988-1002.2005.
• [348] VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome.Blood. 2007 Aug 15;110(4):1238-50. doi: 10.1182/blood-2006-02-003772. Epub 2007 Apr 9.
• [349] Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Clin Cancer Res. 2017 Aug 1;23(15):4511-4522. doi: 10.1158/1078-0432.CCR-16-2628. Epub 2017 Feb 28.
• [350] Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.Biol Pharm Bull. 2019;42(3):481-488. doi: 10.1248/bpb.b18-00892.
• [351] The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance.Blood. 2019 Oct 3;134(14):1154-1158. doi: 10.1182/blood.2019000855. Epub 2019 Aug 21.
• [352] Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.Cancer Cell. 2016 Jan 11;29(1):32-48. doi: 10.1016/j.ccell.2015.12.007.
• [353] Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.Leuk Res. 2018 May;68:105-111. doi: 10.1016/j.leukres.2018.02.003. Epub 2018 Feb 7.
• [354] Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis.Leukemia. 2019 Oct;33(10):2506-2521. doi: 10.1038/s41375-019-0462-4. Epub 2019 Apr 1.
• [355] Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.J Immunol. 2014 May 15;192(10):4592-600. doi: 10.4049/jimmunol.1302517. Epub 2014 Apr 18.
• [356] Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.Clin Cancer Res. 2016 Feb 1;22(3):746-56. doi: 10.1158/1078-0432.CCR-15-1054. Epub 2015 Sep 25.
• [357] The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development.Nat Cell Biol. 2015 May;17(5):665-77. doi: 10.1038/ncb3158. Epub 2015 Apr 27.
• [358] Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?.Autophagy. 2019 May;15(5):927-929. doi: 10.1080/15548627.2019.1586259. Epub 2019 Mar 1.
• [359] The expression analysis of LATS2 gene in de novo AML patients.Med Oncol. 2014 May;31(5):961. doi: 10.1007/s12032-014-0961-0. Epub 2014 Apr 18.
• [360] Transcriptional memory of cells of origin overrides -catenin requirement of MLL cancer stem cells.EMBO J. 2017 Nov 2;36(21):3139-3155. doi: 10.15252/embj.201797994. Epub 2017 Oct 4.
• [361] The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1.J Cell Biochem. 2016 Jan;117(1):49-58. doi: 10.1002/jcb.25246.
• [362] MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia.Oncol Lett. 2018 Apr;15(4):5611-5619. doi: 10.3892/ol.2018.8050. Epub 2018 Feb 14.
• [363] LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.Cell Mol Immunol. 2020 Mar;17(3):272-282. doi: 10.1038/s41423-019-0321-2. Epub 2019 Nov 7.
• [364] Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.Cell Death Dis. 2017 Jun 1;8(6):e2849. doi: 10.1038/cddis.2017.253.
• [365] Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.Blood. 2017 Mar 9;129(10):1320-1332. doi: 10.1182/blood-2016-08-734798. Epub 2017 Jan 3.
• [366] Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.Haematologica. 2003 Jun;88(6):654-8.
• [367] Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia.Cancer Genet. 2017 Dec;218-219:15-19. doi: 10.1016/j.cancergen.2017.09.001. Epub 2017 Sep 13.
• [368] The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.
• [369] Current state of nonengrafting donor leukocyte infusion (focus on microtransplantation for acute myeloid leukemia).Curr Opin Hematol. 2019 Nov;26(6):373-378. doi: 10.1097/MOH.0000000000000539.
• [370] Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen.J Steroid Biochem Mol Biol. 2019 Mar;187:166-173. doi: 10.1016/j.jsbmb.2018.11.015. Epub 2018 Nov 30.
• [371] Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819873927. doi: 10.1177/1533033819873927.
• [372] MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia.Cell Death Dis. 2018 Jul 26;9(8):814. doi: 10.1038/s41419-018-0837-x.
• [373] Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.Oncogene. 2017 May 4;36(18):2589-2598. doi: 10.1038/onc.2016.416. Epub 2016 Nov 7.
• [374] Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.Oncogene. 2018 Oct;37(41):5520-5533. doi: 10.1038/s41388-018-0333-x. Epub 2018 Jun 12.
• [375] Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.Anticancer Res. 2018 Jan;38(1):199-204. doi: 10.21873/anticanres.12208.
• [376] Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.Mol Pharmacol. 2015 Aug;88(2):380-9. doi: 10.1124/mol.115.098012. Epub 2015 Jun 4.
• [377] Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.Eur J Med Chem. 2017 Oct 20;139:762-772. doi: 10.1016/j.ejmech.2017.08.006. Epub 2017 Aug 3.
• [378] Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11.
• [379] CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Mol Ther. 2016 Sep 29;24(9):1615-26. doi: 10.1038/mt.2016.116. Epub 2016 Jun 6.
• [380] Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.Exp Hematol. 2019 Feb;70:97-108. doi: 10.1016/j.exphem.2018.12.002. Epub 2018 Dec 26.
• [381] Retinoic acid and 6-formylindolo(3,2-b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML.Leuk Lymphoma. 2019 Jul;60(7):1697-1708. doi: 10.1080/10428194.2018.1543880. Epub 2018 Dec 20.
• [382] Neuropathy correlated with imbalanced Foxp3/IL-17 in bone marrow microenvironment of patients with acute myeloid leukemia.Oncotarget. 2016 Apr 26;7(17):24455-65. doi: 10.18632/oncotarget.8227.
• [383] The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.Leuk Lymphoma. 2012 May;53(5):952-7. doi: 10.3109/10428194.2011.635862. Epub 2011 Dec 7.
• [384] RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.Nat Commun. 2018 Mar 21;9(1):1163. doi: 10.1038/s41467-018-03513-4.
• [385] Antiproliferative and Immunoregulatory Effects of Azelaic Acid Against Acute Myeloid Leukemia via the Activation of Notch Signaling Pathway.Front Pharmacol. 2019 Nov 29;10:1396. doi: 10.3389/fphar.2019.01396. eCollection 2019.
• [386] Association between single nucleotide polymorphisms within HLA region and disease relapse for patients with hematopoietic stem cell transplantation.Sci Rep. 2019 Sep 24;9(1):13731. doi: 10.1038/s41598-019-50111-5.
• [387] Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia.Per Med. 2019 Nov;16(6):479-490. doi: 10.2217/pme-2018-0077. Epub 2019 Oct 24.
• [388] Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.Leuk Lymphoma. 2007 Oct;48(10):1997-2007. doi: 10.1080/10428190701534424.
• [389] Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.
• [390] Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia.Int J Hematol. 2018 Sep;108(3):246-253. doi: 10.1007/s12185-018-2464-9. Epub 2018 May 8.
• [391] Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.Clin Epigenetics. 2018 Jun 19;10:83. doi: 10.1186/s13148-018-0516-x. eCollection 2018.
• [392] Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.Blood Adv. 2019 Feb 12;3(3):242-255. doi: 10.1182/bloodadvances.2018024182.
• [393] Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.Oncotarget. 2016 Jan 19;7(3):2765-79. doi: 10.18632/oncotarget.6409.
• [394] EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.Blood. 2015 Jan 1;125(1):140-3. doi: 10.1182/blood-2014-07-591529. Epub 2014 Oct 20.
• [395] Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.Future Med Chem. 2018 Apr 1;10(7):823-835. doi: 10.4155/fmc-2017-0298. Epub 2018 Feb 13.
• [396] Myeloid maturation potentiates STAT3-mediated atypical IFN- signaling and upregulation of PD-1 ligands in AML and MDS.Sci Rep. 2019 Aug 12;9(1):11697. doi: 10.1038/s41598-019-48256-4.
• [397] Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.Int J Hematol. 2017 May;105(5):697-701. doi: 10.1007/s12185-016-2167-z. Epub 2016 Dec 20.
• [398] The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.Haematologica. 2014 May;99(5):858-64. doi: 10.3324/haematol.2013.096487. Epub 2013 Dec 13.
• [399] Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia.Cancer Gene Ther. 2020 Feb;27(1-2):15-21. doi: 10.1038/s41417-018-0071-9. Epub 2018 Dec 22.
• [400] mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.Biochem Biophys Res Commun. 2017 Feb 5;483(2):897-903. doi: 10.1016/j.bbrc.2017.01.031. Epub 2017 Jan 9.
• [401] High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1- signaling pathway.Oncol Lett. 2019 Jun;17(6):5395-5402. doi: 10.3892/ol.2019.10256. Epub 2019 Apr 16.
• [402] Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.J Cell Mol Med. 2015 Sep;19(9):2262-72. doi: 10.1111/jcmm.12617. Epub 2015 Jun 16.
• [403] Nuclear Inositide Signaling Via Phospholipase C.J Cell Biochem. 2017 Aug;118(8):1969-1978. doi: 10.1002/jcb.25894. Epub 2017 Apr 25.
• [404] Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-1) as a potential target for t(8;21) AML.Oncotarget. 2017 Jun 27;8(40):67344-67354. doi: 10.18632/oncotarget.18631. eCollection 2017 Sep 15.
• [405] Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas.Appl Immunohistochem Mol Morphol. 2001 Mar;9(1):29-34.
• [406] Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.Cancers (Basel). 2019 Nov 11;11(11):1774. doi: 10.3390/cancers11111774.
• [407] The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia.PLoS One. 2011 Jan 20;6(1):e16340. doi: 10.1371/journal.pone.0016340.
• [408] The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia.Free Radic Biol Med. 2020 Jan;146:275-286. doi: 10.1016/j.freeradbiomed.2019.11.013. Epub 2019 Nov 12.
• [409] Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.Exp Ther Med. 2018 Jun;15(6):5431-5435. doi: 10.3892/etm.2018.6111. Epub 2018 Apr 30.
• [410] Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10.
• [411] Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res. 2009 Nov 15;315(19):3250-8. doi: 10.1016/j.yexcr.2009.09.005. Epub 2009 Sep 10.
• [412] PRKCH regulates hematopoietic stem cell function and predicts poor prognosis in acute myeloid leukemia.Exp Hematol. 2017 Sep;53:43-47. doi: 10.1016/j.exphem.2017.05.006. Epub 2017 Jun 6.
• [413] Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.Exp Hematol. 2018 Nov;67:18-31. doi: 10.1016/j.exphem.2018.08.004. Epub 2018 Aug 17.
• [414] PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia.Blood. 2019 Aug 8;134(6):548-560. doi: 10.1182/blood.2019001282. Epub 2019 Jun 19.
• [415] PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.Nat Struct Mol Biol. 2019 Nov;26(11):999-1012. doi: 10.1038/s41594-019-0313-z. Epub 2019 Oct 14.
• [416] Association of an LMP2 polymorphism with acute myeloid leukemia and multiple myeloma.Asian Pac J Cancer Prev. 2013;14(11):6399-402. doi: 10.7314/apjcp.2013.14.11.6399.
• [417] Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. Epub 2019 Feb 21.
• [418] Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway.PLoS One. 2010 Nov 16;5(11):e14018. doi: 10.1371/journal.pone.0014018.
• [419] PRL-2 increases Epo and IL-3 responses in hematopoietic cells.Blood Cells Mol Dis. 2010 Apr 15;44(4):209-14. doi: 10.1016/j.bcmd.2010.02.013. Epub 2010 Mar 11.
• [420] Non-canonical activation of -catenin by PRL-3 phosphatase in acute myeloid leukemia.Oncogene. 2019 Feb;38(9):1508-1519. doi: 10.1038/s41388-018-0526-3. Epub 2018 Oct 10.
• [421] Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
• [422] FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.Haematologica. 2019 Dec;104(12):2418-2428. doi: 10.3324/haematol.2018.208843. Epub 2019 Apr 11.
• [423] A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.Oncotarget. 2014 Dec 30;5(24):12675-93. doi: 10.18632/oncotarget.2564.
• [424] The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.J Renin Angiotensin Aldosterone Syst. 2019 Apr-Jun;20(2):1470320319851310. doi: 10.1177/1470320319851310.
• [425] RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22.
• [426] Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling Pathway.Front Pharmacol. 2018 Jun 26;9:673. doi: 10.3389/fphar.2018.00673. eCollection 2018.
• [427] Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.PLoS One. 2015 Mar 20;10(3):e0119831. doi: 10.1371/journal.pone.0119831. eCollection 2015.
• [428] FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.Cancers (Basel). 2019 Nov 20;11(12):1827. doi: 10.3390/cancers11121827.
• [429] RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.
• [430] Identification of miRNA-mRNA Network Associated with Acute Myeloid Leukemia Survival.Med Sci Monit. 2017 Oct 1;23:4705-4714. doi: 10.12659/msm.903989.
• [431] A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.Am J Hematol. 2014 Aug;89(8):E103-8. doi: 10.1002/ajh.23735. Epub 2014 Apr 28.
• [432] Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.Int J Oncol. 2018 Mar;52(3):656-678. doi: 10.3892/ijo.2017.4233. Epub 2017 Dec 28.
• [433] Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.Blood. 2017 Feb 9;129(6):771-782. doi: 10.1182/blood-2016-06-720433. Epub 2016 Dec 12.
• [434] Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice.Leukemia. 2020 Mar;34(3):721-734. doi: 10.1038/s41375-019-0577-7. Epub 2019 Oct 21.
• [435] Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).Leuk Lymphoma. 2017 May;58(5):1068-1075. doi: 10.1080/10428194.2016.1235274. Epub 2016 Oct 13.
• [436] SEMA3A partially reverses VEGF effects through binding to neuropilin-1.Stem Cell Res. 2017 Jul;22:70-78. doi: 10.1016/j.scr.2017.05.012. Epub 2017 Jun 3.
• [437] Expression of septin 2 and association with clinicopathological parameters in colorectal cancer.Oncol Lett. 2019 Sep;18(3):2376-2383. doi: 10.3892/ol.2019.10528. Epub 2019 Jun 26.
• [438] MEF2C Phosphorylation Is Required forChemotherapy Resistance in Acute Myeloid Leukemia.Cancer Discov. 2018 Apr;8(4):478-497. doi: 10.1158/2159-8290.CD-17-1271. Epub 2018 Feb 5.
• [439] Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo.Blood. 2020 Jan 2;135(1):56-70. doi: 10.1182/blood.2019001576.
• [440] How many surgically-treated angiomyolipomas are related to tuberous sclerosis complex? Insights from a retrospective multicenter study.Minerva Urol Nefrol. 2020 Apr;72(2):200-206. doi: 10.23736/S0393-2249.19.03522-7. Epub 2019 Oct 10.
• [441] Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.Mol Carcinog. 2017 Jan;56(1):130-148. doi: 10.1002/mc.22478. Epub 2016 Mar 7.
• [442] Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells.Apoptosis. 2015 Aug;20(8):1099-108. doi: 10.1007/s10495-015-1137-x.
• [443] Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.Chemotherapy. 2016;61(6):313-8. doi: 10.1159/000445370. Epub 2016 Apr 28.
• [444] High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia.J Cell Physiol. 2019 Nov;234(11):20322-20328. doi: 10.1002/jcp.28632. Epub 2019 Apr 4.
• [445] CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.Cancer Cell. 2016 Nov 14;30(5):792-805. doi: 10.1016/j.ccell.2016.10.003. Epub 2016 Oct 27.
• [446] Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.Leuk Res. 2019 May;80:1-10. doi: 10.1016/j.leukres.2019.02.011. Epub 2019 Feb 28.
• [447] Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. 2016 Jun;99(6):651-60.
• [448] High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy.Cancer Gene Ther. 2019 May;26(5-6):119-127. doi: 10.1038/s41417-018-0044-z. Epub 2018 Sep 4.
• [449] SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.Oncotarget. 2017 Mar 7;8(10):16712-16727. doi: 10.18632/oncotarget.15147.
• [450] Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).Am J Hematol. 2010 Jul;85(7):477-81. doi: 10.1002/ajh.21723.
• [451] SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.Oncol Rep. 2015 Sep;34(3):1406-14. doi: 10.3892/or.2015.4114. Epub 2015 Jul 8.
• [452] lncRNA SNHG3 facilitates acute myeloid leukemia cell growth via the regulation of miR-758-3p/SRGN axis.J Cell Biochem. 2020 Feb;121(2):1023-1031. doi: 10.1002/jcb.29336. Epub 2019 Aug 26.
• [453] SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.
• [454] MIF-Induced Stromal PKC/IL8 Is Essential in Human Acute Myeloid Leukemia.Cancer Res. 2017 Jan 15;77(2):303-311. doi: 10.1158/0008-5472.CAN-16-1095. Epub 2016 Nov 21.
• [455] Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner.Leukemia. 2018 Mar;32(3):588-596. doi: 10.1038/leu.2017.261. Epub 2017 Aug 18.
• [456] Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome.Int J Lab Hematol. 2016 Feb;38(1):81-9. doi: 10.1111/ijlh.12445. Epub 2015 Nov 7.
• [457] The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733.
• [458] MicroRNA-29b mediates altered innate immune development in acute leukemia.J Clin Invest. 2016 Dec 1;126(12):4404-4416. doi: 10.1172/JCI85413. Epub 2016 Oct 24.
• [459] Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.J Biol Chem. 2019 Mar 29;294(13):4898-4910. doi: 10.1074/jbc.RA118.006795. Epub 2019 Jan 31.
• [460] Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.Leukemia. 2009 Jul;23(7):1345-8. doi: 10.1038/leu.2009.66. Epub 2009 Apr 2.
• [461] MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.Ann Hematol. 2018 Jan;97(1):63-72. doi: 10.1007/s00277-017-3158-8. Epub 2017 Oct 27.
• [462] Affinity separation and subsequent terminal differentiation of acute myeloid leukemia cells using the human transferrin receptor (CD71) as a capture target.Analyst. 2019 May 13;144(10):3369-3380. doi: 10.1039/c8an02357c.
• [463] Thrombopoietin mimetics for patients with myelodysplastic syndromes.Cochrane Database Syst Rev. 2017 Sep 30;9(9):CD009883. doi: 10.1002/14651858.CD009883.pub2.
• [464] Increased levels of a chromosome 21-encoded tumour invasion and metastasis factor (TIAM1) mRNA in bone marrow of Down syndrome children during the acute phase of AML(M7).Genes Chromosomes Cancer. 1998 Sep;23(1):61-6.
• [465] Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.Biol Blood Marrow Transplant. 2019 May;25(5):861-867. doi: 10.1016/j.bbmt.2019.01.013. Epub 2019 Jan 11.
• [466] NDRG2 and TLR7 as novel DNA methylation prognostic signatures for acute myelocytic leukemia.J Cell Physiol. 2020 Apr;235(4):3790-3797. doi: 10.1002/jcp.29273. Epub 2019 Oct 15.
• [467] NF-B-dependent RANKL expression in a mouse model of immature T-cell leukemia.Biochem Biophys Res Commun. 2019 Mar 5;510(2):272-277. doi: 10.1016/j.bbrc.2019.01.089. Epub 2019 Jan 30.
• [468] Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)--TNF Receptor-2 Pathway.Front Immunol. 2018 Jun 5;9:1274. doi: 10.3389/fimmu.2018.01274. eCollection 2018.
• [469] CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms.Am J Dermatopathol. 2017 May;39(5):351-357. doi: 10.1097/DAD.0000000000000755.
• [470] CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.Hum Gene Ther. 2018 May;29(5):626-639. doi: 10.1089/hum.2017.241. Epub 2018 Mar 19.
• [471] Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism.Cancers (Basel). 2019 Feb 22;11(2):260. doi: 10.3390/cancers11020260.
• [472] Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells.Haematologica. 2019 Oct;104(10):2006-2016. doi: 10.3324/haematol.2018.192062. Epub 2019 Feb 28.
• [473] EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology.SLAS Discov. 2019 Mar;24(3):398-413. doi: 10.1177/2472555218816276. Epub 2019 Jan 7.
• [474] Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.Mol Oncol. 2019 Oct;13(10):2062-2078. doi: 10.1002/1878-0261.12541. Epub 2019 Aug 31.
• [475] The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.Oncol Lett. 2017 Aug;14(2):1464-1470. doi: 10.3892/ol.2017.6322. Epub 2017 Jun 6.
• [476] Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.Leuk Res. 2008 Jun;32(6):944-53. doi: 10.1016/j.leukres.2007.11.038. Epub 2008 Feb 21.
• [477] TRPM2 in Cancer.Cell Calcium. 2019 Jun;80:8-17. doi: 10.1016/j.ceca.2019.03.002. Epub 2019 Mar 6.
• [478] Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.Int J Cancer. 2015 Oct 15;137(8):1855-69. doi: 10.1002/ijc.29573. Epub 2015 May 8.
• [479] Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia.Leuk Lymphoma. 2000 Feb;36(5-6):463-6. doi: 10.3109/10428190009148393.
• [480] BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.BMC Cancer. 2018 Jul 11;18(1):731. doi: 10.1186/s12885-018-4661-6.
• [481] Peperomin E and its orally bioavailable analog induce oxidative stress-mediated apoptosis of acute myeloid leukemia progenitor cells by targeting thioredoxin reductase.Redox Biol. 2019 Jun;24:101153. doi: 10.1016/j.redox.2019.101153. Epub 2019 Mar 8.
• [482] Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.Biochem Pharmacol. 2017 Mar 15;128:12-25. doi: 10.1016/j.bcp.2016.12.022. Epub 2016 Dec 30.
• [483] Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
• [484] A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene.Genes Chromosomes Cancer. 2018 Oct;57(10):522-524. doi: 10.1002/gcc.22646. Epub 2018 Aug 14.
• [485] Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.Genes Chromosomes Cancer. 2019 Sep;58(9):669-672. doi: 10.1002/gcc.22751. Epub 2019 Apr 8.
• [486] Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia.Transl Oncol. 2018 Jun;11(3):567-574. doi: 10.1016/j.tranon.2018.02.018. Epub 2018 Mar 12.
• [487] Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.Orphanet J Rare Dis. 2018 Feb 20;13(1):34. doi: 10.1186/s13023-018-0775-9.
• [488] VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.
• [489] Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53() murine model.Oncoimmunology. 2018 Jul 30;7(9):e1468954. doi: 10.1080/2162402X.2018.1468954. eCollection 2018.
• [490] NF-B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.Leukemia. 2015 Mar;29(3):535-47. doi: 10.1038/leu.2014.231. Epub 2014 Aug 5.
• [491] The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.Leukemia. 2018 Apr;32(4):911-919. doi: 10.1038/leu.2017.342. Epub 2017 Dec 6.
• [492] An unexpected protein interaction promotes drug resistance in leukemia.Nat Commun. 2017 Nov 16;8(1):1547. doi: 10.1038/s41467-017-01678-y.
• [493] ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation.Hematology. 2019 Dec;24(1):129-133. doi: 10.1080/10245332.2018.1532648. Epub 2018 Oct 16.
• [494] DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups.Br J Haematol. 2012 Oct;159(2):182-90. doi: 10.1111/bjh.12029. Epub 2012 Aug 28.
• [495] Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.Oncogene. 2017 Mar;36(11):1487-1502. doi: 10.1038/onc.2016.310. Epub 2016 Nov 21.
• [496] Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.Oncogene. 2018 Feb 8;37(6):787-797. doi: 10.1038/onc.2017.376. Epub 2017 Oct 23.
• [497] High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.Cancer Res. 2011 Mar 1;71(5):1999-2009. doi: 10.1158/0008-5472.CAN-10-3018. Epub 2011 Jan 6.
• [498] Expression and Relationship of SAMHD1 with Other Apoptotic and Autophagic Genes in Acute Myeloid Leukemia Patients.Acta Haematol. 2020;143(1):51-59. doi: 10.1159/000500822. Epub 2019 Aug 21.
• [499] Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.Blood. 2007 Aug 1;110(3):1022-4. doi: 10.1182/blood-2006-12-061176. Epub 2007 May 2.
• [500] Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.Eur J Clin Pharmacol. 2012 Dec;68(12):1577-86. doi: 10.1007/s00228-012-1291-9. Epub 2012 May 5.
• [501] CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions.Cell Rep. 2019 Feb 12;26(7):1906-1918.e8. doi: 10.1016/j.celrep.2019.01.050.
• [502] Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).Blood Cancer J. 2019 Dec 6;9(12):99. doi: 10.1038/s41408-019-0262-0.
• [503] B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22).Am J Clin Pathol. 2013 Sep;140(3):355-62. doi: 10.1309/AJCPFBCFXP94AKWJ.
• [504] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [505] Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.Leukemia. 2011 Dec;25(12):1825-33. doi: 10.1038/leu.2011.172. Epub 2011 Jul 15.
• [506] Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.
• [507] Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.Cancer Cell. 2018 Mar 12;33(3):386-400.e5. doi: 10.1016/j.ccell.2018.01.012. Epub 2018 Feb 22.
• [508] RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation.Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1897-902. doi: 10.1073/pnas.1019059108. Epub 2011 Jan 11.
• [509] GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.Apoptosis. 2013 Jul;18(7):882-95. doi: 10.1007/s10495-013-0840-8.
• [510] Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients.Leuk Res. 2010 Oct;34(10):1308-13. doi: 10.1016/j.leukres.2009.11.030. Epub 2010 Jan 12.
• [511] Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.Carcinogenesis. 2013 Mar;34(3):667-77. doi: 10.1093/carcin/bgs386. Epub 2012 Dec 13.
• [512] Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation.J Biol Chem. 2011 Dec 2;286(48):41479-41488. doi: 10.1074/jbc.M111.284687. Epub 2011 Oct 6.
• [513] Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms.J Hematol Oncol. 2011 Sep 27;4:39. doi: 10.1186/1756-8722-4-39.
• [514] The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.Leukemia. 2012 May;26(5):918-26. doi: 10.1038/leu.2011.319. Epub 2011 Nov 25.
• [515] The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.Blood. 2013 Sep 12;122(11):1900-13. doi: 10.1182/blood-2012-11-466425. Epub 2013 Jul 29.
• [516] Transcriptomic analysis of the PI3K/Akt signaling pathway reveals the dual role of the c-Jun oncogene in cytotoxicity and the development of resistance in HL-60 leukemia cells in response to arsenic trioxide.Adv Clin Exp Med. 2017 Dec;26(9):1335-1342. doi: 10.17219/acem/65475.
• [517] Clinical significance of the TNF- receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia.Cytokine. 2018 Nov;111:523-529. doi: 10.1016/j.cyto.2018.05.025. Epub 2018 Jun 1.
• [518] Methylation level of CpG islands in GGH gene promoter in pediatric acute leukemia.PLoS One. 2017 Mar 9;12(3):e0173472. doi: 10.1371/journal.pone.0173472. eCollection 2017.
• [519] Characterization of upregulated adhesion GPCRs in acute myeloid leukemia.Transl Res. 2019 Oct;212:26-35. doi: 10.1016/j.trsl.2019.05.004. Epub 2019 May 17.
• [520] Discovery of novel glycogen synthase kinase-3 inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.Eur J Med Chem. 2019 Jun 1;171:221-234. doi: 10.1016/j.ejmech.2019.03.039. Epub 2019 Mar 20.
• [521] Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.J Med Chem. 2018 Jul 26;61(14):6056-6074. doi: 10.1021/acs.jmedchem.8b00393. Epub 2018 Jul 14.
• [522] Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.Am J Cancer Res. 2019 Jan 1;9(1):94-107. eCollection 2019.
• [523] Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.Front Immunol. 2018 Sep 26;9:2227. doi: 10.3389/fimmu.2018.02227. eCollection 2018.
• [524] LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia.Mol Med Rep. 2017 Sep;16(3):3687-3693. doi: 10.3892/mmr.2017.7029. Epub 2017 Jul 18.
• [525] IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival.Sci Rep. 2019 Feb 11;9(1):1729. doi: 10.1038/s41598-018-38408-3.
• [526] Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol).Immunobiology. 2019 Jul;224(4):526-531. doi: 10.1016/j.imbio.2019.05.001. Epub 2019 May 2.
• [527] Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia.Cytokine Growth Factor Rev. 2018 Oct;43:1-7. doi: 10.1016/j.cytogfr.2018.06.001. Epub 2018 Jun 7.
• [528] Downregulation of TREM-like transcript-1 and collagen receptor 2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia.Haematologica. 2019 Jun;104(6):1244-1255. doi: 10.3324/haematol.2018.188904. Epub 2018 Dec 13.
• [529] JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.Leukemia. 2019 Jun;33(6):1400-1410. doi: 10.1038/s41375-018-0354-z. Epub 2019 Jan 8.
• [530] LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p.Life Sci. 2020 Jan 15;241:117161. doi: 10.1016/j.lfs.2019.117161. Epub 2019 Dec 11.
• [531] Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.Blood. 2019 Jan 10;133(2):168-179. doi: 10.1182/blood-2018-02-833475. Epub 2018 Nov 29.
• [532] Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.Leuk Res. 2013 Nov;37(11):1538-44. doi: 10.1016/j.leukres.2013.07.022. Epub 2013 Oct 3.
• [533] The prognostic value of matrix metalloproteinase-7 and matrix metalloproteinase-15 in acute myeloid leukemia.J Cell Biochem. 2019 Jun;120(6):10613-10624. doi: 10.1002/jcb.28351. Epub 2019 Feb 27.
• [534] Genetic variation in the folate metabolic pathway and risk of childhood leukemia.Blood. 2010 May 13;115(19):3923-9. doi: 10.1182/blood-2009-10-249722. Epub 2010 Jan 25.
• [535] The Expanding World of N-MYC-Driven Tumors.Cancer Discov. 2018 Feb;8(2):150-163. doi: 10.1158/2159-8290.CD-17-0273. Epub 2018 Jan 22.
• [536] Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy.Biomaterials. 2018 Jun;167:80-90. doi: 10.1016/j.biomaterials.2018.03.013. Epub 2018 Mar 14.
• [537] A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.Leukemia. 1995 Jul;9(7):1233-9.
• [538] Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.BMC Cancer. 2012 Dec 5;12:576. doi: 10.1186/1471-2407-12-576.
• [539] Combined effects of FLT3 and NF-B selective inhibitors on acute myeloid leukemia in vivo.J Biochem Mol Toxicol. 2012 Jan;26(1):35-43. doi: 10.1002/jbt.20411. Epub 2011 Sep 16.
• [540] Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.Cancer Res. 2018 Jan 1;78(1):75-87. doi: 10.1158/0008-5472.CAN-17-0946. Epub 2017 Nov 9.
• [541] Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.Blood. 2012 May 10;119(19):4499-511. doi: 10.1182/blood-2011-02-336446. Epub 2012 Mar 20.
• [542] RACK1 promotes the proliferation of THP1 acute myeloid leukemia cells.Mol Cell Biochem. 2013 Dec;384(1-2):197-202. doi: 10.1007/s11010-013-1798-0. Epub 2013 Sep 3.
• [543] Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.Leukemia. 2017 May;31(5):1154-1165. doi: 10.1038/leu.2016.287. Epub 2016 Oct 17.
• [544] MiR-592 functions as a tumor suppressor in acute myeloid leukemia by targeting ROCK1 and predicts patients' prognosis.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1610-1619. doi: 10.26355/eurrev_201902_17120.
• [545] RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.
• [546] Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.Target Oncol. 2019 Jun;14(3):351-364. doi: 10.1007/s11523-019-00638-4.
• [547] SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.Leukemia. 2019 Nov;33(11):2585-2598. doi: 10.1038/s41375-019-0456-2. Epub 2019 Apr 9.
• [548] A novel treatment strategy targeting shugoshin 1 in hematological malignancies.Leuk Res. 2013 Jan;37(1):76-82. doi: 10.1016/j.leukres.2012.10.002. Epub 2012 Oct 24.
• [549] LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia.Mol Cell. 2018 Mar 15;69(6):1017-1027.e6. doi: 10.1016/j.molcel.2018.02.011. Epub 2018 Mar 8.
• [550] Engagement of SIRP inhibits growth and induces programmed cell death in acute myeloid leukemia cells.PLoS One. 2013;8(1):e52143. doi: 10.1371/journal.pone.0052143. Epub 2013 Jan 8.
• [551] Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.
• [552] Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia.Exp Hematol. 2019 Aug;76:38-48.e2. doi: 10.1016/j.exphem.2019.07.002. Epub 2019 Jul 8.
• [553] Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells.Biochem Biophys Res Commun. 2019 Nov 19;519(4):887-893. doi: 10.1016/j.bbrc.2019.09.087. Epub 2019 Sep 25.
• [554] Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10.
• [555] A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.Cancer Res. 2019 Jul 1;79(13):3372-3382. doi: 10.1158/0008-5472.CAN-18-0189. Epub 2019 May 7.
• [556] TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.Am J Hematol. 2013 Dec;88(12):1055-61. doi: 10.1002/ajh.23567. Epub 2013 Sep 30.
• [557] Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.Leuk Res. 2017 Jun;57:112-118. doi: 10.1016/j.leukres.2017.03.011. Epub 2017 Mar 21.
• [558] E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBP for ubiquitin-mediated proteasome degradation.Cell Death Dis. 2013 Apr 18;4(4):e590. doi: 10.1038/cddis.2013.120.
• [559] Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.Mol Cancer Ther. 2013 Dec;12(12):2651-62. doi: 10.1158/1535-7163.MCT-13-0103-T. Epub 2013 Oct 15.
• [560] Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.Cancer Lett. 2018 Sep 1;431:150-160. doi: 10.1016/j.canlet.2018.05.034. Epub 2018 May 30.
• [561] Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.Leukemia. 2001 Oct;15(10):1544-53. doi: 10.1038/sj.leu.2402236.
• [562] DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.Blood. 2008 Sep 1;112(5):2013-6. doi: 10.1182/blood-2008-01-128595. Epub 2008 Jun 19.
• [563] Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.Leukemia. 2008 Aug;22(8):1576-86. doi: 10.1038/leu.2008.103. Epub 2008 May 8.
• [564] Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
• [565] Probing the Anticancer Action of Novel Ferrocene Analogues of MNK Inhibitors.Molecules. 2018 Aug 23;23(9):2126. doi: 10.3390/molecules23092126.
• [566] OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
• [567] Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.Leuk Res. 2017 Feb;53:57-64. doi: 10.1016/j.leukres.2016.12.004. Epub 2016 Dec 20.
• [568] Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.Oncol Res Treat. 2018;41(7-8):461-465. doi: 10.1159/000487804. Epub 2018 Jul 6.
• [569] NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.Leukemia. 2016 Feb;30(2):473-83. doi: 10.1038/leu.2015.234. Epub 2015 Aug 26.
• [570] Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy.Oncol Rep. 2015 Jul;34(1):488-94. doi: 10.3892/or.2015.3959. Epub 2015 May 7.
• [571] Downregulation of GLUT3 Promotes Apoptosis and Chemosensitivity of Acute Myeloid Leukemia Cells via EGFR Signaling.Arch Iran Med. 2018 Feb 1;21(2):73-78.
• [572] Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential.Cancer Cell. 2016 Nov 14;30(5):779-791. doi: 10.1016/j.ccell.2016.09.006. Epub 2016 Oct 13.
• [573] A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity.Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110051. doi: 10.1016/j.msec.2019.110051. Epub 2019 Aug 19.
• [574] Potential mechanisms of resistance to cytarabine in AML patients.Leuk Res. 2002 Jul;26(7):621-9. doi: 10.1016/s0145-2126(01)00184-9.
• [575] Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia.Oncogene. 1996 Jan 18;12(2):437-44.
• [576] BAT-25 and BAT-26, two mononucleotide microsatellites, are not sensitive markers of microsatellite instability in acute myeloid leukaemia.Br J Haematol. 2004 Jan;124(2):160-5. doi: 10.1046/j.1365-2141.2003.04750.x.
• [577] Emerging role of EPHX1 in chemoresistance of acute myeloid leukemia by regurlating drug-metabolizing enzymes and apoptotic signaling.Mol Carcinog. 2019 May;58(5):808-819. doi: 10.1002/mc.22973. Epub 2019 Jan 28.
• [578] Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay.Leukemia. 1996 Feb;10(2):362-7.
• [579] 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.Haematologica. 2004 May;89(5):617-9.
• [580] Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern.Med Oncol. 2013 Mar;30(1):368. doi: 10.1007/s12032-012-0368-8. Epub 2013 Jan 6.
• [581] Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells.Blood. 2005 Feb 1;105(3):1246-55. doi: 10.1182/blood-2004-05-2041. Epub 2004 Sep 23.
• [582] Genetic analysis and clinical picture of severe congenital neutropenia in Israel.Pediatr Blood Cancer. 2015 Jan;62(1):103-8. doi: 10.1002/pbc.25251. Epub 2014 Oct 4.
• [583] Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.
• [584] Targeting Glutamine Metabolism and Redox State for Leukemia Therapy.Clin Cancer Res. 2019 Jul 1;25(13):4079-4090. doi: 10.1158/1078-0432.CCR-18-3223. Epub 2019 Apr 2.
• [585] Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.Haematologica. 2017 Jun;102(6):1054-1065. doi: 10.3324/haematol.2016.159053. Epub 2017 Mar 9.
• [586] Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia.Blood Cells Mol Dis. 2019 Jul;77:43-50. doi: 10.1016/j.bcmd.2019.03.008. Epub 2019 Mar 28.
• [587] Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.Pharmacogenet Genomics. 2015 Jan;25(1):1-7. doi: 10.1097/FPC.0000000000000097.
• [588] Relationship between NAT2 polymorphisms and onset risk of acute leukemia: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9259-9266. doi: 10.26355/eurrev_201911_19418.
• [589] Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.Biomaterials. 2018 Jun;167:132-142. doi: 10.1016/j.biomaterials.2018.03.025. Epub 2018 Mar 14.
• [590] Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes.Leuk Lymphoma. 1996 Nov;23(5-6):431-6. doi: 10.3109/10428199609054850.
• [591] Positional cloning and next-generation sequencing identified a TGM6 mutation in a large Chinese pedigree with acute myeloid leukaemia.Eur J Hum Genet. 2015 Feb;23(2):218-23. doi: 10.1038/ejhg.2014.67. Epub 2014 Apr 23.
• [592] Thiopurine methyltransferase activity in children with acute myeloid leukemia.Oncol Lett. 2018 Oct;16(4):4699-4706. doi: 10.3892/ol.2018.9191. Epub 2018 Jul 23.
• [593] ABO Blood Type Incompatibility Is Not a Risk Factor of Outcomes for Acute Myeloid Leukemia (AML) Patients After Unmanipulated Haplo-identical Peripheral Blood Hematopoietic Stem Cell Transplantation.Ann Transplant. 2019 Jun 14;24:350-358. doi: 10.12659/AOT.916004.
• [594] Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase.Oncotarget. 2017 Jun 19;8(66):109915-109923. doi: 10.18632/oncotarget.18565. eCollection 2017 Dec 15.
• [595] NAT10 upregulation indicates a poor prognosis in acute myeloid leukemia.Curr Probl Cancer. 2020 Apr;44(2):100491. doi: 10.1016/j.currproblcancer.2019.06.006. Epub 2019 Jul 2.
• [596] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [597] t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: specific expression patterns of ABI1 gene in leukemia and solid tumor cell lines.Genes Chromosomes Cancer. 2001 Sep;32(1):1-10. doi: 10.1002/gcc.1160.
• [598] Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13).Genes Chromosomes Cancer. 1999 Nov;26(3):192-202. doi: 10.1002/(sici)1098-2264(199911)26:3<192::aid-gcc2>3.0.co;2-e.
• [599] Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
• [600] T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p.Cancer Genet Cytogenet. 2004 Apr 1;150(1):62-5. doi: 10.1016/j.cancergencyto.2003.08.003.
• [601] High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.Cancer Med. 2019 Apr;8(4):1771-1778. doi: 10.1002/cam4.2053. Epub 2019 Mar 7.
• [602] Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia.Haematologica. 2020 Jul;105(7):1857-1867. doi: 10.3324/haematol.2019.219188. Epub 2019 Sep 26.
• [603] WTX is rarely mutated in acute myeloid leukemia.Haematologica. 2008 Jun;93(6):947-8. doi: 10.3324/haematol.12509. Epub 2008 May 6.
• [604] Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.J Hum Genet. 2015 Dec;60(12):749-54. doi: 10.1038/jhg.2015.105. Epub 2015 Sep 10.
• [605] The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.Pharmacogenomics. 2012 Aug;13(11):1257-69. doi: 10.2217/pgs.12.102.
• [606] Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2145-50. doi: 10.1073/pnas.040569197.
• [607] CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.Mol Cancer Res. 2005 Oct;3(10):585-96. doi: 10.1158/1541-7786.MCR-05-0111.
• [608] Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13.
• [609] Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute Leukemia.Anticancer Res. 2015 Dec;35(12):6615-22.
• [610] B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.Leuk Res. 1993 Jul;17(7):549-55. doi: 10.1016/0145-2126(93)90083-w.
• [611] Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome.Chin Med J (Engl). 1998 Aug;111(8):690-3.
• [612] Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma.Hum Mol Genet. 2003 Sep 15;12(18):2349-58. doi: 10.1093/hmg/ddg237. Epub 2003 Jul 22.
• [613] BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.Pathol Oncol Res. 2019 Apr;25(2):541-548. doi: 10.1007/s12253-018-0476-7. Epub 2018 Oct 25.
• [614] Mutations within the FLR exon of NF1 are rare in myelodysplastic syndromes and acute myelocytic leukemias.Leukemia. 1993 Jul;7(7):1058-60.
• [615] Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis.Haematologica. 2002 Jun;87(6):569-77.
• [616] Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death.Apoptosis. 2013 Aug;18(8):963-79. doi: 10.1007/s10495-013-0842-6.
• [617] Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet. 2002 Dec;32(4):633-8. doi: 10.1038/ng1015. Epub 2002 Nov 18.
• [618] Synthesis of a novel cytokine and its gene (LD78) expressions in hematopoietic fresh tumor cells and cell lines.J Clin Invest. 1989 Dec;84(6):1707-12. doi: 10.1172/JCI114353.
• [619] A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.Blood. 2006 Sep 1;108(5):1716-23. doi: 10.1182/blood-2006-04-016113. Epub 2006 May 2.
• [620] The microRNA miR-196b acts as a tumor suppressor in Cdx2-driven acute myeloid leukemia.Haematologica. 2020 Jun;105(6):e285-e289. doi: 10.3324/haematol.2019.223297. Epub 2019 Sep 26.
• [621] A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF in leukemic cells.Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.
• [622] Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.Eur J Haematol. 2005 Jan;74(1):24-34. doi: 10.1111/j.1600-0609.2004.00333.x.
• [623] Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.Clin Cancer Res. 2007 Feb 1;13(3):1019-28. doi: 10.1158/1078-0432.CCR-06-1602.
• [624] Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.Am J Hematol. 2005 Dec;80(4):282-7. doi: 10.1002/ajh.20503.
• [625] RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18694-9. doi: 10.1073/pnas.0704433104. Epub 2007 Nov 13.
• [626] Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR.Pediatr Hematol Oncol. 2006 Mar;23(2):115-27. doi: 10.1080/08880010500457780.
• [627] STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.Blood. 1996 Mar 1;87(5):1692-7.
• [628] MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.Oncogene. 2012 Jan 5;31(1):80-92. doi: 10.1038/onc.2011.208. Epub 2011 Jun 6.
• [629] Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model.Leuk Res. 1996 Jul;20(7):581-9. doi: 10.1016/0145-2126(96)00004-5.
• [630] Inv(11)(p15q22)/NUP98-DDX10 fusion and isoforms in a new case of de novo acute myeloid leukemia.Cancer Genet. 2013 Mar;206(3):92-6. doi: 10.1016/j.cancergen.2013.02.001. Epub 2013 Mar 20.
• [631] DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.
• [632] DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia.Leuk Res. 2014 May;38(5):601-7. doi: 10.1016/j.leukres.2014.02.012. Epub 2014 Mar 3.
• [633] p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells.Oncogene. 1996 Sep 5;13(5):1017-26.
• [634] p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.Leuk Res. 2005 May;29(5):557-64. doi: 10.1016/j.leukres.2004.11.003. Epub 2005 Jan 26.
• [635] Human DMTF1 antagonizes DMTF1 regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.Biochim Biophys Acta. 2015 Sep;1849(9):1198-208. doi: 10.1016/j.bbagrm.2015.07.009. Epub 2015 Jul 15.
• [636] RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.
• [637] Differential expression of terminal transferase (TdT) in acute lymphocytic leukaemia expressing myeloid antigens and TdT positive acute myeloid leukaemia as compared to myeloid antigen negative acute lymphocytic leukaemia.Br J Haematol. 1993 Jul;84(3):416-22. doi: 10.1111/j.1365-2141.1993.tb03095.x.
• [638] Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.Cancer Lett. 2003 Sep 25;199(2):185-92. doi: 10.1016/s0304-3835(03)00352-5.
• [639] Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.Prostate. 2007 Feb 1;67(2):146-53. doi: 10.1002/pros.20481.
• [640] Partial deletion of chromosome 1 in a case of acute myelocytic leukemia.Cancer Genet Cytogenet. 2002 Nov;139(1):60-2. doi: 10.1016/s0165-4608(02)00597-6.
• [641] The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases.Leuk Res. 2003 May;27(5):387-92. doi: 10.1016/s0145-2126(02)00214-x.
• [642] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.Int J Hematol. 2008 Sep;88(2):209-211. doi: 10.1007/s12185-008-0123-2. Epub 2008 Aug 1.
• [643] Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.Blood. 2012 Aug 2;120(5):1107-17. doi: 10.1182/blood-2011-11-394932. Epub 2012 Jun 7.
• [644] ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).Leuk Res. 2006 Aug;30(8):1037-42. doi: 10.1016/j.leukres.2005.10.014. Epub 2005 Nov 21.
• [645] A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia.Cytogenet Genome Res. 2019;157(4):213-219. doi: 10.1159/000499640. Epub 2019 Apr 12.
• [646] A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse.Blood. 2004 Apr 1;103(7):2744-52. doi: 10.1182/blood-2003-07-2280. Epub 2003 Dec 4.
• [647] Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.Oncogene. 2007 Apr 5;26(16):2299-307. doi: 10.1038/sj.onc.1210043. Epub 2006 Oct 16.
• [648] Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.Exp Hematol. 2003 Nov;31(11):1066-72. doi: 10.1016/j.exphem.2003.08.003.
• [649] The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.Cancer Res. 1997 Mar 1;57(5):799-802.
• [650] Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.Leukemia. 2006 Jun;20(6):979-86. doi: 10.1038/sj.leu.2404203.
• [651] International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood. 1997 Mar 15;89(6):2079-88.
• [652] HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.Leukemia. 2013 Jun;27(6):1358-68. doi: 10.1038/leu.2012.366. Epub 2012 Dec 18.
• [653] Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.Blood. 2011 Jun 30;117(26):7112-20. doi: 10.1182/blood-2011-01-329078. Epub 2011 May 11.
• [654] Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation.Genes Chromosomes Cancer. 2005 Mar;42(3):269-79. doi: 10.1002/gcc.20147.
• [655] Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.Br J Haematol. 2008 Sep;142(5):745-53. doi: 10.1111/j.1365-2141.2008.07242.x. Epub 2008 Jun 3.
• [656] Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit.J Biol Chem. 2008 Oct 10;283(41):27444-27451. doi: 10.1074/jbc.M709703200. Epub 2008 Aug 11.
• [657] CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells.PLoS One. 2014 Feb 10;9(2):e85328. doi: 10.1371/journal.pone.0085328. eCollection 2014.
• [658] Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1).Genes Chromosomes Cancer. 2005 Feb;42(2):170-8. doi: 10.1002/gcc.20113.
• [659] S-phase DNA content and aneuploidy of immunophenotypic defined subpopulations in acute myeloid leukemia determined by multi-parameter flow cytometry.Leuk Res. 1991;15(9):827-35. doi: 10.1016/0145-2126(91)90467-8.
• [660] IL-21-mediated expansion of V9V2 T cells is limited by the Tim-3 pathway.Int Immunopharmacol. 2019 Apr;69:136-142. doi: 10.1016/j.intimp.2019.01.027. Epub 2019 Jan 29.
• [661] Prognostic value of lymphocyte surface markers in acute myeloid leukemia.Blood. 1991 May 15;77(10):2242-50.
• [662] Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia.Blood. 2006 Dec 1;108(12):3916-8. doi: 10.1182/blood-2006-05-022921. Epub 2006 Aug 10.
• [663] Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.Oncogene. 2006 Nov 9;25(53):7041-58. doi: 10.1038/sj.onc.1209689. Epub 2006 May 29.
• [664] Downregulation of miR?35a predicts poor prognosis in acute myeloid leukemia and regulates leukemia progression via modulating HOXA10 expression.Mol Med Rep. 2018 Jul;18(1):1134-1140. doi: 10.3892/mmr.2018.9066. Epub 2018 May 23.
• [665] Characteristic patterns of HOX gene expression in different types of human leukemia.Int J Cancer. 1993 Jan 21;53(2):237-44. doi: 10.1002/ijc.2910530211.
• [666] Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia.Leukemia. 2002 Jul;16(7):1293-301. doi: 10.1038/sj.leu.2402532.
• [667] The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15).Cancer Res. 2002 Jan 1;62(1):33-7.
• [668] Thymic precursor cells generate acute myeloid leukemia in NUP98-PHF23/NUP98-HOXD13 double transgenic mice.Sci Rep. 2019 Nov 20;9(1):17213. doi: 10.1038/s41598-019-53610-7.
• [669] ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.Oncogene. 2009 Feb 26;28(8):1099-109. doi: 10.1038/onc.2008.457. Epub 2008 Dec 15.
• [670] The functional polymorphisms of ARID5B and IKZF1 are associated with acute myeloid leukemia risk in a Han Chinese population.Gene. 2018 Mar 20;647:115-120. doi: 10.1016/j.gene.2017.12.059. Epub 2017 Dec 29.
• [671] Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor.Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18502-7. doi: 10.1073/pnas.0702388104. Epub 2007 Nov 14.
• [672] The expression of IL-6 and its related genes in acute leukemia.Leuk Lymphoma. 1996 Mar;21(1-2):49-52. doi: 10.3109/10428199609067579.
• [673] IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.Biol Res. 2019 Mar 15;52(1):11. doi: 10.1186/s40659-019-0218-7.
• [674] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.
• [675] Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.Leukemia. 2001 Jul;15(7):1072-80. doi: 10.1038/sj.leu.2402159.
• [676] The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1.
• [677] Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.Cancer Sci. 2008 Aug;99(8):1523-7. doi: 10.1111/j.1349-7006.2008.00865.x.
• [678] Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.PLoS Genet. 2013;9(10):e1003765. doi: 10.1371/journal.pgen.1003765. Epub 2013 Oct 10.
• [679] Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.Haematologica. 2014 Sep;99(9):1456-64. doi: 10.3324/haematol.2013.101386. Epub 2014 Jun 3.
• [680] AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14).Oncogene. 2000 Sep 7;19(38):4446-50. doi: 10.1038/sj.onc.1203789.
• [681] Investigation of methylation at Hha I sites using the hypervariable probe M27 beta allows improved clonal analysis in myeloid leukaemia and demonstrates differences in methylation between leukaemic and remission samples.Leukemia. 1994 Jan;8(1):190-4.
• [682] hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells.Mol Cancer Ther. 2008 Sep;7(9):2798-806. doi: 10.1158/1535-7163.MCT-08-0276.
• [683] Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.Br J Haematol. 2011 Jun;153(5):612-22. doi: 10.1111/j.1365-2141.2011.08586.x. Epub 2011 Apr 13.
• [684] Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukemia with t(11;12)(p15;q13).Genes Chromosomes Cancer. 2003 Jan;36(1):107-12. doi: 10.1002/gcc.10139.
• [685] Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.Br J Haematol. 2008 May;141(4):504-11. doi: 10.1111/j.1365-2141.2008.07072.x. Epub 2008 Mar 3.
• [686] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.
• [687] The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.Haematologica. 2005 Dec;90(12):1699-701.
• [688] Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.Cancer Res. 2010 Jun 15;70(12):4949-60. doi: 10.1158/0008-5472.CAN-09-1962. Epub 2010 May 25.
• [689] The PAF1c Subunit CDC73 Is Required for Mouse Hematopoietic Stem Cell Maintenance but Displays Leukemia-Specific Gene Regulation.Stem Cell Reports. 2019 May 14;12(5):1069-1083. doi: 10.1016/j.stemcr.2019.03.010. Epub 2019 Apr 25.
• [690] AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.Blood. 2003 May 15;101(10):3778-83. doi: 10.1182/blood-2002-08-2641. Epub 2003 Jan 30.
• [691] Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.Cancer Cell. 2011 Sep 13;20(3):357-69. doi: 10.1016/j.ccr.2011.07.016.
• [692] Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLLAF9 translocation.Mol Med Rep. 2020 Feb;21(2):883-893. doi: 10.3892/mmr.2019.10849. Epub 2019 Nov 26.
• [693] MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia.Exp Hematol. 1997 Oct;25(11):1111-7.
• [694] Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function.Mol Cell Biol. 2006 Aug;26(15):5809-26. doi: 10.1128/MCB.00024-06.
• [695] A radiation hybrid breakpoint map of the acute myeloid leukemia (AML) and limb-girdle muscular dystrophy 1A (LGMD1A) regions of chromosome 5q31 localizing 122 expressed sequences.Genomics. 1999 Apr 1;57(1):24-35. doi: 10.1006/geno.1999.5765.
• [696] Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids.Br J Haematol. 1990 Aug;75(4):489-95. doi: 10.1111/j.1365-2141.1990.tb07787.x.
• [697] NBS1 rs1805794G>C polymorphism is associated with decreased risk of acute myeloid leukemia in a Chinese population.Mol Biol Rep. 2013 May;40(5):3749-56. doi: 10.1007/s11033-012-2451-9. Epub 2013 Jan 3.
• [698] Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.Int J Hematol. 2014 Jan;99(1):21-31. doi: 10.1007/s12185-013-1466-x. Epub 2013 Nov 21.
• [699] Survival in acute myeloid leukemia is associated with NKp44 splice variants.Oncotarget. 2016 May 31;7(22):32933-45. doi: 10.18632/oncotarget.8782.
• [700] A case of childhood acute myeloid leukemia AML (M5) with a neocentric chromosome neo(1)(qter-->q23 approximately 24::q23 approximately 24-->q43-->neo-->q43-->qter) and tetrasomy of chromosomes 8 and 21.Cancer Genet Cytogenet. 2009 Sep;193(2):123-6. doi: 10.1016/j.cancergencyto.2009.05.001.
• [701] Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia.Blood. 1996 Nov 1;88(9):3555-61.
• [702] Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias.Blood. 2004 Sep 15;104(6):1833-40. doi: 10.1182/blood-2003-10-3577. Epub 2004 Jun 8.
• [703] Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia.Carcinogenesis. 2002 Apr;23(4):559-64. doi: 10.1093/carcin/23.4.559.
• [704] Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.Oncogene. 2013 Nov 14;32(46):5359-68. doi: 10.1038/onc.2013.40. Epub 2013 Mar 11.
• [705] The nuclear migration gene NudC and human hematopoiesis.Leuk Lymphoma. 2000 Nov;39(5-6):447-54. doi: 10.3109/10428190009113375.
• [706] Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.Blood. 2011 Jun 2;117(22):5931-40. doi: 10.1182/blood-2010-08-304485. Epub 2011 Apr 6.
• [707] Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population.Genet Test Mol Biomarkers. 2016 Nov;20(11):696-701. doi: 10.1089/gtmb.2016.0007. Epub 2016 Sep 9.
• [708] Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia.Eur J Haematol. 2008 Aug;81(2):112-22. doi: 10.1111/j.1600-0609.2008.01083.x. Epub 2008 Jun 28.
• [709] RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.Cancer Res. 2007 Mar 1;67(5):1997-2005. doi: 10.1158/0008-5472.CAN-06-3093.
• [710] Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.Leukemia. 2019 Jul;33(7):1620-1634. doi: 10.1038/s41375-019-0390-3. Epub 2019 Feb 8.
• [711] Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.Exp Hematol. 2012 Dec;40(12):1016-27. doi: 10.1016/j.exphem.2012.08.001. Epub 2012 Aug 8.
• [712] The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells.Leukemia. 2011 Apr;25(4):655-62. doi: 10.1038/leu.2010.301. Epub 2011 Jan 25.
• [713] cDNA cloning of human myeloperoxidase: decrease in myeloperoxidase mRNA upon induction of HL-60 cells.Proc Natl Acad Sci U S A. 1987 Apr;84(7):2057-61. doi: 10.1073/pnas.84.7.2057.
• [714] Human CAP10-Like Protein 46kDa Gene Promotes Malignancy in Colorectal Cancer.OMICS. 2017 May;21(5):266-274. doi: 10.1089/omi.2017.0037.
• [715] The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene.Blood. 1995 Sep 15;86(6):2073-6.
• [716] Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia.Eur J Cancer Prev. 2008 Apr;17(2):125-32. doi: 10.1097/CEJ.0b013e3282b6fd68.
• [717] High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.Am J Hematol. 2005 May;79(1):26-35. doi: 10.1002/ajh.20337.
• [718] NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15).Blood. 1999 Jul 15;94(2):741-7.
• [719] A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.Cancer Lett. 2020 Jan 1;468:1-13. doi: 10.1016/j.canlet.2019.10.007. Epub 2019 Oct 5.
• [720] Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells.Biochem Biophys Res Commun. 2017 Jan 22;482(4):802-807. doi: 10.1016/j.bbrc.2016.11.114. Epub 2016 Nov 23.
• [721] Expression of recombination activating genes-1 and-2 immunoglobulin heavy chain gene rearrangements in acute myeloid leukemia: evaluation of biological and clinical significance in a series of 76 uniformly treated patients and review of the literature.Haematologica. 2003 Mar;88(3):268-74.
• [722] A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.Haematologica. 2007 Jun;92(6):744-52. doi: 10.3324/haematol.10869.
• [723] RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia.J Biol Chem. 2002 Aug 23;277(34):30508-14. doi: 10.1074/jbc.M111330200. Epub 2002 Mar 5.
• [724] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.Br J Haematol. 2005 Jul;130(2):233-48. doi: 10.1111/j.1365-2141.2005.05594.x.
• [725] The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity.Leuk Lymphoma. 2002 Apr;43(4):851-8. doi: 10.1080/10428190290016999.
• [726] Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia.Ann Hematol. 2005 Jun;84(6):368-75. doi: 10.1007/s00277-005-1035-3. Epub 2005 Mar 24.
• [727] Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.Am J Hematol. 2010 Aug;85(8):569-74. doi: 10.1002/ajh.21746.
• [728] Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.Scand J Clin Lab Invest. 2019 Feb-Apr;79(1-2):65-70. doi: 10.1080/00365513.2018.1555854. Epub 2019 Jan 12.
• [729] Methylation profiling in acute myeloid leukemia.Blood. 2001 May 1;97(9):2823-9. doi: 10.1182/blood.v97.9.2823.
• [730] FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23).Leukemia. 2004 May;18(5):998-1005. doi: 10.1038/sj.leu.2403334.
• [731] MLL-SEPT5 fusion transcript in infant acute myeloid leukemia with t(11;22)(q23;q11).Leuk Lymphoma. 2014 Mar;55(3):662-7. doi: 10.3109/10428194.2013.809528. Epub 2013 Aug 20.
• [732] AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25).Cancer Res. 1999 Sep 1;59(17):4261-5.
• [733] Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.Blood. 2011 Dec 15;118(25):6638-48. doi: 10.1182/blood-2011-05-354712. Epub 2011 Oct 26.
• [734] Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.Blood. 2008 May 1;111(9):4716-22. doi: 10.1182/blood-2007-10-113068. Epub 2008 Feb 25.
• [735] Virulence determinants in vancomycin-resistant Enterococcus faecium vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders.J Hosp Infect. 2008 Feb;68(2):137-44. doi: 10.1016/j.jhin.2007.10.017.
• [736] Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes.Oncogene. 2007 Jul 19;26(33):4797-805. doi: 10.1038/sj.onc.1210281. Epub 2007 Feb 19.
• [737] Mutational analysis of the ST7 gene in human myeloid tumor cell lines.Oncol Rep. 2003 Nov-Dec;10(6):1737-9.
• [738] Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.Blood. 2012 May 31;119(22):5071-7. doi: 10.1182/blood-2012-01-406116. Epub 2012 Feb 27.
• [739] Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia.Cancer Res. 2002 Oct 1;62(19):5408-12.
• [740] Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.Leukemia. 2006 Jul;20(7):1211-6. doi: 10.1038/sj.leu.2404239. Epub 2006 May 11.
• [741] Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.
• [742] TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.Haematologica. 2005 May;90(5):612-24.
• [743] CD30L up-regulates CD30 and IL-4 expression by T cells.FEBS Lett. 2001 Nov 23;508(3):418-22. doi: 10.1016/s0014-5793(01)03076-9.
• [744] Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.Blood. 1997 Dec 1;90(11):4271-7.
• [745] Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.Blood. 2007 May 1;109(9):4023-7. doi: 10.1182/blood-2006-01-031781. Epub 2007 Jan 23.
• [746] Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis.Blood. 2007 Apr 15;109(8):3244-52. doi: 10.1182/blood-2006-09-046672. Epub 2006 Dec 7.
• [747] The role of p73 in hematological malignancies.Leukemia. 2006 May;20(5):757-66. doi: 10.1038/sj.leu.2404166.
• [748] Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.Cell Death Dis. 2017 Jul 13;8(7):e2927. doi: 10.1038/cddis.2017.317.
• [749] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).Cancer Genet Cytogenet. 2010 Oct 1;202(1):38-42. doi: 10.1016/j.cancergencyto.2010.06.004.
• [750] High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome.Leukemia. 2010 Dec;24(12):2048-55. doi: 10.1038/leu.2010.211. Epub 2010 Sep 23.
• [751] The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.Br J Haematol. 2009 Jun;145(6):761-74. doi: 10.1111/j.1365-2141.2009.07691.x. Epub 2009 Apr 20.
• [752] Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.
• [753] Examination of copy number variations of CHST9 in multiple types of hematologic malignancies.Cancer Genet Cytogenet. 2010 Dec;203(2):176-9. doi: 10.1016/j.cancergencyto.2010.07.132.
• [754] Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.Cell. 2016 Apr 7;165(2):303-16. doi: 10.1016/j.cell.2016.03.015.
• [755] Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.EBioMedicine. 2017 Dec;26:112-125. doi: 10.1016/j.ebiom.2017.11.013. Epub 2017 Nov 21.
• [756] Splicing factor DHX15 affects tp53 and mdm2 expression via alternate splicing and promoter usage.Hum Mol Genet. 2019 Dec 15;28(24):4173-4185. doi: 10.1093/hmg/ddz261.
• [757] BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.Leuk Lymphoma. 2016;57(4):828-34. doi: 10.3109/10428194.2015.1088648. Epub 2015 Dec 23.
• [758] Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFR Mutation.Acta Haematol. 2018;140(2):67-70. doi: 10.1159/000492485. Epub 2018 Sep 5.
• [759] Identification of new markers discriminating between myeloid and lymphoid acute leukemia.Hematology. 2010 Aug;15(4):193-203. doi: 10.1179/102453310X12647083620769.
• [760] Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia.Am J Hematol. 2009 Feb;84(2):79-86. doi: 10.1002/ajh.21332.
• [761] Galectin-12 inhibits granulocytic differentiation of human NB4 promyelocytic leukemia cells while promoting lipogenesis.J Leukoc Biol. 2016 Oct;100(4):657-664. doi: 10.1189/jlb.1HI0316-134R. Epub 2016 Jun 2.
• [762] ETV6-LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98-HOXA9.Genes Chromosomes Cancer. 2016 Mar;55(3):242-50. doi: 10.1002/gcc.22327. Epub 2015 Nov 6.
• [763] The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia.J Virol. 2005 May;79(9):5249-58. doi: 10.1128/JVI.79.9.5249-5258.2005.
• [764] MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1.Oncotarget. 2016 May 3;7(18):25276-90. doi: 10.18632/oncotarget.8252.
• [765] Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.J Clin Oncol. 2009 Feb 10;27(5):782-90. doi: 10.1200/JCO.2008.19.3748. Epub 2008 Dec 29.
• [766] AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.
• [767] Beclin-1 and hypoxia-inducible factor-1 genes expression: Potential biomarkers in acute leukemia patients.Cancer Biomark. 2016 Mar 18;16(4):619-26. doi: 10.3233/CBM-160603.
• [768] SUMOylation of insulin-like growth factor 1 receptor, promotes proliferation in acute myeloid leukemia.Cancer Lett. 2015 Feb 1;357(1):297-306. doi: 10.1016/j.canlet.2014.11.052. Epub 2014 Nov 28.
• [769] Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia.Immunol Lett. 2010 May 4;130(1-2):115-24. doi: 10.1016/j.imlet.2009.12.007. Epub 2009 Dec 11.
• [770] Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.Haematologica. 2020 Jan;105(1):148-160. doi: 10.3324/haematol.2018.208835. Epub 2019 Apr 11.
• [771] Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.J Clin Oncol. 1997 May;15(5):1796-802. doi: 10.1200/JCO.1997.15.5.1796.
• [772] Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.Mol Cancer Ther. 2018 Dec;17(12):2575-2585. doi: 10.1158/1535-7163.MCT-18-0186. Epub 2018 Sep 28.
• [773] APRIL gene expression in a cohort of Egyptian acute myeloid leukemia patients: Clinical and prognostic significance.Cancer Genet. 2018 Jan;220:24-31. doi: 10.1016/j.cancergen.2017.10.003. Epub 2017 Oct 24.
• [774] CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.Cancer Med. 2019 Mar;8(3):1279-1288. doi: 10.1002/cam4.2007. Epub 2019 Feb 10.
• [775] A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.
• [776] Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.Blood. 2012 Jun 7;119(23):5492-501. doi: 10.1182/blood-2011-07-365890. Epub 2012 Apr 23.
• [777] Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26.
• [778] Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Expert Opin Investig Drugs. 2019 Oct;28(10):835-849. doi: 10.1080/13543784.2019.1667331. Epub 2019 Sep 19.
• [779] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [780] c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.J Cell Biochem. 2008 Aug 15;104(6):2091-106. doi: 10.1002/jcb.21765.
• [781] The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia.Int J Mol Sci. 2019 Nov 28;20(23):6003. doi: 10.3390/ijms20236003.
• [782] DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.Cancer Med. 2019 Oct;8(14):6393-6402. doi: 10.1002/cam4.2540. Epub 2019 Sep 4.
• [783] Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.Blood Adv. 2019 Oct 22;3(20):3111-3122. doi: 10.1182/bloodadvances.2019000518.
• [784] Coexistence of p210(BCR-ABL) and CBF-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.Oncol Lett. 2017 Nov;14(5):5171-5178. doi: 10.3892/ol.2017.6812. Epub 2017 Aug 24.
• [785] Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome.Haematologica. 2018 Apr;103(4):614-625. doi: 10.3324/haematol.2017.167288. Epub 2018 Jan 11.
• [786] Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.Transfus Apher Sci. 2019 Jun;58(3):318-322. doi: 10.1016/j.transci.2019.03.018. Epub 2019 Mar 29.
• [787] Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.Mol Med Rep. 2015 May;11(5):3948-54. doi: 10.3892/mmr.2015.3196. Epub 2015 Jan 13.
• [788] Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma. 2004 May;45(5):979-85.
• [789] CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.Ann Hematol. 2007 May;86(5):329-37. doi: 10.1007/s00277-007-0269-7. Epub 2007 Mar 6.
• [790] Prognostic impact of p15 gene aberrations in acute leukemia.Leuk Lymphoma. 2017 Feb;58(2):257-265. doi: 10.1080/10428194.2016.1201574. Epub 2016 Jul 12.
• [791] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.Int J Mol Med. 2018 Feb;41(2):679-686. doi: 10.3892/ijmm.2017.3271. Epub 2017 Nov 17.
• [792] Overexpression of MYCT1 Inhibits Proliferation and Induces Apoptosis in Human Acute Myeloid Leukemia HL-60 and KG-1a Cells in vitro and in vivo.Front Pharmacol. 2018 Sep 18;9:1045. doi: 10.3389/fphar.2018.01045. eCollection 2018.
• [793] NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.Int J Mol Sci. 2016 Oct 20;17(10):1694. doi: 10.3390/ijms17101694.
• [794] NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.Mol Cell. 2015 Dec 17;60(6):847-59. doi: 10.1016/j.molcel.2015.10.033. Epub 2015 Nov 25.
• [795] Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.Curr Treat Options Oncol. 2019 Feb 11;20(2):15. doi: 10.1007/s11864-019-0612-y.
• [796] NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.Leuk Res. 2016 Jun;45:1-7. doi: 10.1016/j.leukres.2016.03.006. Epub 2016 Mar 30.
• [797] KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.Exp Mol Pathol. 2008 Dec;85(3):227-31. doi: 10.1016/j.yexmp.2008.09.004. Epub 2008 Oct 11.
• [798] Mutated and non-mutated TP53 as targets in the treatment of leukaemia.Br J Haematol. 2008 May;141(4):445-53. doi: 10.1111/j.1365-2141.2008.07046.x. Epub 2008 Mar 12.
• [799] Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia.Onco Targets Ther. 2017 Jul 20;10:3635-3644. doi: 10.2147/OTT.S136502. eCollection 2017.
• [800] Prognostic Significance of Secreted Frizzled-Related Protein 2 Expression in Cytogenetically Normal Primary Acute Myeloid Leukemia.Am J Med Sci. 2015 Nov;350(5):369-73. doi: 10.1097/MAJ.0000000000000567.
• [801] Stabilization of NF-B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia.Cell Rep. 2018 Jan 9;22(2):350-358. doi: 10.1016/j.celrep.2017.12.055.
• [802] SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia.Mol Cancer Res. 2018 May;16(5):791-804. doi: 10.1158/1541-7786.MCR-17-0493. Epub 2018 Feb 26.
• [803] Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.Mol Ther. 2013 Apr;21(4):877-86. doi: 10.1038/mt.2013.11. Epub 2013 Feb 5.
• [804] Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).Leuk Lymphoma. 2020 Mar;61(3):588-603. doi: 10.1080/10428194.2019.1678151. Epub 2019 Oct 29.
• [805] ABR, a novel inducer of transcription factor C/EBP, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia.Oncotarget. 2017 Oct 26;8(61):103626-103639. doi: 10.18632/oncotarget.22093. eCollection 2017 Nov 28.
• [806] ACER3 supports development of acute myeloid leukemia.Biochem Biophys Res Commun. 2016 Sep 9;478(1):33-38. doi: 10.1016/j.bbrc.2016.07.099. Epub 2016 Jul 25.
• [807] Expression level of ACOT7 influences the prognosis in acute myeloid leukemia patients.Cancer Biomark. 2019;26(4):441-449. doi: 10.3233/CBM-182287.
• [808] ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation.Cancer Lett. 2019 Feb 1;442:193-201. doi: 10.1016/j.canlet.2018.10.028. Epub 2018 Oct 26.
• [809] ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway.Cancer Manag Res. 2019 Sep 20;11:8547-8555. doi: 10.2147/CMAR.S210504. eCollection 2019.
• [810] CD97 is a critical regulator of acute myeloid leukemia stem cell function.J Exp Med. 2019 Oct 7;216(10):2362-2377. doi: 10.1084/jem.20190598. Epub 2019 Aug 1.
• [811] LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1.Mol Cancer. 2018 Aug 22;17(1):127. doi: 10.1186/s12943-018-0879-9.
• [812] The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes.Br J Haematol. 2016 Jul;174(2):292-301. doi: 10.1111/bjh.14056. Epub 2016 Mar 28.
• [813] The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia.Nat Commun. 2018 Apr 24;9(1):1622. doi: 10.1038/s41467-018-03854-0.
• [814] Clinical and molecular epidemiology of neonatal leukemia in Brazil.Leuk Lymphoma. 2015 Apr;56(4):903-9. doi: 10.3109/10428194.2014.938327. Epub 2015 Jan 30.
• [815] hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy.Nat Commun. 2019 Aug 23;10(1):3812. doi: 10.1038/s41467-019-11795-5.
• [816] Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.Leukemia. 1997 Feb;11(2):206-11. doi: 10.1038/sj.leu.2400558.
• [817] Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia.Cell Death Dis. 2018 Jun 7;9(6):688. doi: 10.1038/s41419-018-0706-7.
• [818] ANP32A regulates histone H3 acetylation and promotes leukemogenesis.Leukemia. 2018 Jul;32(7):1587-1597. doi: 10.1038/s41375-018-0010-7. Epub 2018 Feb 2.
• [819] Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy.Braz J Med Biol Res. 2008 Jul;41(7):571-8. doi: 10.1590/s0100-879x2008000700004.
• [820] Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Cancer Res. 2017 Sep 1;77(17):4579-4588. doi: 10.1158/0008-5472.CAN-16-3394. Epub 2017 Jun 27.
• [821] An ARC-Regulated IL1/Cox-2/PGE2/-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.Cancer Res. 2019 Mar 15;79(6):1165-1177. doi: 10.1158/0008-5472.CAN-18-0921. Epub 2019 Jan 23.
• [822] Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes.J Natl Cancer Inst. 2008 Sep 3;100(17):1247-59. doi: 10.1093/jnci/djn253. Epub 2008 Aug 26.
• [823] The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.Oncogene. 2018 May;37(19):2532-2544. doi: 10.1038/s41388-018-0131-5. Epub 2018 Feb 20.
• [824] Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.Leuk Lymphoma. 2017 May;58(5):1207-1218. doi: 10.1080/10428194.2016.1235272. Epub 2016 Oct 13.
• [825] Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.Cancer Chemother Pharmacol. 2018 Jan;81(1):217-222. doi: 10.1007/s00280-017-3459-6. Epub 2017 Nov 8.
• [826] Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.Blood. 2015 Jun 25;125(26):4060-8. doi: 10.1182/blood-2014-10-608133. Epub 2015 Apr 20.
• [827] Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.
• [828] Genome-wide characterization of lncRNAs in acute myeloid leukemia.Brief Bioinform. 2018 Jul 20;19(4):627-635. doi: 10.1093/bib/bbx007.
• [829] Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.Leuk Lymphoma. 2017 Oct;58(10):2426-2438. doi: 10.1080/10428194.2017.1289522. Epub 2017 Mar 9.
• [830] Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice.Nat Genet. 2011 May;43(5):470-5. doi: 10.1038/ng.796. Epub 2011 Mar 27.
• [831] Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.Exp Mol Med. 2018 Apr 20;50(4):1-8. doi: 10.1038/s12276-018-0067-4.
• [832] NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients.Oncotarget. 2017 Jun 16;8(44):76003-76014. doi: 10.18632/oncotarget.18537. eCollection 2017 Sep 29.
• [833] The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.Br J Haematol. 2002 Aug;118(2):521-34. doi: 10.1046/j.1365-2141.2002.03637.x.
• [834] BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.
• [835] miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.Leukemia. 2018 Feb;32(2):573. doi: 10.1038/leu.2017.310. Epub 2017 Dec 22.
• [836] Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.
• [837] C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.Int J Hematol. 2018 Dec;108(6):652-657. doi: 10.1007/s12185-018-2514-3. Epub 2018 Aug 6.
• [838] Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.Cancer Genet. 2020 Jan;240:15-22. doi: 10.1016/j.cancergen.2019.10.006. Epub 2019 Nov 1.
• [839] KIR Donor Selection: Feasibility in Identifying better Donors.Biol Blood Marrow Transplant. 2019 Jan;25(1):e28-e32. doi: 10.1016/j.bbmt.2018.08.022. Epub 2018 Aug 24.
• [840] BEX1 acts as a tumor suppressor in acute myeloid leukemia.Oncotarget. 2015 Aug 28;6(25):21395-405. doi: 10.18632/oncotarget.4095.
• [841] A new signaling cascade linking BMP4, BMPR1A, Np73 and NANOG impacts on stem-like human cell properties and patient outcome.Cell Death Dis. 2018 Sep 27;9(10):1011. doi: 10.1038/s41419-018-1042-7.
• [842] CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia.Cells. 2019 Dec 5;8(12):1580. doi: 10.3390/cells8121580.
• [843] Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.Mol Cells. 2018 May 31;41(5):465-475. doi: 10.14348/molcells.2018.0051. Epub 2018 May 15.
• [844] CRL4(DCAF2) negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis.J Exp Med. 2018 Aug 6;215(8):1999-2017. doi: 10.1084/jem.20180210. Epub 2018 Jul 17.
• [845] Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.Mol Carcinog. 2015 Dec;54(12):1815-9. doi: 10.1002/mc.22252. Epub 2014 Dec 9.
• [846] A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells.Cell Signal. 2015 Feb;27(2):204-14. doi: 10.1016/j.cellsig.2014.11.007. Epub 2014 Nov 15.
• [847] Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Mol Ther. 2015 Jan;23(1):184-91. doi: 10.1038/mt.2014.164. Epub 2014 Sep 1.
• [848] Identification of DNA methylation prognostic signature of acute myelocytic leukemia.PLoS One. 2018 Jun 22;13(6):e0199689. doi: 10.1371/journal.pone.0199689. eCollection 2018.
• [849] The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.Mol Cancer Res. 2019 Jul;17(7):1468-1479. doi: 10.1158/1541-7786.MCR-18-1327. Epub 2019 Apr 23.
• [850] Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.Cancers (Basel). 2019 Nov 3;11(11):1717. doi: 10.3390/cancers11111717.
• [851] MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2.Int J Hematol. 2017 Aug;106(2):258-265. doi: 10.1007/s12185-017-2232-2. Epub 2017 Apr 13.
• [852] Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.Blood Adv. 2018 Oct 23;2(20):2724-2731. doi: 10.1182/bloodadvances.2018016840.
• [853] Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.Blood. 2000 Apr 15;95(8):2569-76.
• [854] CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.Mol Oncol. 2019 Oct;13(10):2107-2120. doi: 10.1002/1878-0261.12549. Epub 2019 Aug 20.
• [855] Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.PLoS One. 2019 May 10;14(5):e0216368. doi: 10.1371/journal.pone.0216368. eCollection 2019.
• [856] Secreted 3-integrin enhances natural killer cell activity against acute myeloid leukemia cells.PLoS One. 2014 Jun 11;9(2):e98936. doi: 10.1371/journal.pone.0098936. eCollection 2014.
• [857] Novel Targeted Nano-Parthenolide Molecule against NF-kB in Acute Myeloid Leukemia.Molecules. 2019 Jun 3;24(11):2103. doi: 10.3390/molecules24112103.
• [858] Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy.Life Sci. 2019 Mar 15;221:187-195. doi: 10.1016/j.lfs.2019.02.003. Epub 2019 Feb 2.
• [859] RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.Pathobiology. 2019;86(2-3):162-166. doi: 10.1159/000493688. Epub 2018 Nov 5.
• [860] Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.Oncotarget. 2016 Sep 20;7(38):62377-62385. doi: 10.18632/oncotarget.11481.
• [861] CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/-catenin signaling pathway.Pediatr Res. 2019 Jun;85(7):1024-1031. doi: 10.1038/s41390-019-0370-3. Epub 2019 Mar 12.
• [862] CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.Cell Stem Cell. 2015 Oct 1;17(4):412-21. doi: 10.1016/j.stem.2015.08.008. Epub 2015 Sep 18.
• [863] Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias.J Clin Pathol. 2008 Jul;61(7):844-7. doi: 10.1136/jcp.2007.047324.
• [864] Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.Leukemia. 1996 Dec;10(12):1897-900.
• [865] Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.Blood. 2019 Jul 18;134(3):263-276. doi: 10.1182/blood.2018862383. Epub 2019 May 10.
• [866] The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007 May 1;109(9):3895-905. doi: 10.1182/blood-2006-08-040147. Epub 2007 Jan 18.
• [867] CEBPE expression is an independent prognostic factor for acute myeloid leukemia.J Transl Med. 2019 Jun 4;17(1):188. doi: 10.1186/s12967-019-1944-x.
• [868] CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.Leukemia. 2019 Jul;33(7):1608-1619. doi: 10.1038/s41375-019-0382-3. Epub 2019 Jan 24.
• [869] Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).Mol Cancer. 2015 Apr 11;14:81. doi: 10.1186/s12943-015-0353-x.
• [870] Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.Blood. 2015 Sep 17;126(12):1462-72. doi: 10.1182/blood-2015-03-631606. Epub 2015 Aug 11.
• [871] C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.Leukemia. 2018 Mar;32(3):828-836. doi: 10.1038/leu.2017.280. Epub 2017 Sep 5.
• [872] The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia.Leukemia. 2009 Feb;23(2):251-61. doi: 10.1038/leu.2008.300. Epub 2008 Nov 6.
• [873] The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.
• [874] Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.Cancer Discov. 2019 Jul;9(7):890-909. doi: 10.1158/2159-8290.CD-19-0117. Epub 2019 May 2.
• [875] A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.BMC Cancer. 2019 Jan 10;19(1):50. doi: 10.1186/s12885-019-5265-5.
• [876] NUP214-RAC1 and RAC1-COL12A1 Fusion in Complex Variant Translocations Involving Chromosomes 6, 7 and 9 in an Acute Myeloid Leukemia Case with DEK-NUP214.Cytogenet Genome Res. 2015;146(4):279-84. doi: 10.1159/000441464. Epub 2015 Oct 31.
• [877] High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia.Cancer Sci. 2017 Sep;108(9):1850-1857. doi: 10.1111/cas.13311. Epub 2017 Aug 20.
• [878] High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.EBioMedicine. 2016 Dec;14:55-64. doi: 10.1016/j.ebiom.2016.11.025. Epub 2016 Nov 22.
• [879] Weighted Gene Coexpression Network Analysis Identifies Cysteine-Rich Intestinal Protein 1 (CRIP1) as a Prognostic Gene Associated with Relapse in Patients with Acute Myeloid Leukemia.Med Sci Monit. 2019 Oct 2;25:7396-7406. doi: 10.12659/MSM.918092.
• [880] Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia.Transfus Apher Sci. 2019 Dec;58(6):102666. doi: 10.1016/j.transci.2019.10.008. Epub 2019 Nov 5.
• [881] HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries.J Vis Exp. 2019 Mar 31;(145):10.3791/59382. doi: 10.3791/59382.
• [882] CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).Med Sci Monit. 2017 Apr 9;23:1725-1732. doi: 10.12659/msm.900305.
• [883] The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.Crit Rev Oncol Hematol. 2014 Apr;90(1):1-16. doi: 10.1016/j.critrevonc.2013.10.003. Epub 2013 Oct 12.
• [884] Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL. J Leukoc Biol. 2017 Dec;102(6):1357-1370. doi: 10.1189/jlb.1A0317-132R. Epub 2017 Oct 4.
• [885] Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.Epigenetics. 2015;10(6):526-35. doi: 10.1080/15592294.2015.1048060.
• [886] Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w.
• [887] LncRNA HOTTIP promotes proliferation and cell cycle progression of acute myeloid leukemia cells.Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2908-2915. doi: 10.26355/eurrev_201904_17569.
• [888] Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?.Cancers (Basel). 2019 Feb 21;11(2):252. doi: 10.3390/cancers11020252.
• [889] Pre-diagnostic serum concentrations of organochlorines and risk of acute myeloid leukemia: A nested case-control study in the Norwegian Janus Serum Bank Cohort.Environ Int. 2019 Apr;125:229-235. doi: 10.1016/j.envint.2019.01.066. Epub 2019 Feb 2.
• [890] Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.Blood. 2011 Jul 28;118(4):903-15. doi: 10.1182/blood-2010-11-318022. Epub 2011 Jun 7.
• [891] Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.Leuk Res. 2011 Sep;35(9):1188-92. doi: 10.1016/j.leukres.2011.02.001. Epub 2011 Mar 3.
• [892] Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.Leukemia. 2002 Mar;16(3):386-92. doi: 10.1038/sj.leu.2402388.
• [893] DIXDC1 promotes the growth of acute myeloid leukemia cells by upregulating the Wnt/-catenin signaling pathway.Biomed Pharmacother. 2018 Nov;107:1548-1555. doi: 10.1016/j.biopha.2018.08.144. Epub 2018 Sep 5.
• [894] Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies.Ann N Y Acad Sci. 2009 Sep;1176:178-90. doi: 10.1111/j.1749-6632.2009.04565.x.
• [895] High expression of DOCK2 indicates good prognosis in acute myeloid leukemia.J Cancer. 2019 Oct 15;10(24):6088-6094. doi: 10.7150/jca.33244. eCollection 2019.
• [896] MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.FASEB J. 2019 Apr;33(4):5268-5286. doi: 10.1096/fj.201801035R. Epub 2019 Jan 22.
• [897] Tracing the development of acute myeloid leukemia in CBL syndrome.Blood. 2014 Mar 20;123(12):1883-6. doi: 10.1182/blood-2013-10-533844. Epub 2014 Feb 3.
• [898] Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.J Cell Physiol. 2018 Sep;233(9):6604-6614. doi: 10.1002/jcp.26271. Epub 2018 Mar 14.
• [899] Prognostic role of DOK family adapters in acute myeloid leukemia.Cancer Gene Ther. 2019 Sep;26(9-10):305-312. doi: 10.1038/s41417-018-0052-z. Epub 2018 Oct 22.
• [900] miR-199a-5p Represses Protective Autophagy and Overcomes Chemoresistance by Directly Targeting DRAM1 in Acute Myeloid Leukemia.J Oncol. 2019 Sep 15;2019:5613417. doi: 10.1155/2019/5613417. eCollection 2019.
• [901] Mutations of the E2F4 gene in hematological malignancies having microsatellite instability.Blood. 2000 Feb 15;95(4):1509-10.
• [902] Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.J Exp Clin Cancer Res. 2015 Jan 22;34(1):4. doi: 10.1186/s13046-014-0118-1.
• [903] Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.Int J Mol Sci. 2017 Jul 5;18(7):1440. doi: 10.3390/ijms18071440.
• [904] The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.BMC Cancer. 2019 Apr 25;19(1):389. doi: 10.1186/s12885-019-5602-8.
• [905] Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.Leukemia. 2020 Feb;34(2):391-403. doi: 10.1038/s41375-019-0568-8. Epub 2019 Sep 6.
• [906] Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia.Cell Rep. 2018 Oct 30;25(5):1109-1117.e5. doi: 10.1016/j.celrep.2018.10.021.
• [907] Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells.Mol Cell Biochem. 2018 Jan;438(1-2):191-198. doi: 10.1007/s11010-017-3127-5. Epub 2017 Aug 12.
• [908] EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.Cancer Sci. 2016 Dec;107(12):1745-1754. doi: 10.1111/cas.13080. Epub 2016 Nov 25.
• [909] Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells.Leukemia. 2014 May;28(5):1081-91. doi: 10.1038/leu.2013.316. Epub 2013 Oct 29.
• [910] A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.J Exp Clin Cancer Res. 2018 Jan 22;37(1):12. doi: 10.1186/s13046-018-0682-x.
• [911] Silver nanoparticles exhibit size-dependent differential toxicity and induce expression of syncytin-1 in FA-AML1 and MOLT-4 leukaemia cell lines.Mutagenesis. 2016 Nov;31(6):695-702. doi: 10.1093/mutage/gew043. Epub 2016 Aug 30.
• [912] Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS.PLoS One. 2018 Jan 25;13(1):e0191734. doi: 10.1371/journal.pone.0191734. eCollection 2018.
• [913] Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute myeloid leukemia by impairing procaspase-8 dimerization.Cell Death Dis. 2018 May 1;9(5):516. doi: 10.1038/s41419-018-0511-3.
• [914] Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.Clin Cancer Res. 2005 Jun 15;11(12):4504-11. doi: 10.1158/1078-0432.CCR-05-0036.
• [915] Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.Oncotarget. 2017 Aug 4;8(40):68208-68220. doi: 10.18632/oncotarget.19919. eCollection 2017 Sep 15.
• [916] Discussing and managing hematologic germ line variants.Blood. 2016 Nov 24;128(21):2497-2503. doi: 10.1182/blood-2016-06-716704.
• [917] F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation.Blood. 2012 Mar 29;119(13):3132-41. doi: 10.1182/blood-2011-06-358911. Epub 2012 Feb 8.
• [918] HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia.J Immunol Res. 2014;2014:636292. doi: 10.1155/2014/636292. Epub 2014 Mar 13.
• [919] Fasciculation and elongation zeta-1 protein (FEZ1) interacts with the retinoic acid receptor and participates in transcriptional regulation of the Hoxb4 gene.FEBS Open Bio. 2017 Dec 9;8(1):4-14. doi: 10.1002/2211-5463.12338. eCollection 2018 Jan.
• [920] Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia.Onco Targets Ther. 2019 May 1;12:3295-3304. doi: 10.2147/OTT.S194549. eCollection 2019.
• [921] Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia.Cancer Gene Ther. 2019 Feb;26(1-2):17-25. doi: 10.1038/s41417-018-0027-0. Epub 2018 Jun 18.
• [922] BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.Mol Cell. 2015 Jun 18;58(6):1028-39. doi: 10.1016/j.molcel.2015.04.011. Epub 2015 May 14.
• [923] Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.Blood Adv. 2019 Oct 22;3(20):3052-3061. doi: 10.1182/bloodadvances.2019000197.
• [924] Increased FLYWCH1 Expression is Negatively Correlated with Wnt/-catenin Target Gene Expression in Acute Myeloid Leukemia Cells.Int J Mol Sci. 2019 Jun 4;20(11):2739. doi: 10.3390/ijms20112739.
• [925] Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia.Oncol Lett. 2019 Aug;18(2):1521-1529. doi: 10.3892/ol.2019.10424. Epub 2019 May 31.
• [926] Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients.BMC Cancer. 2019 Sep 18;19(1):930. doi: 10.1186/s12885-019-5967-8.
• [927] Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.Cancer Genet Cytogenet. 2007 Sep;177(2):143-6. doi: 10.1016/j.cancergencyto.2007.05.021.
• [928] Association of Leukemia Target Genes Tet2, Bcl2, and Slc23a2 in Vitamin C Pathways.Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):333-344. doi: 10.21873/cgp.20138.
• [929] Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia.Biochim Biophys Acta. 2014 Sep;1842(9):1681-92. doi: 10.1016/j.bbadis.2014.06.014. Epub 2014 Jun 19.
• [930] Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.Leuk Res. 2018 Apr;67:99-108. doi: 10.1016/j.leukres.2018.01.020. Epub 2018 Jan 31.
• [931] Investigating the microRNA-mRNA regulatory network in acute myeloid leukemia.Oncol Lett. 2017 Oct;14(4):3981-3988. doi: 10.3892/ol.2017.6686. Epub 2017 Jul 28.
• [932] lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/-catenin signaling pathway.Am J Transl Res. 2019 Nov 15;11(11):7104-7114. eCollection 2019.
• [933] Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia.Mol Med Rep. 2016 Aug;14(2):1339-44. doi: 10.3892/mmr.2016.5387. Epub 2016 Jun 10.
• [934] CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.Clin Chem Lab Med. 2017 Jan 1;55(1):123-131. doi: 10.1515/cclm-2016-0205.
• [935] MLL/GAS7 fusion in a pediatric case of t(11;17)(q23;p13)-positive precursor B-cell acute lymphoblastic leukemia.Haematologica. 2006 Sep;91(9):1287-8.
• [936] LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.Leukemia. 2020 Mar;34(3):746-758. doi: 10.1038/s41375-019-0614-6. Epub 2019 Nov 1.
• [937] CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.Br J Haematol. 2019 Feb;184(3):337-347. doi: 10.1111/bjh.15725. Epub 2018 Dec 28.
• [938] Gene expression profiling of HL-60 cells following knockdown of nucleostemin using DNA microarrays.Oncol Rep. 2014 Aug;32(2):739-47. doi: 10.3892/or.2014.3240. Epub 2014 Jun 6.
• [939] Glutathione S-transferase gene polymorphisms and susceptibility to acute myeloid leukemia: meta-analyses.Jpn J Clin Oncol. 2014 Nov;44(11):1070-81. doi: 10.1093/jjco/hyu121. Epub 2014 Aug 21.
• [940] Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6.
• [941] MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.Exp Hematol. 2015 Sep;43(9):794-802.e4. doi: 10.1016/j.exphem.2015.05.010. Epub 2015 Jun 11.
• [942] Motor skill delays in pre-school children with leukemia one year after treatment: Hematopoietic stem cell transplantation therapy as an important risk factor.PLoS One. 2017 Oct 24;12(10):e0186787. doi: 10.1371/journal.pone.0186787. eCollection 2017.
• [943] MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.Tumour Biol. 2016 Jun;37(6):7461-71. doi: 10.1007/s13277-015-4581-x. Epub 2015 Dec 17.
• [944] RUNX1 cooperates with FLT3-ITD to induce leukemia.J Exp Med. 2017 Mar 6;214(3):737-752. doi: 10.1084/jem.20160927. Epub 2017 Feb 17.
• [945] Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing.Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):e28-e31. doi: 10.1097/PAI.0000000000000477.
• [946] Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.Sci Rep. 2017 Apr 28;7:45960. doi: 10.1038/srep45960.
• [947] Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.Bone Marrow Transplant. 2018 Sep;53(9):1170-1179. doi: 10.1038/s41409-018-0123-7. Epub 2018 Mar 16.
• [948] The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.Oncotarget. 2016 Nov 8;7(45):73960-73970. doi: 10.18632/oncotarget.12170.
• [949] Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.Leuk Res. 2019 Jan;76:15-23. doi: 10.1016/j.leukres.2018.11.007. Epub 2018 Nov 17.
• [950] The Role of the HOXA Gene Family in Acute Myeloid Leukemia.Genes (Basel). 2019 Aug 16;10(8):621. doi: 10.3390/genes10080621.
• [951] The role of HOXB2 and HOXB3 in acute myeloid leukemia.Biochem Biophys Res Commun. 2015 Nov 27;467(4):742-7. doi: 10.1016/j.bbrc.2015.10.071. Epub 2015 Oct 22.
• [952] Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13).Cancer Res. 2002 Aug 15;62(16):4571-4.
• [953] Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells.Leukemia. 1998 Nov;12(11):1724-32. doi: 10.1038/sj.leu.2401106.
• [954] MiR-10b regulates the proliferation and apoptosis of pediatric acute myeloid leukemia through targeting HOXD10.Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7371-7378. doi: 10.26355/eurrev_201811_16275.
• [955] Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells.J Cell Biochem. 2015 Jun;116(6):1101-12. doi: 10.1002/jcb.25066.
• [956] Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.Cancer Lett. 2019 Oct 1;461:132-143. doi: 10.1016/j.canlet.2019.07.008. Epub 2019 Jul 13.
• [957] A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.J Med Chem. 2019 Jul 11;62(13):6035-6046. doi: 10.1021/acs.jmedchem.9b00145. Epub 2019 Jun 19.
• [958] The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.PLoS One. 2014 May 8;9(5):e96822. doi: 10.1371/journal.pone.0096822. eCollection 2014.
• [959] High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia.Cancer Gene Ther. 2020 Feb;27(1-2):38-44. doi: 10.1038/s41417-019-0093-y. Epub 2019 Mar 29.
• [960] Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.J Hematol Oncol. 2017 Jul 11;10(1):138. doi: 10.1186/s13045-017-0507-y.
• [961] IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia.Cell Physiol Biochem. 2018;51(4):1945-1956. doi: 10.1159/000495719. Epub 2018 Dec 4.
• [962] Leukemic IL-17RB signaling regulates leukemic survival and chemoresistance.FASEB J. 2019 Aug;33(8):9565-9576. doi: 10.1096/fj.201900099R. Epub 2019 May 28.
• [963] Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.Cell Death Dis. 2014 Dec 4;5(12):e1557. doi: 10.1038/cddis.2014.502.
• [964] Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia.Cell Rep. 2018 Jan 16;22(3):638-652. doi: 10.1016/j.celrep.2017.12.063.
• [965] Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.J Cell Physiol. 2019 Jun;234(6):9438-9446. doi: 10.1002/jcp.27629. Epub 2018 Oct 14.
• [966] A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis.Oncotarget. 2015 Oct 13;6(31):30664-74. doi: 10.18632/oncotarget.5133.
• [967] Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein.Mol Cell Biochem. 2010 Jul;340(1-2):7-14. doi: 10.1007/s11010-010-0394-9. Epub 2010 Feb 16.
• [968] HBO1 is required for the maintenance of leukaemia stem cells.Nature. 2020 Jan;577(7789):266-270. doi: 10.1038/s41586-019-1835-6. Epub 2019 Dec 11.
• [969] Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis.Cancer Res. 2017 Apr 1;77(7):1753-1762. doi: 10.1158/0008-5472.CAN-16-2374. Epub 2017 Feb 15.
• [970] KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.Leuk Lymphoma. 2018 Jan;59(1):204-213. doi: 10.1080/10428194.2017.1324156. Epub 2017 May 25.
• [971] Loss of KDM6A confers drug resistance in acute myeloid leukemia.Leukemia. 2020 Jan;34(1):50-62. doi: 10.1038/s41375-019-0497-6. Epub 2019 Jun 14.
• [972] Comparison of the KIR3DS1/Bw4 distribution in Chinese healthy and acute myeloid leukemia individuals.Hum Immunol. 2015 Mar;76(2-3):79-82. doi: 10.1016/j.humimm.2015.01.024. Epub 2015 Jan 27.
• [973] MicroRNA-21 promotes proliferation in acute myeloid leukemia by targeting Krppel-like factor 5.Oncol Lett. 2019 Sep;18(3):3367-3372. doi: 10.3892/ol.2019.10667. Epub 2019 Jul 25.
• [974] KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.J Immunol. 2015 May 1;194(9):4222-30. doi: 10.4049/jimmunol.1402124. Epub 2015 Mar 25.
• [975] Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.Exp Hematol. 2019 Jan;69:37-42. doi: 10.1016/j.exphem.2018.10.001. Epub 2018 Oct 10.
• [976] MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.Eur J Haematol. 2018 May;100(5):436-443. doi: 10.1111/ejh.13037. Epub 2018 Mar 1.
• [977] Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.Blood. 2010 Oct 14;116(15):2812-21. doi: 10.1182/blood-2010-02-270611. Epub 2010 Jun 28.
• [978] La-related protein 4B maintains murine MLL-AF9 leukemia stem cell self-renewal by regulating cell cycle progression.Exp Hematol. 2015 Apr;43(4):309-18.e2. doi: 10.1016/j.exphem.2014.12.003. Epub 2014 Dec 20.
• [979] Sister chromatid exchanges in leukemic patients.Cancer Genet Cytogenet. 1985 Feb 1;15(1-2):169-75. doi: 10.1016/0165-4608(85)90145-1.
• [980] Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.Leukemia. 2020 Apr;34(4):1027-1037. doi: 10.1038/s41375-019-0635-1. Epub 2019 Nov 22.
• [981] LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia.Cancer Res. 2014 Jun 1;74(11):3043-53. doi: 10.1158/0008-5472.CAN-13-2321. Epub 2014 Mar 31.
• [982] The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).Genes Chromosomes Cancer. 2014 Apr;53(4):299-308. doi: 10.1002/gcc.22140. Epub 2014 Jan 21.
• [983] The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients.Cell J. 2018 Jul;20(2):204-210. doi: 10.22074/cellj.2018.5210. Epub 2018 Mar 18.
• [984] LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.Mol Cancer Res. 2017 Mar;15(3):294-303. doi: 10.1158/1541-7786.MCR-16-0275-T. Epub 2016 Dec 23.
• [985] The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.J Exp Med. 2013 Jan 14;210(1):15-22. doi: 10.1084/jem.20120596. Epub 2012 Dec 31.
• [986] A novel LPP fusion gene indicates the crucial role of truncated LPP proteins in lipomas and pulmonary chondroid hamartomas.Cytogenet Cell Genet. 2001;95(3-4):153-6. doi: 10.1159/000059338.
• [987] Leucine-Rich Alpha-2-Glycoprotein1 Gene Interferes with Regulation of Apoptosis in Leukemia KASUMI-1 Cells.Med Sci Monit. 2018 Nov 20;24:8348-8356. doi: 10.12659/MSM.911249.
• [988] The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.Leukemia. 2019 Aug;33(8):1868-1880. doi: 10.1038/s41375-018-0361-0. Epub 2019 Jan 30.
• [989] H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia.Cancer Genet. 2018 Apr;222-223:9-12. doi: 10.1016/j.cancergen.2018.01.004. Epub 2018 Feb 17.
• [990] DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.Leuk Lymphoma. 2015;56(10):2914-22. doi: 10.3109/10428194.2015.1015123. Epub 2015 Jul 6.
• [991] First case of B ALL with KMT2A-MAML2 rearrangement: a case report.BMC Cancer. 2017 May 23;17(1):363. doi: 10.1186/s12885-017-3368-4.
• [992] MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.
• [993] Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2020 Jan;26(1):197-203. doi: 10.1016/j.bbmt.2019.09.006. Epub 2019 Sep 10.
• [994] Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia.Int J Hematol. 2012 Mar;95(3):285-90. doi: 10.1007/s12185-012-1022-0. Epub 2012 Feb 18.
• [995] MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.Cell Rep. 2016 Jul 12;16(2):498-507. doi: 10.1016/j.celrep.2016.05.094. Epub 2016 Jun 23.
• [996] METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.
• [997] NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes.PLoS Genet. 2019 Nov 1;15(11):e1008463. doi: 10.1371/journal.pgen.1008463. eCollection 2019 Nov.
• [998] Involvement of AF1q/MLLT11 in the progression of ovarian cancer.Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.
• [999] [Application of reverse transcription-multiplex nested PCR to detect MLL rearrangement in AML-M4/M5].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Aug;22(4):444-6.
• [1000] ChREBP promotes the differentiation of leukemia-initiating cells to inhibit leukemogenesis through the TXNIP/RUNX1 pathways.Oncotarget. 2016 Jun 21;7(25):38347-38358. doi: 10.18632/oncotarget.9520.
• [1001] Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: Data from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and review of the literature.Genes Chromosomes Cancer. 2018 Jul;57(7):359-365. doi: 10.1002/gcc.22538. Epub 2018 Apr 30.
• [1002] Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia.J Pediatr Hematol Oncol. 2006 Nov;28(11):763-7. doi: 10.1097/01.mph.0000243660.48808.72.
• [1003] Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.Int J Cancer. 2019 Oct 15;145(8):2201-2208. doi: 10.1002/ijc.32028. Epub 2019 Jan 11.
• [1004] Anti-NXP2-antibody-positive immune-mediated necrotizing myopathy associated with acute myeloid leukemia: A case report.Medicine (Baltimore). 2018 Jul;97(28):e11501. doi: 10.1097/MD.0000000000011501.
• [1005] Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGF/EMT signaling pathway.Oncol Lett. 2018 Aug;16(2):2701-2708. doi: 10.3892/ol.2018.8890. Epub 2018 Jun 4.
• [1006] Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma.Leuk Lymphoma. 2014 Aug;55(8):1893-903. doi: 10.3109/10428194.2013.864762. Epub 2014 Feb 17.
• [1007] Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.J Transl Med. 2014 Jun 25;12:182. doi: 10.1186/1479-5876-12-182.
• [1008] Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.Cancer Discov. 2018 Nov;8(11):1376-1389. doi: 10.1158/2159-8290.CD-17-0841. Epub 2018 Aug 16.
• [1009] Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1203-1213. doi: 10.26355/eurrev_201902_17013.
• [1010] Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015.
• [1011] circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.Blood. 2019 Oct 31;134(18):1533-1546. doi: 10.1182/blood.2019000802.
• [1012] Truncation of MYH8 tail in AML: a novel prognostic marker with increase cell migration and epithelial-mesenchymal transition utilizing RAF/MAPK pathway.Carcinogenesis. 2020 Jul 10;41(6):817-827. doi: 10.1093/carcin/bgz146.
• [1013] Prognostic impact of MYH9 expression on patients with acute myeloid leukemia.Oncotarget. 2017 Jan 3;8(1):156-163. doi: 10.18632/oncotarget.10613.
• [1014] Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis.Cancer Immunol Immunother. 2019 Dec;68(12):1971-1978. doi: 10.1007/s00262-019-02408-7. Epub 2019 Oct 24.
• [1015] High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.
• [1016] Expression of autophagy genes in acute myeloid leukemia: associations with clinical characteristics and prognosis.Neoplasma. 2018 Sep 19;65(5):807-814. doi: 10.4149/neo_2018_171028N691. Epub 2018 Jun 17.
• [1017] High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
• [1018] Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.BMC Genomics. 2015 Apr 17;16(1):309. doi: 10.1186/s12864-015-1445-0.
• [1019] Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.Oncotarget. 2019 Sep 10;10(52):5493. doi: 10.18632/oncotarget.27198. eCollection 2019 Sep 10.
• [1020] Antioxidant and selective anticancer activities of two Euphorbia species in human acute myeloid leukemia.Biomed Pharmacother. 2017 Jun;90:375-385. doi: 10.1016/j.biopha.2017.03.072. Epub 2017 Apr 2.
• [1021] NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.Leukemia. 2018 Dec;32(12):2536-2545. doi: 10.1038/s41375-018-0147-4. Epub 2018 Jun 5.
• [1022] Nuclear factor of activated T-cells, NFATC1, governs FLT3(ITD)-driven hematopoietic stem cell transformation and a poor prognosis in AML.J Hematol Oncol. 2019 Jul 8;12(1):72. doi: 10.1186/s13045-019-0765-y.
• [1023] Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.
• [1024] Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.Tumour Biol. 2017 Apr;39(4):1010428317699123. doi: 10.1177/1010428317699123.
• [1025] Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.Br J Haematol. 2014 Nov;167(3):376-84. doi: 10.1111/bjh.13054. Epub 2014 Jul 31.
• [1026] NPAS2 regulates proliferation of acute myeloid leukemia cells via CDC25A-mediated cell cycle progression and apoptosis.J Cell Biochem. 2019 May;120(5):8731-8741. doi: 10.1002/jcb.28160. Epub 2018 Dec 9.
• [1027] Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.Biol Blood Marrow Transplant. 2019 Sep;25(9):1803-1809. doi: 10.1016/j.bbmt.2019.05.014. Epub 2019 May 22.
• [1028] LRRC33 is a novel binding and potential regulating protein of TGF-1 function in human acute myeloid leukemia cells.PLoS One. 2019 Oct 10;14(10):e0213482. doi: 10.1371/journal.pone.0213482. eCollection 2019.
• [1029] 8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia.J Hematol Oncol. 2014 Sep 23;7:68. doi: 10.1186/s13045-014-0068-2.
• [1030] NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.Pharmacogenet Genomics. 2014 Sep;24(9):436-41. doi: 10.1097/FPC.0000000000000072.
• [1031] LncRNA SNHG1 overexpression regulates the proliferation of acute myeloid leukemia cells through miR-488-5p/NUP205 axis.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5896-5903. doi: 10.26355/eurrev_201907_18334.
• [1032] NUP214 in Leukemia: It's More than Transport.Cells. 2019 Jan 21;8(1):76. doi: 10.3390/cells8010076.
• [1033] Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22.Hum Genet. 2001 Apr;108(4):304-9. doi: 10.1007/s004390100498.
• [1034] Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells.Clin Cancer Res. 2016 Jul 1;22(13):3320-7. doi: 10.1158/1078-0432.CCR-15-2282. Epub 2016 Jan 26.
• [1035] PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia.Oncotarget. 2018 Apr 24;9(31):22123-22136. doi: 10.18632/oncotarget.25204. eCollection 2018 Apr 24.
• [1036] Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.Theranostics. 2018 Jul 30;8(16):4359-4371. doi: 10.7150/thno.26900. eCollection 2018.
• [1037] Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.J Transl Med. 2019 Mar 29;17(1):102. doi: 10.1186/s12967-019-1851-1.
• [1038] Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF.Cancer Res. 2004 Aug 15;64(16):5570-7. doi: 10.1158/0008-5472.CAN-04-0050.
• [1039] A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.Oncotarget. 2017 Jul 12;8(44):76174-76188. doi: 10.18632/oncotarget.19192. eCollection 2017 Sep 29.
• [1040] Downregulation of PDIA3 inhibits proliferation and invasion of human acute myeloid leukemia cells.Onco Targets Ther. 2018 May 17;11:2925-2935. doi: 10.2147/OTT.S162407. eCollection 2018.
• [1041] PRISM: methylation pattern-based, reference-free inference of subclonal makeup.Bioinformatics. 2019 Jul 15;35(14):i520-i529. doi: 10.1093/bioinformatics/btz327.
• [1042] Transcription factor C/EBP- induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.Cell Death Differ. 2016 Jul;23(7):1232-42. doi: 10.1038/cdd.2016.1. Epub 2016 Feb 12.
• [1043] PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.
• [1044] Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.Sci Rep. 2018 Sep 13;8(1):13741. doi: 10.1038/s41598-018-32205-8.
• [1045] PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia.Cancer Genet. 2019 Apr;233-234:56-66. doi: 10.1016/j.cancergen.2019.04.002. Epub 2019 Apr 11.
• [1046] Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.Leukemia. 2010 Feb;24(2):429-37. doi: 10.1038/leu.2009.247. Epub 2009 Dec 10.
• [1047] Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.BMC Med Genet. 2015 Jun 17;16:39. doi: 10.1186/s12881-015-0185-y.
• [1048] RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18.
• [1049] Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.Leukemia. 2017 May;31(5):1069-1078. doi: 10.1038/leu.2016.324. Epub 2016 Nov 11.
• [1050] The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.Cancers (Basel). 2019 Oct 26;11(11):1663. doi: 10.3390/cancers11111663.
• [1051] Wogonoside induces depalmitoylation and translocation of PLSCR1 and N-RAS in primary acute myeloid leukaemia cells.J Cell Mol Med. 2018 Apr;22(4):2117-2130. doi: 10.1111/jcmm.13481. Epub 2018 Jan 29.
• [1052] Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia.Exp Cell Res. 2019 Nov 15;384(2):111653. doi: 10.1016/j.yexcr.2019.111653. Epub 2019 Sep 28.
• [1053] Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.Oncotarget. 2015 Sep 22;6(28):25109-20. doi: 10.18632/oncotarget.4668.
• [1054] Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome.Leukemia. 2000 Oct;14(10):1757-65. doi: 10.1038/sj.leu.2401897.
• [1055] Low Expression of Pseudogene POU5F1B Affects Diagnosis and Prognosis in Acute Myeloid Leukemia (AML).Med Sci Monit. 2019 Jul 4;25:4952-4959. doi: 10.12659/MSM.914352.
• [1056] Significance of Inactivated Genes in Leukemia: Pathogenesis and Prognosis.Cell J. 2017 Spring;19(Suppl 1):9-26. doi: 10.22074/cellj.2017.4908. Epub 2017 May 17.
• [1057] Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.Leukemia. 2014 Feb;28(2):311-20. doi: 10.1038/leu.2013.338. Epub 2013 Nov 13.
• [1058] The protein phosphatase 2A regulatory subunit B55 is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.Biochim Biophys Acta. 2014 Sep;1843(9):1969-77. doi: 10.1016/j.bbamcr.2014.05.006. Epub 2014 May 21.
• [1059] Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.Nat Commun. 2014 Jun 23;5:4177. doi: 10.1038/ncomms5177.
• [1060] Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.
• [1061] PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.J Clin Invest. 2018 Aug 1;128(8):3250-3264. doi: 10.1172/JCI99862. Epub 2018 Jul 23.
• [1062] MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.Leuk Lymphoma. 2015 Feb;56(2):460-71. doi: 10.3109/10428194.2014.924115. Epub 2014 Jun 25.
• [1063] Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.Cell. 2017 Feb 23;168(5):890-903.e15. doi: 10.1016/j.cell.2017.01.013. Epub 2017 Feb 2.
• [1064] Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia.Mol Cell Biol. 2018 Sep 28;38(20):e00259-18. doi: 10.1128/MCB.00259-18. Print 2018 Oct 15.
• [1065] PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway.Onco Targets Ther. 2019 Dec 12;12:10931-10941. doi: 10.2147/OTT.S233234. eCollection 2019.
• [1066] Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.Oncol Lett. 2017 May;13(5):3309-3313. doi: 10.3892/ol.2017.5839. Epub 2017 Mar 10.
• [1067] Expression profile analysis of long non-coding RNA in acute myeloid leukemia by microarray and bioinformatics.Cancer Sci. 2018 Feb;109(2):340-353. doi: 10.1111/cas.13465. Epub 2018 Jan 27.
• [1068] Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features.Cancers (Basel). 2019 Nov 22;11(12):1844. doi: 10.3390/cancers11121844.
• [1069] Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.Genes Chromosomes Cancer. 2016 Nov;55(11):847-54. doi: 10.1002/gcc.22384. Epub 2016 Jul 4.
• [1070] Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.Cancer Res. 2020 Feb 1;80(3):458-470. doi: 10.1158/0008-5472.CAN-18-2932. Epub 2019 Nov 29.
• [1071] UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.
• [1072] Monozygotic twins diagnosed simultaneously with RAM immunophenotype acute myeloid leukemia.Pediatr Transplant. 2018 Dec;22(8):e13291. doi: 10.1111/petr.13291. Epub 2018 Sep 15.
• [1073] miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.Leukemia. 2018 May;32(5):1180-1188. doi: 10.1038/s41375-018-0015-2. Epub 2018 Feb 2.
• [1074] All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.Cell Death Dis. 2019 Dec 10;10(12):944. doi: 10.1038/s41419-019-2172-2.
• [1075] Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Oncogene. 2017 Jun 8;36(23):3263-3273. doi: 10.1038/onc.2016.471. Epub 2016 Dec 19.
• [1076] NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias.Leuk Res. 2015 Jul;39(7):769-72. doi: 10.1016/j.leukres.2015.04.014. Epub 2015 May 7.
• [1077] The splicing factor RBM25 controls MYC activity in acute myeloid leukemia.Nat Commun. 2019 Jan 11;10(1):172. doi: 10.1038/s41467-018-08076-y.
• [1078] SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness.Sci Rep. 2019 Jun 24;9(1):9139. doi: 10.1038/s41598-019-45579-0.
• [1079] Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.Leukemia. 2015 Jun;29(6):1379-89. doi: 10.1038/leu.2014.350. Epub 2014 Dec 26.
• [1080] Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.Cancer Lett. 2007 Dec 8;258(1):38-44. doi: 10.1016/j.canlet.2007.08.005. Epub 2007 Sep 27.
• [1081] PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.Leuk Res. 2011 Oct;35(10):1367-75. doi: 10.1016/j.leukres.2011.03.024. Epub 2011 Apr 22.
• [1082] Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells.Blood. 2018 Apr 19;131(16):1833-1845. doi: 10.1182/blood-2017-05-787226. Epub 2018 Jan 25.
• [1083] The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia.Arch Immunol Ther Exp (Warsz). 2019 Apr;67(2):109-123. doi: 10.1007/s00005-019-00535-8. Epub 2019 Feb 28.
• [1084] tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.Leuk Lymphoma. 2015;56(10):2931-44. doi: 10.3109/10428194.2015.1011157. Epub 2015 Feb 24.
• [1085] Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.Hematology. 2014 Jun;19(4):225-31. doi: 10.1179/1607845413Y.0000000127. Epub 2013 Nov 25.
• [1086] shRNA-mediated RPS15A silencing inhibits U937 acute myeloid leukemia cell proliferation and enhances apoptosis.Mol Med Rep. 2016 May;13(5):4400-6. doi: 10.3892/mmr.2016.5064. Epub 2016 Mar 30.
• [1087] Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.Leukemia. 2017 Jan;31(1):213-221. doi: 10.1038/leu.2016.159. Epub 2016 Jun 3.
• [1088] Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet. 2014 Aug 15;23(16):4315-27. doi: 10.1093/hmg/ddu148. Epub 2014 Apr 4.
• [1089] RAS-Responsive Element-Binding Protein 1 Blocks the Granulocytic Differentiation of Myeloid Leukemia Cells.Oncol Res. 2019 Jul 12;27(7):809-818. doi: 10.3727/096504018X15451301487729. Epub 2019 Apr 8.
• [1090] p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
• [1091] SALL1 expression in acute myeloid leukemia.Oncotarget. 2017 Dec 15;9(7):7442-7452. doi: 10.18632/oncotarget.23448. eCollection 2018 Jan 26.
• [1092] Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.Mol Carcinog. 2018 Jun;57(6):735-744. doi: 10.1002/mc.22794. Epub 2018 Mar 6.
• [1093] SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Pathol Res Pract. 2018 May;214(5):706-712. doi: 10.1016/j.prp.2018.03.010. Epub 2018 Mar 7.
• [1094] A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.Cell. 2018 Feb 22;172(5):1007-1021.e17. doi: 10.1016/j.cell.2018.01.032.
• [1095] Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms.Exp Hematol. 2014 Jun;42(6):448-56.e4. doi: 10.1016/j.exphem.2014.02.005. Epub 2014 Mar 4.
• [1096] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [1097] INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.J Exp Clin Cancer Res. 2018 Jan 17;37(1):8. doi: 10.1186/s13046-018-0675-9.
• [1098] SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.Leuk Lymphoma. 2018 Apr;59(4):918-930. doi: 10.1080/10428194.2017.1344843. Epub 2017 Jul 6.
• [1099] Elevated SH3BP5 Correlates with Poor Outcome and Contributes to the Growth of Acute Myeloid Leukemia Cells.Biomolecules. 2019 Sep 19;9(9):505. doi: 10.3390/biom9090505.
• [1100] Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.Tumour Biol. 2017 Oct;39(10):1010428317720643. doi: 10.1177/1010428317720643.
• [1101] Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability.BMC Cancer. 2019 May 10;19(1):435. doi: 10.1186/s12885-019-5633-1.
• [1102] Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia.Cancer Sci. 2019 Jul;110(7):2200-2210. doi: 10.1111/cas.14033. Epub 2019 May 29.
• [1103] Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1.Nucleic Acids Res. 2018 Apr 20;46(7):3412-3428. doi: 10.1093/nar/gky119.
• [1104] Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.Haematologica. 2008 Nov;93(11):1728-33. doi: 10.3324/haematol.13044. Epub 2008 Sep 11.
• [1105] Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4.Blood Cells Mol Dis. 2002 Mar-Apr;28(2):221-33. doi: 10.1006/bcmd.2002.0487.
• [1106] Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia.Leukemia. 2000 Jul;14(7):1247-52. doi: 10.1038/sj.leu.2401807.
• [1107] Smc3 is required for mouse embryonic and adult hematopoiesis.Exp Hematol. 2019 Feb;70:70-84.e6. doi: 10.1016/j.exphem.2018.11.008. Epub 2018 Dec 13.
• [1108] Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.Leuk Lymphoma. 2018 Oct;59(10):2423-2430. doi: 10.1080/10428194.2017.1387906. Epub 2017 Oct 18.
• [1109] SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.Int J Mol Sci. 2014 Sep 25;15(9):17065-76. doi: 10.3390/ijms150917065.
• [1110] Wheat Germ Agglutinin as a Potential Therapeutic Agent for Leukemia.Front Oncol. 2019 Feb 21;9:100. doi: 10.3389/fonc.2019.00100. eCollection 2019.
• [1111] The fission yeast homolog of the human transcription factor EAP30 blocks meiotic spindle pole body amplification.Dev Cell. 2005 Jul;9(1):63-73. doi: 10.1016/j.devcel.2005.04.016.
• [1112] AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses.Blood. 2018 Jan 4;131(1):131-143. doi: 10.1182/blood-2017-02-768762. Epub 2017 Oct 23.
• [1113] JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.Blood Rev. 2020 Mar;40:100634. doi: 10.1016/j.blre.2019.100634. Epub 2019 Oct 25.
• [1114] Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma.Mol Cancer Res. 2019 Apr;17(4):1002-1012. doi: 10.1158/1541-7786.MCR-18-0316. Epub 2019 Jan 11.
• [1115] SOX12: a novel potential target for acute myeloid leukaemia.Br J Haematol. 2017 Feb;176(3):421-430. doi: 10.1111/bjh.14425. Epub 2016 Nov 18.
• [1116] Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics.Clin Chem Lab Med. 2014 Dec;52(12):1843-50. doi: 10.1515/cclm-2014-0487.
• [1117] Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia.Leuk Res. 2018 Apr;67:32-38. doi: 10.1016/j.leukres.2018.02.001. Epub 2018 Feb 6.
• [1118] SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells.Sci Rep. 2019 Mar 4;9(1):3388. doi: 10.1038/s41598-019-39926-4.
• [1119] Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia.Blood. 2015 Jun 18;125(25):3928-36. doi: 10.1182/blood-2014-06-580993. Epub 2015 May 4.
• [1120] The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.Clin Cancer Res. 2004 Oct 1;10(19):6544-50. doi: 10.1158/1078-0432.CCR-04-0911.
• [1121] Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.Blood. 2003 Feb 1;101(3):955-60. doi: 10.1182/blood-2002-06-1930. Epub 2002 Aug 22.
• [1122] LSD1/KDM1A inhibitors in clinical trials: advances and prospects.J Hematol Oncol. 2019 Dec 4;12(1):129. doi: 10.1186/s13045-019-0811-9.
• [1123] Elevated SPINK2 gene expression is a predictor of poor prognosis in acute myeloid leukemia.Oncol Lett. 2019 Sep;18(3):2877-2884. doi: 10.3892/ol.2019.10665. Epub 2019 Jul 25.
• [1124] Expression of sorcin predicts poor outcome in acute myeloid leukemia.Leuk Res. 2003 Feb;27(2):125-31. doi: 10.1016/s0145-2126(02)00083-8.
• [1125] STK3 is a therapeutic target for a subset of acute myeloid leukemias.Oncotarget. 2018 May 22;9(39):25458-25473. doi: 10.18632/oncotarget.25238. eCollection 2018 May 22.
• [1126] Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.J Med Genet. 2006 Apr;43(4):e14. doi: 10.1136/jmg.2005.035253.
• [1127] Expression of serologically identified tumor antigens in acute leukemias.Leuk Res. 2003 Jul;27(7):655-60. doi: 10.1016/s0145-2126(02)00230-8.
• [1128] Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?.Cancer Genet. 2017 Oct;216-217:74-78. doi: 10.1016/j.cancergen.2017.07.002. Epub 2017 Jul 31.
• [1129] TAF1 plays a critical role in AML1-ETO driven leukemogenesis.Nat Commun. 2019 Oct 29;10(1):4925. doi: 10.1038/s41467-019-12735-z.
• [1130] A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia.Cancer Cell. 2018 Jan 8;33(1):13-28.e8. doi: 10.1016/j.ccell.2017.12.002.
• [1131] An update meta-analysis and systematic review of TAP polymorphisms as potential biomarkers for judging cancer risk.Pathol Res Pract. 2018 Oct;214(10):1556-1563. doi: 10.1016/j.prp.2018.07.018. Epub 2018 Jul 29.
• [1132] LIFR-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway.Leuk Res. 2014 Oct;38(10):1237-44. doi: 10.1016/j.leukres.2014.07.004. Epub 2014 Jul 22.
• [1133] The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.Blood. 2012 Jun 7;119(23):5584-90. doi: 10.1182/blood-2011-11-389809. Epub 2012 Apr 24.
• [1134] Promoter methylation of the candidate tumor suppressor gene TCF21 in myelodysplastic syndrome and acute myeloid leukemia.Am J Transl Res. 2019 Jun 15;11(6):3450-3460. eCollection 2019.
• [1135] Investigation of copy-number variations of C8orf4 in hematological malignancies.Med Oncol. 2011 Dec;28 Suppl 1:S647-52. doi: 10.1007/s12032-010-9698-6. Epub 2010 Sep 29.
• [1136] Hepatic angiomyolipomas may overexpress TFE3, but have no relevant genetic alterations.Hum Pathol. 2017 Mar;61:41-48. doi: 10.1016/j.humpath.2016.11.003. Epub 2016 Nov 16.
• [1137] Promoter of TFPI-2 is hypermethylated in Chinese pediatric acute myeloid leukemia.J Pediatr Hematol Oncol. 2012 Jan;34(1):43-6. doi: 10.1097/MPH.0b013e3182277276.
• [1138] Analysis of HFE and TFR2 gene mutations in patients with acute leukemia.Leuk Res. 2005 Jun;29(6):661-4. doi: 10.1016/j.leukres.2005.01.001. Epub 2005 Feb 12.
• [1139] TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.Leukemia. 2015 May;29(5):1018-31. doi: 10.1038/leu.2014.307. Epub 2014 Oct 28.
• [1140] A novel epigenetic AML1-ETO/THAP10/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis.EMBO Mol Med. 2017 Jul;9(7):933-949. doi: 10.15252/emmm.201607180.
• [1141] Aurora A and NF-B Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA.Cancer Res. 2017 Jan 15;77(2):494-508. doi: 10.1158/0008-5472.CAN-16-1004. Epub 2016 Nov 10.
• [1142] TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.J Hematol Oncol. 2016 Nov 25;9(1):128. doi: 10.1186/s13045-016-0360-4.
• [1143] Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses.J Biomed Sci. 2019 Aug 31;26(1):63. doi: 10.1186/s12929-019-0557-2.
• [1144] Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.Asian Pac J Cancer Prev. 2016;17(3):1519-29. doi: 10.7314/apjcp.2016.17.3.1519.
• [1145] Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.Oncotarget. 2017 May 9;8(19):31959-31976. doi: 10.18632/oncotarget.16657.
• [1146] Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.Blood. 2008 Apr 15;111(8):4338-47. doi: 10.1182/blood-2007-07-103291. Epub 2008 Feb 7.
• [1147] AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein.Blood. 2011 Apr 21;117(16):4328-37. doi: 10.1182/blood-2009-09-242545. Epub 2011 Jan 18.
• [1148] TMEM18: A Novel Prognostic Marker in Acute Myeloid Leukemia.Acta Haematol. 2018;140(2):71-76. doi: 10.1159/000492742. Epub 2018 Sep 10.
• [1149] Ectopic expression of human airway trypsin-like protease 4 in acute myeloid leukemia promotes cancer cell invasion and tumor growth.Cancer Med. 2019 May;8(5):2348-2359. doi: 10.1002/cam4.2074. Epub 2019 Mar 7.
• [1150] Prognostic role of TPD52 in acute myeloid leukemia: A retrospective multicohort analysis.J Cell Biochem. 2019 Mar;120(3):3672-3678. doi: 10.1002/jcb.27645. Epub 2018 Sep 11.
• [1151] Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.
• [1152] Tumor Necrosis Factor Receptor Type 1-Associated Death Domain Protein Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.Am J Med Sci. 2019 Feb;357(2):111-115. doi: 10.1016/j.amjms.2018.10.015. Epub 2018 Nov 20.
• [1153] Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFB pathway and overexpressed in AML.Int J Oncol. 2013 Jul;43(1):246-54. doi: 10.3892/ijo.2013.1924. Epub 2013 Apr 29.
• [1154] MicroRNA-126 attenuates cell apoptosis by targeting TRAF7 in acute myeloid leukemia cells.Biochem Cell Biol. 2018 Dec;96(6):840-846. doi: 10.1139/bcb-2018-0017.
• [1155] Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):115-127.e15. doi: 10.1016/j.clml.2014.07.011. Epub 2014 Aug 12.
• [1156] Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.Oncotarget. 2015 Feb 20;6(5):2794-811. doi: 10.18632/oncotarget.3056.
• [1157] Contribution and prognostic value of TSGA10 gene expression in patients with acute myeloid leukemia (AML).Pathol Res Pract. 2019 Mar;215(3):506-511. doi: 10.1016/j.prp.2019.01.003. Epub 2019 Jan 7.
• [1158] The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Pediatr Blood Cancer. 2010 Sep;55(3):414-20. doi: 10.1002/pbc.22511.
• [1159] Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.Amino Acids. 2011 Mar;40(3):943-51. doi: 10.1007/s00726-010-0718-9. Epub 2010 Aug 14.
• [1160] Transcription factor AP-2 regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression.Int J Biochem Cell Biol. 2013 Aug;45(8):1647-56. doi: 10.1016/j.biocel.2013.04.024. Epub 2013 May 6.
• [1161] Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.Bone Marrow Transplant. 2018 Oct;53(10):1295-1303. doi: 10.1038/s41409-018-0169-6. Epub 2018 Apr 16.
• [1162] Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.
• [1163] Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.Blood. 2012 Aug 16;120(7):1473-84. doi: 10.1182/blood-2011-12-395335. Epub 2012 Jun 26.
• [1164] BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.Ann Hematol. 2018 Aug;97(8):1391-1397. doi: 10.1007/s00277-018-3331-8. Epub 2018 Apr 25.
• [1165] Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.Oncotarget. 2017 Mar 7;8(10):16220-16232. doi: 10.18632/oncotarget.8742.
• [1166] HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.PLoS One. 2013 Dec 11;8(12):e83018. doi: 10.1371/journal.pone.0083018. eCollection 2013.
• [1167] Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia.J Chemother. 2011 Jun;23(3):150-7. doi: 10.1179/joc.2011.23.3.150.
• [1168] Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.Br J Haematol. 2018 Mar;180(6):919-924. doi: 10.1111/bjh.15129. Epub 2018 Feb 14.
• [1169] MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.Biomed Pharmacother. 2018 Jan;97:1189-1194. doi: 10.1016/j.biopha.2017.11.002. Epub 2017 Nov 11.
• [1170] MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide.Oncol Res. 2019 Sep 23;27(9):1035-1042. doi: 10.3727/096504019X15528367532612. Epub 2019 Apr 8.
• [1171] Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34.Blood. 1989 Feb 15;73(3):777-81.
• [1172] BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy.Haematologica. 2013 Dec;98(12):1886-95. doi: 10.3324/haematol.2013.087452. Epub 2013 Jun 28.
• [1173] Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.Tumour Biol. 2013 Feb;34(1):531-42. doi: 10.1007/s13277-012-0578-x. Epub 2012 Nov 18.
• [1174] CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1.Sci Rep. 2013 Oct 4;3:2861. doi: 10.1038/srep02861.
• [1175] C/EBP deregulation results in differentiation arrest in acute myeloid leukemia.J Clin Invest. 2012 Dec;122(12):4490-504. doi: 10.1172/JCI65102. Epub 2012 Nov 19.
• [1176] The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients.Blood. 2012 Sep 27;120(13):2690-9. doi: 10.1182/blood-2012-02-412759. Epub 2012 Aug 22.
• [1177] Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.J Cell Physiol. 2018 Jun;233(6):4707-4714. doi: 10.1002/jcp.26253. Epub 2018 Jan 15.
• [1178] New fusion transcripts identified in normal karyotype acute myeloid leukemia.PLoS One. 2012;7(12):e51203. doi: 10.1371/journal.pone.0051203. Epub 2012 Dec 12.
• [1179] Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBP to prevent Trib1-driven acute myeloid leukemia.Blood Adv. 2017 Sep 1;1(20):1682-1693. doi: 10.1182/bloodadvances.2017007054. eCollection 2017 Sep 12.
• [1180] In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.Oncotarget. 2017 Jan 24;8(4):6341-6352. doi: 10.18632/oncotarget.13856.
• [1181] Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.
• [1182] DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype.Cell Oncol (Dordr). 2013 Oct;36(5):395-403. doi: 10.1007/s13402-013-0145-5. Epub 2013 Aug 27.
• [1183] Acute myeloid leukemia with t(7;21)(q11.2;q22) expresses a novel, reversed-sequence RUNX1-DTX2 chimera.Int J Hematol. 2012 Aug;96(2):268-73. doi: 10.1007/s12185-012-1112-z. Epub 2012 Jun 4.
• [1184] The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells.Cell Death Dis. 2012 Oct 25;3(10):e413. doi: 10.1038/cddis.2012.151.
• [1185] Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.Blood. 1998 Mar 1;91(5):1700-5.
• [1186] A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia.Gene. 2013 Oct 15;529(1):144-7. doi: 10.1016/j.gene.2013.07.105. Epub 2013 Aug 9.
• [1187] Eomes(+)T-bet(low) CD8(+) T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.
• [1188] High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.J Transl Med. 2019 Jun 6;17(1):191. doi: 10.1186/s12967-019-1926-z.
• [1189] FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients.Leuk Res. 2012 Nov;36(11):1339-46. doi: 10.1016/j.leukres.2012.06.011. Epub 2012 Aug 16.
• [1190] Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232. doi: 10.1016/j.bbmt.2018.07.007. Epub 2018 Aug 7.
• [1191] Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.Biochem Biophys Res Commun. 2013 Aug 23;438(2):283-8. doi: 10.1016/j.bbrc.2013.07.056. Epub 2013 Jul 24.
• [1192] Array-based DNA methylation profiling in acute myeloid leukaemia.Br J Haematol. 2011 Oct;155(1):65-72. doi: 10.1111/j.1365-2141.2011.08801.x. Epub 2011 Jul 26.
• [1193] GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.Cancer Med. 2017 Jan;6(1):267-274. doi: 10.1002/cam4.984. Epub 2016 Nov 28.
• [1194] FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.Mol Oncol. 2013 Jun;7(3):402-18. doi: 10.1016/j.molonc.2012.11.003. Epub 2012 Nov 29.
• [1195] A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.Leukemia. 2019 Jul;33(7):1773-1782. doi: 10.1038/s41375-019-0385-0. Epub 2019 Jan 29.
• [1196] Growth and differentiation effects of Homer3 on a leukemia cell line.Asian Pac J Cancer Prev. 2013;14(4):2525-8. doi: 10.7314/apjcp.2013.14.4.2525.
• [1197] Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.PLoS One. 2011;6(11):e28011. doi: 10.1371/journal.pone.0028011. Epub 2011 Nov 23.
• [1198] The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia.Exp Cell Res. 2018 Apr 15;365(2):185-193. doi: 10.1016/j.yexcr.2018.02.036. Epub 2018 Mar 6.
• [1199] JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/-catenin/CCND1 signaling.J Clin Invest. 2018 May 1;128(5):1737-1751. doi: 10.1172/JCI93198. Epub 2018 Mar 26.
• [1200] KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.Blood. 2011 Apr 7;117(14):3869-80. doi: 10.1182/blood-2010-10-312736. Epub 2011 Feb 10.
• [1201] A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22).Cancer Genet. 2012 Nov;205(11):608-11. doi: 10.1016/j.cancergen.2012.10.001. Epub 2012 Oct 24.
• [1202] The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.Front Immunol. 2019 Jul 11;10:1594. doi: 10.3389/fimmu.2019.01594. eCollection 2019.
• [1203] Functional variant (-1304T>G) in the MKK4 promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population.Cancer Sci. 2011 Aug;102(8):1462-8. doi: 10.1111/j.1349-7006.2011.01965.x. Epub 2011 May 25.
• [1204] Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia.Oncotarget. 2017 Nov 30;8(66):110444-110459. doi: 10.18632/oncotarget.22789. eCollection 2017 Dec 15.
• [1205] The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.
• [1206] MN1 and PTEN gene expression in acute myeloid leukemia.Cancer Biomark. 2017;18(2):177-182. doi: 10.3233/CBM-160235.
• [1207] Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.
• [1208] MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.Blood. 2012 Sep 27;120(13):2719-22. doi: 10.1182/blood-2012-04-422352. Epub 2012 Jun 7.
• [1209] A three-way translocation of MLL, MLLT11, and the novel reciprocal partner gene MYO18A in a child with acute myeloid leukemia.Cancer Genet. 2012 May;205(5):261-5. doi: 10.1016/j.cancergen.2012.02.006.
• [1210] NKL homeobox gene activities in normal and malignant myeloid cells.PLoS One. 2019 Dec 11;14(12):e0226212. doi: 10.1371/journal.pone.0226212. eCollection 2019.
• [1211] Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.Leukemia. 2012 Feb;26(2):289-95. doi: 10.1038/leu.2011.200. Epub 2011 Aug 9.
• [1212] Nebulette is the second member of the nebulin family fused to the MLL gene in infant leukemia.Cancer Genet Cytogenet. 2010 Apr 15;198(2):151-4. doi: 10.1016/j.cancergencyto.2009.12.013.
• [1213] NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7.
• [1214] Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.Leuk Res. 2012 Oct;36(10):1300-3. doi: 10.1016/j.leukres.2012.06.010. Epub 2012 Jul 9.
• [1215] Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.Ann Hematol. 2017 Apr;96(4):559-565. doi: 10.1007/s00277-016-2912-7. Epub 2017 Jan 5.
• [1216] miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia.Oncogene. 2013 Aug 1;32(31):3648-54. doi: 10.1038/onc.2012.398. Epub 2012 Sep 10.
• [1217] Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.Leuk Res. 2010 Jul;34(7):942-5. doi: 10.1016/j.leukres.2010.01.008. Epub 2010 Jan 31.
• [1218] Nuclear phospholipase C in biological control and cancer.Crit Rev Eukaryot Gene Expr. 2011;21(3):291-301. doi: 10.1615/critreveukargeneexpr.v21.i3.50.
• [1219] POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).Mol Cancer. 2013 Jan 18;12:5. doi: 10.1186/1476-4598-12-5.
• [1220] Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.Leuk Res. 2011 Apr;35(4):516-21. doi: 10.1016/j.leukres.2010.08.002. Epub 2010 Sep 9.
• [1221] The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Mol Cancer Res. 2013 Aug;11(8):815-27. doi: 10.1158/1541-7786.MCR-12-0695. Epub 2013 May 3.
• [1222] Deregulation of protein phosphatase expression in acute myeloid leukemia.Med Oncol. 2013 Jun;30(2):517. doi: 10.1007/s12032-013-0517-8. Epub 2013 Feb 26.
• [1223] PURA, the gene encoding Pur-alpha, member of an ancient nucleic acid-binding protein family with mammalian neurological functions.Gene. 2018 Feb 15;643:133-143. doi: 10.1016/j.gene.2017.12.004. Epub 2017 Dec 6.
• [1224] Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.J Cell Biochem. 2018 Feb;119(2):2073-2083. doi: 10.1002/jcb.26369. Epub 2017 Oct 18.
• [1225] Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.Blood. 2011 Nov 10;118(19):5235-45. doi: 10.1182/blood-2011-04-351817. Epub 2011 Sep 22.
• [1226] Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients.Exp Hematol. 2012 Mar;40(3):177-186.e6. doi: 10.1016/j.exphem.2011.11.008. Epub 2011 Nov 25.
• [1227] Methylation level of Rap1GAP and the clinical significance in MDS.Oncol Lett. 2018 Dec;16(6):7287-7294. doi: 10.3892/ol.2018.9503. Epub 2018 Sep 26.
• [1228] Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.Biol Blood Marrow Transplant. 2020 Mar;26(3):519-528. doi: 10.1016/j.bbmt.2019.11.001. Epub 2019 Nov 9.
• [1229] Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.Front Oncol. 2019 Oct 9;9:1027. doi: 10.3389/fonc.2019.01027. eCollection 2019.
• [1230] DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia.Oncotarget. 2013 Oct;4(10):1712-20. doi: 10.18632/oncotarget.1280.
• [1231] Repression of the RHOH gene by JunD.Biochem J. 2011 Jul 1;437(1):75-88. doi: 10.1042/BJ20100829.
• [1232] Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing.Leukemia. 2011 May;25(5):821-7. doi: 10.1038/leu.2011.19. Epub 2011 Feb 22.
• [1233] Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery.J Hematol Oncol. 2014 Jan 9;7:5. doi: 10.1186/1756-8722-7-5.
• [1234] Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.Cancer Res. 2017 Jan 1;77(1):207-218. doi: 10.1158/0008-5472.CAN-16-1386. Epub 2016 Oct 26.
• [1235] Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia.J Cell Physiol. 2019 May;234(5):6161-6172. doi: 10.1002/jcp.27393. Epub 2018 Sep 24.
• [1236] Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.Clin Chim Acta. 2012 Oct 9;413(19-20):1542-8. doi: 10.1016/j.cca.2012.06.025. Epub 2012 Jun 29.
• [1237] Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats.PLoS One. 2012;7(3):e33213. doi: 10.1371/journal.pone.0033213. Epub 2012 Mar 29.
• [1238] A Pilot Study of Aberrant CpG Island Hypermethylation of SPRED1 in Acute Myeloloid Leukemia.Int J Med Sci. 2019 Jan 1;16(2):324-330. doi: 10.7150/ijms.27757. eCollection 2019.
• [1239] Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.Eur J Haematol. 2017 Dec;99(6):544-552. doi: 10.1111/ejh.12972. Epub 2017 Oct 13.
• [1240] Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.Mol Pharmacol. 2010 May;77(5):828-35. doi: 10.1124/mol.109.061507. Epub 2010 Feb 16.
• [1241] Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.J Biosci Bioeng. 2012 Jul;114(1):96-103. doi: 10.1016/j.jbiosc.2012.02.016. Epub 2012 Mar 17.
• [1242] TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells.Cell Death Dis. 2013 Apr 4;4(4):e573. doi: 10.1038/cddis.2013.107.